ASEBIO Report 2011

asebio

españa, technology for life.

Edited by Spanish Association of Bioenterprises (ASEBIO)

1st edition: September 2012
Design and editorial coordination: iLUNE

Executive summary

1

Situation of the Spanish biotechnology sector

EXECUTIVE SUMMARY

Another year on, the main indicators for the Spanish biotechnology sector continue to improve:

- 1,715 companies state that they have worked on biotechnology in 2010, representing growth of 12.8% on 2009.
- 617 companies demonstrated that biotechnology is their main and/or exclusive line of work (+30% on 2009).
- The number of jobs in the sector as a whole now stands at 163,526. In a particularly adverse economic-financial scenario, 6000 new jobs have been created over the last year (increase of 3.8% on 2009).
- The turnover of companies claiming to use biotechnology in some of their processes rose 11% in 2010, topping 60,121 million Euro, representing 5.72% of national GDP.

Table 1 summarises the main results extracted from the Survey on Innovation in Businesses in its 2010 edition. It shows how practically all the reference indicators have continued to rise over the last year, reaching double figure rates. This spectacular growth is illustrated graphically in Graphs 1, 2 and 3. In addition, Table 2 shows how the main study variables change depending on whether the biotechnology work is considered as main and/or exclusive, secondary or a necessary tool for production.

Among the reasons explaining this significant growth, it is advisable to highlight the effect attributed to the emergence of a new technology-intensive sector and the production model-changing phenomenon that the Spanish economy has been undergoing over the last few years in the light of certain maturing industrial sectors that are running out of steam.

As can be seen in Table 1, many of the sector's reference indicators have grown during the last year between 11 and 13%. Specifically, companies that carry out activities related to biotechnology, turnover, staff employed in biotechnology R&D, internal spending on biotechnology R&D or companies performing biotechnology R&D.

The sector turnover is distributed as follows: 58.42% of the total is generated by companies where biotechnology is considered as a secondary business line, whilst 27.70% comes from companies where biotechnology represents a necessary production tool and the remaining 13.88% is attributed to any where biotechnology is a main and/or exclusive activity (henceforth biotec). Regarding biotechnology staff, 47% corresponds to jobs generated in companies where biotechnology is the main activity, 13% in companies where it is a secondary business line and the remaining 40% in any that consider it as a necessary tool for production.

The most important growth has been recorded in the number of biotecs, with 30%, and the number of patents requested that has increased by 17.3%, although the latter remains far below the European average. It should be highlighted that biotecs apply for the most patents (71% of the total) followed by companies that consider biotechnology as a necessary tool for production (23% of total). Finally, biotechnology employment has grown 3.8% (6000 net jobs created over the last year) despite the unprecedented destruction of employment in Spain over this period.

TABLE 1. Main results from the biotechnology module of the 2010 survey on innovation in businesses.
Source: INE, Survey on Innovation in Business 2010.

Main variables	Under 250 employees	Over 250 employees	2010 total	2009 total	Difference	Growth rate
Companies that carry out activities related to biotechnology:	**1,632**	**82**	**1,715**	**1,521**	**194**	**12.8%**
Companies where biotechnology is a main and/or exclusive activity (biotec)	596	21	617	475	142	29.9%
Companies where biotechnology is a secondary business line	191	18	209	190	19	10.2%
Companies where biotechnology is a necessary tool for production	845	43	889	856	33	3.8%
Companies that carry out R&D activities in biotechnology	**900**	**68**	**969**	**858**	**111**	**12.9%**
Total Employment	**41,457**	**122,069**	**163,526**	**157,523**	**6,003**	**3.8%**
Turnover (million Euros)	**6,955**	**53,166**	**60,122**	**54,172**	**5,950**	**11.0%**
R&D staff in biotechnology (no. of people):	**6,411**	**1,847**	**8,258**	**7,367**	**891**	**12.1%**
A) Total by occupation						
Researchers	3,786	1,029	4,816	4,242	574	13.5%
Technicians and auxiliaries	2,625	818	3,442	3,125	317	10.1%
B) Women within this set	3,450	1,129	4,580	4,115	465	11.3%
Researchers	1,930	605	2,535	2,236	299	13.4%
Technicians and auxiliaries	1,520	524	2,045	1,879	166	8.8%
Internal R&D spending on biotechnology (thousand Euros):	**416,267**	**152,012**	**568,280**	**511,152**	**57,128**	**11.2%**
A) By type of spending						
Running costs	326,351	140,604	466,955	438,696	28,259	6.4%
• Salary for researchers	123,279	46,401	169,680	151,786	17,894	11.8%
• Salary for technicians and auxiliaries	61,728	21,856	83,584	78,545	5,039	6.4%
• Other running costs	141,344	72,348	213,691	208,365	5,326	2.6%
Capital Costs	89,916	11,408	101,324	72,456	28,868	39.8%
• Land and buildings	39,687	3,027	42,714	14,657	28,057	191.4%
• Equipment and instruments	47,162	8,042	55,203	52,678	2,525	4.8%
• Acquiring specific software for R&D	3,067	340	3,407	5,121	-1,714	-33.5%
B) By funding origin						
National funding	368,943	110,951	479,894	459,131	20,763	4.5%
• Own resources	220,781	77,275	298,056	311,396	-13,340	-4.3%
• From companies	21,314	12,731	34,046	28,695	5,351	18.6%
• From public administrations	124,032	19,206	143,238	114,180	29,058	25.4%
• From universities	394	3	398	794	-396	-49.9%
• From private non-profit-making institutions	2,421	1,735	4,156	4,066	91	2.2%
Funds from abroad	47,324	41,062	88,386	52,022	36,364	69.9%
• From European Union programmes	8,226	1,116	9,341	8,679	662	7.6%
• Other funds from abroad	39,098	39,946	79,044	43,342	35,702	82.4%
% companies that have requested biotechnology patents	**12%**	**23%**	**13%**	**12%**	**NA**	**NA**
Number of patents requested	**595**	**48**	**643**	**548**	**95**	**17.3%**

Table 2: Distribution of main sector indicators in 2009 and 2010 by type of activity in biotechnology.
Source: INE, Survey on Innovation in Business 2010.

Main variables	Main			Secondary			Tool			Total in 2010	Total in 2009
	Value in 2009	Value in 2010	% of total in 2010	Value in 2009	Value in 2010	% of total in 2010	Value in 2009	Value in 2010	% of total in 2010		
Units that carry out activities related to Biotechnology	475	617	40.6%	190	209	13.7%	856	889	58.45%	**1,715**	**1,521**
Units that perform R&D in Biotechnology	386.1	492	57.3%	135	144	16.8%	337	333	38.79%	**969**	**858**
Biotechnology staff (no. of people)	4,195.1	5.963	80.9%	841	1,563	21.2%	2,331	5,071	68.83%	**12,597**	**7,367**
Spending on biotechnology (thousand Euros)	502,512.4	585.482	68.2%	80,349	98,780	11.5%	275,267	195,150	22.74%	**879,412**	**858,129**
Internal R&D spending on biotechnology (thousand Euros)	344,431.7	398.884	78.0%	52,095	60,657	11.9%	114,626	108,738	21.27%	**568,280**	**511,152**
% Companies that have requested patents in biotechnology	25.3	24	NA	12,9	9	NA	4,5	6	NA	**13**	**12**
Number of patents requested	360.2	454	NA	53	38	NA	135	151	NA	**643**	**548**
Turnover (thousand Euros)	7,872.481	8,343,433	15.4%	31,332,127	35,124,682	64.8%	14,967,126	16,653,416	30.74%	**60,121,530**	**54,171,734**
Total Employment	38,150.4	35,917	22.8%	41,789	45,938	29.2%	77,584	81,671	51.85%	**163,526**	**157,523**

As in previous reports, the percentage of women working in the field of biotechnology R&D (55.46%) is a little higher than men (44.54%). In companies with over 250 employees, this percentage exceeds 61%.

The biotechnology sector structure remains characterised mainly by companies with under 250 employees both in the case of biotechnology user companies (95.16%) and biotecs (96.60%). Despite this, biotech companies with fewer than 250 employees only generate 11.57% of the sector's total turnover and employ 25.35%.

Another relevant indicator for a technology-intensive sector is internal spending on biotechnology R&D. This indicator has seen an increase of 11.2% bringing it to 568 million Euros. On the whole (84%), these funds come from the national field. Sources of financing are distributed as follows: own resources (52.45%), public administrations (25.21%), other companies (5.99%) and private non profit making institutions and universities (together not exceeding 1%).

In general terms, the sector-based distribution of companies with biotechnology work remains the same as the previous year, as shown in graph 5. In this way, applications in the food field (53%) predominate, followed by human health (31%), agriculture and forestry production (16%), environmental applications (14%), animal health and aquiculture (14%) and finally, other industrial applications (12%). For the first time, the ASEBIO report is analysing the sector distribution of biotech companies.



GRAPH 1: EVOLUTION OF EMPLOYMENT (number of workers)



GRAPH 2: EVOLUTION OF TURNOVER (in million Euros)



GRAPH 3: EVOLUTION OF R&D SPENDING (in million Euros)



GRAPH 4: EVOLUTION OF THE NUMBER OF COMPANIES WITH BIOTECHNOLOGY WORK



GRAPH 5. PERCENTAGE OF COMPANIES BY FINAL APPLICATION AREA FOR USING BIOTECHNOLOGY

Source: INE, Survey on Innovation in Business 2010.

Among the companies completely dedicated to biotechnology, the majority are companies that work in human health (54%) and secondarily, there are applications in the food field.

Territorial analysis of the indicators

Out of the 1,715 companies using biotechnology in Spain, Catalonia has consolidated its position as the region with the highest concentration of companies (19.08%). Behind them, Andalusia, with 14% of the national total, has pulled ahead of the Madrid region for the first time (with 11.85%).

Other particularly active Autonomous Communities include de Castilla y León (8.01%), the Valencia Region (7.87%), Galicia (7.16%) and the Basque Country (6.85%) as shown in graph 6.

Despite Catalonia's leadership in companies using biotechnology, graph 7 demonstrates that the highest number of biotech companies is concentrated in the Madrid Region (17.39%), followed by Catalonia (15.01%) and Andalusia (13.19%). Practically two thirds of private inter-



GRAPH 6. Geographic distribution of companies using biotechnology.



GRAPH 7. Geographic distribution of biotecs.

nal R&D spending is concentrated between Madrid and Catalonia (30.90% in Madrid and 31.29% in Catalonia) and a little over half of the jobs generated by the private sector (28.15% in the Madrid Region and 25.11% in Catalonia).

As occurred for user companies, the following group is made up of Castilla y León (6.42%), Valencia Region (8.07%), Galicia (7.15%) and the Basque Country (8.43%) as shown in graph 6.

Competitive cooperation in the national biotechnology sector

In such an R&D&I intensive sector as biotechnology, it is assumed that public-private collaboration and strategic alliances between companies in the same sector are naturally plentiful. This assumption can be contrasted against analysis of data from the biotechnology module of the INE Survey on Innovation in Business 2010, included in the ASEBIO Report for the first time. This specifically refers to what is known as "innovative companies in biotechnology" defining them as companies making use of biotechnology stating that they carried out technological innovation during the 2008-2010 period, or in other words, companies that have produced any type of product or process innovation over this period.

From the world of Spanish biotech companies (617 in 2010), 60% stated that they have carried out technological innovations during the period between 2008 and 2010. And from this subset of 369 companies innovating in biotechnology, 226 have stated that they work jointly with another organisation.

Graph 8 shows the national R&D&I system agents who have worked the most with innovating companies in biotechnology. As you can see, collaborations with the public sector predominate: Universities or other Higher Education Centres (70.4%) - eminently public institutions - and with Public Research Organisations (51.8%). A second group might encompass working with clients (42.5%), with competitors or other companies in the sector (35.8%) with technology centres (35.4%) and, finally, with consultants, labs or private R&D institutes (34.5%).



Graph 8. Companies innovating in biotechnology who have cooperated in innovation in 2008-2010 according to their cooperation partners. Source: INE, Survey on Innovation in Business 2010.

2

New companies set up in 2011

In total, 69 companies were set up in 2011. By geographic area, once again Andalusia is the region with the highest number of companies set up with 19, followed by Catalonia with 16 companies and the Madrid Region with 10. Valencia closely followed Madrid with 9 companies.

Table 3. Companies dedicated to biotechnology that started up in 2011.
Source: ASEBIO

COMPANY NAME	REGION	WORK CARRIED OUT
4U GENOTEST	REGION OF MADRID	Benchmark genetic analysis lab for end consumers and medical prescribers. Non diagnostic analysis.
ADBRONCUS	CATALONIA	Research, broadcast, develop, carry out and produce diagnostic and therapeutic methods relating to health, respiratory diseases and life sciences in general.
ALIMENTOMICA	BALEARICS	Functional food.
AMARNA STEM CELLS	ANDALUSIA	Biotechnology company focussed on cell therapy to generate nervous tissue.
ANDROCITE	ANDALUSIA	Sequencing and analysis of the human genome for certain population groups to discover new therapeutic targets and thereby develop new therapies.
AQUALGAE	ANDALUSIA	Manufacturing photo-bioreactors for aquiculture.
AQUATIC BIOTECHNOLOGY	ANDALUSIA	R&D&I projects to optimise and close the reproduction cycle in captivity for ornamental fish. Manufacture, supply and maintain ictiotherapy equipment. Qualitative and quantitative analysis of marine invertebrate samples. Manufacturing tools and material required for oceanographic samples and their later analysis. Technical assistance on oceanographic campaigns and biological sampling.
APPLIED FOODS	NAVARRA	Dedicated to developing and producing products working from alimentary bio-polymers. They make GLOOD, the brand of glue and gel colours made out of alimentary products.
ASCIDEA COMPUTATIONAL BIOLOGY SOLUTIONS	CATALONIA	Bio-computing company.
ASTURBIOS BIOTECH	ASTURIAS	Research, development, production and marketing of additives with a microbial origin and biocide functions.
BEACON BIOMEDICINE	REGION OF MADRID	Development and marketing of products for PREMIUM anti-aging cosmetics, based on peptides and iminosugars to lengthen the average lifespan of skin cells and stabilise their microflora, preventing acne, irritation, etc.
BIOBAM BIOINFORMATICS	REGION OF VALENCIA	Developing user-friendly software solutions for biological research and for the scientific community.
BIODAN SCIENCES	REGION OF MADRID	Development and manufacturing of organic active ingredients for the cosmetic and para-pharmacy sector and development of final cosmetics with the same concept.
BIONOS	REGION OF VALENCIA	Molecular mechanisms for proliferation and differentiation using Medaka fish.
BIOSENSUR MICROBIOSENSORES	ANDALUSIA	Detecting/channelling new products with a high technology value for the winemaking industry that can be developed or adapted for the market; in addition to solving certain problems in production processes using these new methods such as the bio-sensory world.

COMPANY NAME	REGION	WORK CARRIED OUT
BIOTEC SYSTEM	REGION OF VALENCIA	Development, individual and joint participation in national and European research and technological development and innovation projects for new technologies in biotechnology, environmental and energy areas.
BIOTECH & BUSINESS CREATION CONSULTANTS	CATALONIA	Consultancy offering services in the biotechnology field.
BIOUNIVESAL	ANDALUSIA	Used domestic oil recycling plant.
BIPSIN	BALEARICS	Medical Device.
BRECA HEALTH CARE	ANDALUSIA	Personalised design and computational validation of prostheses, implants, braces and healthcare material, plus models for pre-operatory studies, using new fast, layer adding manufacturing technologies. This uses a series of technological applications: 3D scanning, processing images on the computer, personalised CAD and computational validation.
CAMBRIX GENOMIC INSTITUTE	ANDALUSIA	Research and development of biomarkers (DNA, ARN and proteins) for molecular diagnosis in human health, personalised medicine and development of drugs. Production and marketing of diagnosis kits for human health and personalised medicine.
CECYPEEUROPE	BASQUE COUNTRY	Pharmaceutics.
CELBIOCAN	CANTABRIA	Biotechnology company with offer of services and specialist products for the oncology sector. In this way, the company can manage to put a human tumour stem cell platform on the market to sift through new drugs for the oncology sector. This service is aimed at biopharmaceutical and biotechnology companies dedicated to developing new tumour compounds.
CENIT SUPPORT SYSTEMS	CASTILLA Y LEON	Bio-computing and other services for biotechnology companies.
CIMAB	CATALONIA	Masculine infertility study by means of oxidative sperm stress.
CITOSPIN	CASTILLA Y LEON	Mesenchymal stem cells.
CONTRACT BIOTECHNOLOGY	BASQUE COUNTRY	On-line Market Place for Biotechnology companies.
DRACONIS PHARMA	CATALONIA	Support for drug discovery in the different stages of research.
DREAMGENICS	ASTURIAS	Research and development. Use of the complete human genome through models and IT applications to help medical diagnosis.
ESTUDIOS GENÉTICOS PARA LA BIODIVERSIDAD	REGION OF VALENCIA	Biotechnology applications in the fields of biodiversity and the agricultural sector (species conservation and control of invasive organisms and agricultural plagues).
GEM BIOSOFT	REGION OF VALENCIA	Data management and software development that provides high quality solutions for common problems in genomics and e-health.
GENERATION RFID	CATALONIA	Bio-computing.
GENOCLINICS BIOTECH	ANDALUSIA	Genetic analysis aimed fundamentally at prevention (genetic susceptibility) and improving treatment of diseases (pharmacogenetics) with an important hereditary factor, such as cancer and cardiovascular diseases.

COMPANY NAME	REGION	WORK CARRIED OUT
GLEN BIOTECH	REGION OF VALENCIA	Development of biological control agents for agricultural and ornamental plants, particularly against plagues in palm trees, analysis of plant samples to detect crop pathogens, search for secondary metabolites with biological activity in the natural environment, etc.
GOMBORI	REGION OF VALENCIA	Scientific activities involving research, development and innovation by means of applying biotechnology, nanotechnology and information technologies.
GREENFUEL INNOVATIONS	CASTILLA Y LEON	Genetic engineering to grow micro-algae for bio-energy purposes.
IDEINNOVA	CATALONIA	Managing funding and subsidies to support R&D projects, technological innovation, industrial investment, training, internationalization, environment and energy.
IKIRIA KNOWLEDGE	ANDALUSIA	Simulation, entertainment and management of knowledge from the surgical process.
INNCELL	REGION OF MADRID	Provides innovating in vitro solutions to the current needs of researchers in the bio-healthcare sector and manufacturers and distributors of products in the dermo-cosmetics sector.
INVEL I+V	ANDALUSIA	Design and development of software for life sciences. Medical research services.
INVESTIGACIÓN Y DESARROLLO FJ SÁNCHEZ	ANDALUSIA	Innovation lab for fats, oils, preserves and semi-preserves.
IPROTEOS	CATALONIA	Research, development and marketing of new therapy approximations.
LAB2BIZ	CATALONIA	Service providers to set up companies, start-up, within the biotechnology sector, including the creation of Business Plans, search for registered capital and consultancy on implantation.
LABORATORIOS QUESPER	ANDALUSIA	Design and generation of pharmaceutical/skin-cosmetic products based on the use of Oleuropein (proliferation of blood vessels).
LIFE LENGTH	REGION OF MADRID	Measuring the percentage of short telomeres in individual cells coming from blood and tissue samples that make up the relevant indicator for telomere dysfunction and cell aging.
LIFEGENETIC	ANDALUSIA	Automated and specialised molecular diagnosis lab based on recombining DNA technology and methods for nuclear acid enzymatic amplification.
LIOMA	REGION OF VALENCIA	Equine genetic selection.
LYKERA BIOMED	CATALONIA	Developing new drugs to treat cancer by attacking tumour cells, tumour stroma and tumour angiogenesis.
MIND THE BYTE	CATALONIA	Research company specialised in providing scientific solutions calculation for researchers.
MYNORIX THERAPEUTICS	CATALONIA	Discovery and development of new treatments for rare diseases, particularly any affecting children.
NANOMYP - NANOMATERIALS AND POLYMERS	ANDALUSIA	Characterisation and supply of molecular stamped polymers, micro and polymeric nanoparticles.
NANOTARGETING	CATALONIA	Developing technical applications for controlled administration of drugs, mainly anti-tumour by means of their encapsulation and transport, use of inorganic materials such as "in vivo" and "ex vivo" diagnosis probes.

COMPANY NAME	REGION	WORK CARRIED OUT
NATURAL SKIN CARE COMPANY	BASQUE COUNTRY	R&D&I in cosmetic products.
NLIFE THERAPEUTICS	ANDALUSIA	Development of molecules to make pharmaceutical products intended for treating diseases in the Central Nervous System.
NUTRIMENTEC	CASTILLA Y LEON	Recycling waste water to produce biogas, agro-industrial services, pharmaceuticals, etc.
POC-IVD MICROPLATAFORMS	BASQUE COUNTRY	Design, manufacturing and integration of "point of care" systems platforms.
PROBISEARCH	REGION OF MADRID	They offer microbiological, immunological and nutritional analysis and diagnosis of breast milk. Bacterial analysis (human and animals) for human benefits and food security.
READYCELL	CATALONIA	Creation and marketing of cell reactives.
REIG JOFRÉ BIOTECH SERVICES	CATALONIA	Specialised in consultancy for companies in the biotechnology sector.
RESTAURA BIOTECH	REGION OF VALENCIA	Bio-cleaning services, preventive conservation and analysis of bio-deterioration, artistic historical heritage, also applying new bio-cleaning techniques on wall painting and stone materials thanks to work done in R&D&I over the last few years.
SMARTLIGS	REGION OF MADRID	Computational services to improve and accelerate the drug development process. Develop internal projects to obtain active compounds that pass the preclinical phase and can then be licensed.
SOLUCIONES CATALÍTICAS IBERCAT	REGION OF MADRID	They offer innovating catalytic solutions for industry from the chemical and sustainable energy sector.
SPECTRAPPLY	ASTURIAS	Research, development and marketing of complete analytical solutions based on IR Infra-red electroscope applied to physical-chemical analysis of the medium.
SUNTEC SOLAR	ANDALUSIA	Manufacturing solar filters for cosmetic and pharmaceutical products.
SYNTHELIA ORGANICS	REGION OF MADRID	R&D on synthetic routes for pharmaceutically interesting compounds and synthesis of intermediates for preclinical medication development.
TERACLON	REGION OF MADRID	Generating shark therapeutic monoclonal antibodies (vNAR´s) based on a technological platform protected and licensed to TERACLON IDF.
VAXDYN	ANDALUSIA	Fast development platform for recombining vaccines for resistant bacteria by means of proteomic and bio-computing techniques to identify bacterial antigens.
WEB AND MULTIMEDIA FOR SCIENCE	ANDALUSIA	Multimedia services for biotechnology and biomedical sector.
ZYRNAT BIOTHERAPEUTICS	CATALONIA	Research, development and innovation of biopharmaceutical products.

3

Business activity

Alliances and Business Development

This is an analysis of the business development work done by ASEBIO-associated entities, counting any formal agreement between, at least, one Spanish biotech company and an entity that implies an explicit commitment to meet different types of common aims (R&D, production, sales, etc.) with an impact on the strategy of the organisations involved.

The study compiles the different types of agreement such as joint-marketing, joint development, exchange of products and markets, etc. without taking into account the conventional buying-selling or service provision relationships. For the second year running, this also includes joint projects within the framework of a national or international programme, for example Innpacto for the former or FP7 for the latter.

If the agreement is made by a multinational company, it counts as if a Spanish partner is implicated in this agreement or the agreement is targeting the Spanish market.

In 2011, a total 112 alliances were registered. 63% of these collaborations took place with other biotechnology companies, 46% with public entities and 38% with a user company.

Regarding partner origin, 70% of agreements were made with national entities, 28% with European entities, 9% with American entities and 5% with Asian organisations.

Launching Products on the Market

During 2011, ASEBIO-associated entities launched a total of 66 products or services on the market.

67% of these launches were aimed at the field of human health, 13% were industrial processes, 12% are aimed at both human and animal health, 4% are Agrifood products or services and 4% concern animal health.

Table 4 includes the complete list of these launches indicating the name of the product or service for which it is recommended, and it gives details of whether this is a functional ingredient, software, diagnosis product, industrial, for research, therapeutic or even a development or research service.



GRAPH 10. Distribution by application field of the products / services launched on the market during 2011 by biotechnology entities associated with ASEBIO.
Source: ASEBIO



GRAPH 9. Distribution of alliances in the Spanish biotech sector 2011 depending on the partner profile. Source: ASEBIO

TABLE 4 Products and services launched on the market in 2011 by Spanish entities associated with ASEBIO. Source: ASEBIO

Entidad	Nombre e indicación	Tipo	Ámbito
AB-BIOTICS	Neurofarmagen v2.1. Genetic analysis to assess likelihood to respond to drugs most frequently used in treating Depression, Schizophrenia, Bipolar Disorder and Epilepsy.	Therapeutic product	Human health
ABBOTT LABORATORIES	HUMIRA (adalimumab). Human monoclonal antibody for combination treatment with methotrexate for polyarticular juvenile idiopathic arthritis (pJIA).	Therapeutic product	Human health
ALGAENERGY	ALGAEPISCIS® and ALGAECARE®. Microalgae with a high protein content, Omega-3 type polyunsaturated fatty acids (PUFAs), carotenoids and high anti-oxidising power. With application for: Animal food (aquiculture and livestock) and human food, cosmetics, drugs industry, functional food, etc.	Product (functional ingredient)	Human and animal health
AMGEN	Denosumab (Prolia®). Osteoporosis treatment for women and for osseous loss associated with hormone suppression.	Therapeutic product	Human health
BIOFTALMIK	Biomaterial applied on the vitreous body allowing a clear view of the patients' retina on the screen.	Industrial product	Human health
BIOFTALMIK	New on-line ordering service for immunological eye disease diagnoses.	Development service	Human health
BIOFTALMIK	LIMBOKIT. Device to diagnose and monitor Limb Deficiency.	Diagnosis product	Human health
BIOFTALMIK (developed jointly with CSIC)	Immediate diagnosis kit for Ocular Pathogens.	Diagnosis product	Human health
BIOMAR (developed jointly with the AGROVET analytical lab)	System to detect antibiotics in milk.	Diagnosis product	Industrial processes
BIOMEDAL	GlutenTox Pro. Fast detection kit for gluten in food, drinks and surfaces.	Diagnosis product	Agrifood
BIOMOL-INFORMATICS	BIOMOL-NGS. DATA ANALYSIS FOR "NEXT GENERATION SEQUENCING". Specialists in genetic diagnosis and analysis of human exome.	Bio-computing service	Human health
BIONATURIS	BNT004: intranasal prophylactic vaccine to prevent nematodes in farming livestock.	Therapeutic product	Animal health
BIONATURIS	BNT005: prophylactic and therapeutic vaccine against canine visceral Leishmaniasis.	Therapeutic product	Animal health
BTI BIOTECHNOLOGY INSTITUTE	Kit PRGF®-Endoret® Ophthalmology. System for obtaining plasma rich in growth factors that can be applied to regenerating damaged ocular tissue, ocular surface diseases such as dry eye, corneal ulcers and epithelial defects.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	Kits and stitches for ultrasonic scalpels.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	Expansive implants.	Therapeutic product	Human health

Entidad	Nombre e indicación	Tipo	Ámbito
BTI BIOTECHNOLOGY INSTITUTE	Multi-Im angled pillars.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	1mm grooved internal scarring pillar.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	Angle-poised hexagonal torque point.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	Osteosynthesis screws.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	Multi-Im screw with smaller head.	Therapeutic product	Human health
BTI BIOTECHNOLOGY INSTITUTE	Two new dental implant extractor models.	Therapeutic product	Human health
ERA BIOTECH	Inteins. They can be used in selective proteolysis of recombining proteins, in purification processes, cycling peptides or marking proteins.	Therapeutic product	Human health
ERA7 BIOINFORMATICS	Complete BG7. Integral Bacterial Genome service with own BG7 method for Next Generation Sequencing.	Bio-computing service	Human and animal health
ERA7 BIOINFORMATICS	Complete MG7. Integral Meta-genomic service with own MG7 method for Next Generation Sequencing.	Bio-computing service	Human and animal health
GAIKER-IK4 with EKOTEK and FACTOR CO2, Environment Industries Cluster (ACLIMA), Transport and Logistics Cluster, LEIA-TECNALIA	Tool for analysing bio-fuel life cycle.	Industrial product	Industrial processes
GAIKER-IK4	Portable test for fast influenza detection.	Diagnosis product	Human health
GAIKER-IK4 and GRUPO CALCINOR	Developing a system to reuse slurry from waste water with sanitary guarantees.	Industrial product	Industrial processes
GENETADI BIOTECH	New ante-natal diagnosis technique.	Diagnosis product	Human health
GENOMICA	CLART® EnteroBac. Tool to diagnose bacterial pathogens causing infectious diarrhoea using molecular biology techniques.	Diagnosis product	Human health
GENOMICA	CLART® SeptiBac+. Working directly from blood culture, it allows multiple detection of a wide range of Gram+ bacteria and fungi implicated in sepsis in a single test.	Diagnosis product	Human health
GENOMICA	SAICLART®. Image processing software for microarrays.	Software	Human health

Entidad	Nombre e indicación	Tipo	Ámbito
INGENIATRICS TECNOLOGÍAS	Scaling of microencapsulation products and services.	Industrial product	Industrial processes
INGENIATRICS TECNOLOGÍAS	Multiplex systems for scale distribution.	Industrial product	Industrial processes
INGENIATRICS TECNOLOGÍAS	Cellena®: 90 - 450 microns.	Diagnosis product	Human and animal health
INGENIATRICS TECNOLOGÍAS	Flow Blurring® NE-4. Nebulizer to improve production, performance and quality in the drying process.	Industrial product	Industrial processes
INGREDIENTIS BIOTECH	Product development; Making use of by-products; Food characterisation.	Development service	Agrifood
INGREDIENTIS BIOTECH	Identification of Bioactive compounds; Evaluation of biological activity; Bioactive-Delivery compounds.	Research service	Human health
INSTITUTE OF GENOMIC MEDICINE	CGX arrays. CGH Array designed particularly for genetic diagnosis.	Diagnosis product	Human health
INTEGROMICS	OmicsHub Proteomics 2.0. Tool to manage and analyse data for mass spectrometry labs.	Software	All
IUCT	Heating Oil. Second generation biofuel for industrial furnaces.	Industrial product	Industrial processes
IUCT	Bio-materials. Emulsifier and antioxidant.	Therapeutic product	Human health
IUCT	DIS-COM-BRA library. Library expansion focussed on the inflammation therapy area.	Therapeutic product	Human health
IUCT	DIS-BIO-CAN library. Library expansion focussed on the cancer therapy area.	Therapeutic product	Human health
NIMGENETICS	KaryoNIM Stem Cells. aCGH microarray to study genetic disturbances that might be present in human stem cell cultures intended for cell therapy.	Diagnosis product	Human health
NIMGENETICS	OncoNIM-CD Cancer Diagnostics. aCGH microarray to study genetic bio-markers related to diagnosing tumour and leukemia samples. Clinical use in diagnosing many types of cancer: Bladder, melanoma, breast, cervix, lung, etc.	Diagnosis product	Human health
NIMGENETICS	Family Cancer OncoNIM-CF. aCGH microarray aimed at complementing genetic studies for family cancer. Clinical use in hereditary tumours in breasts, colon, ovaries, and endocrine cancer.	Diagnosis product	Human health
OPERON	Simple / Stick CRY-GIA-ENT. Fast test using immunochromatography to detect in the Stick Crypto/Giardia/Entamoeba and Simple Crypto/ Giardia/Entamoeba chromatographic immune test is a procedure for qualitative in vitro detection of antigens for Cryptosporidium parvum, Giardia lamblia and Entamoeba histolytica in human faeces.	Diagnosis product	Human health
PHARMAMAR	YONDELIS®. Authorised for sale in 8 new countries to treat soft tissue sarcoma. These countries are; Bahrain, Byelorussia, Canada, Egypt, El Salvador, Indonesia and Quatar.	Therapeutic product	Human health
PHARMAMAR	YONDELIS®. Authorised for sale in 4 new countries to treat recurring platen-sensitive ovarian cancer in combination with Caelyx®. These countries are; Byelorussia, Egypt, El Salvador and Honduras.	Therapeutic product	Human health

Entidad	Nombre e indicación	Tipo	Ámbito
SISTEMAS GENÓMICOS	MamaGeneProfile® Genetic test for hereditary breast and ovarian cancer. Genetic study for hereditary breast and ovarian cancer (CMOH). This test simultaneously studies the BRCA 1 and 2 genes by means of massive sequencing in only three weeks.	Diagnosis product	Human health
SISTEMAS GENÓMICOS	ONCOGeneProfile® Genetic test for breast cancer, Polyposic and nonpolyposic colon cancer, family history and cases of multiple cancer.	Diagnosis product	Human health
SISTEMAS GENÓMICOS	Cardiogeneprofile®: Genetic test to detect family cardiopathies.	Diagnosis product	Human health
SISTEMAS GENÓMICOS	Controlled - personalised re-sequencing service.	Diagnosis product	Human health
SISTEMAS GENÓMICOS	Complete genome analysis - re-sequencing service.	Research product	Human health
SISTEMAS GENÓMICOS	Complete genome analysis - 'DE NOVO' re-sequencing service.	Research product	Human health
SISTEMAS GENÓMICOS	Complete transcriptome analysis - re-sequencing service.	Research product	Human and animal health
SISTEMAS GENÓMICOS	Complete 'DE NOVO' transcriptome analysis service.	Research product	Human and animal health
SISTEMAS GENÓMICOS	CHIP-SEQ analysis service.	Research product	Human health
SISTEMAS GENÓMICOS	Methylation analysis service.	Research product	Human and animal health
SISTEMAS GENÓMICOS	Metagenomic analysis service.	Research product	Industrial processes
TYGENIX	Chondrocelet. Cellular therapy product, first and only approved in the EU that is used to cure certain lesions on knee cartilage.	Therapeutic product	Human health
TYGENIX	Chondromimetic. Collagen implant designed to stimulate repair of osteochondral defects.	Therapeutic product	Human health
VIRCELL	Brucellacapt®: Brucellosis diagnosis.	Diagnosis product	Human health
VIRCELL	VIRAPID® TULAREMIA: Immunochromatography tests. Qualitative detection of total antibodies against Francisella tularensis in samples of serum or plasma.	Diagnosis product	Human health
X-POL BIOTECH	QualiPhi©. Combination of an optimised (chimera) version of the polymerase DNA of the Phi29 bacteriophage and a new formulation that improves the sensitivity of a widespread technique in molecular biology labs: Amplification of DNA.	Therapeutic product	Human health

Strategic Priorities

Since 2005, ASEBIO has been running a survey among their associated entities on their strategic priorities for 2012.

Another year on, internationalising continues to be the major priority for Spanish biotechnology companies.

Launching products on to the market is also one of the main priorities for companies and one of the values that has become more important over the past year.

Regarding other values that have varied the most, acquiring technology licences and recruiting professionals from abroad are two priorities that have become less important since 2011.

TABLE 5 Analysis of strategic priorities for Spanish biotechnology companies for 2012. Source: ASEBIO

PRIORITIES	Relevance 2012	Variation of the position on 2011	
Internationalization	3,33	/=/	0
Launching Products on the Market	3,05	▲	2
Acquiring knowledge and/or technologies	2,95	▼	-1
Entering clinical phases / field tests / scaling	2,67	▼	-1
Licence-out technology	2,51	▲	2
Form alliances with other user companies (drugs, food)	2,50	▼	-1
Contract or form alliances with public centres	2,34	▼	-1
Form alliances with other biotecs	2,27	/=/	0
Expand operations to other business areas	2,00	/=/	0
Refocus R&D activities	1,76	▲	3
Refocus product development	1,70	▲	3
Recruit professionals from abroad	1,32	▼	-2
Set up a Joint venture	1,31	▼	-1
Licence-in technologies	1,23	▼	-3
Outsource production	0,74	/=/	0
Merge with another company	0,71	/=/	0
Reduce operations	0,58	▲	1
Buy out a company	0,42	▼	-1

4

Industrial property and generating knowledge

Industrial property

The information compiled in the Technology Surveillance Report is obtained in accordance with the methodology redesigned by Clarke Modet and the Madrid Scientific Park Foundation. This new methodology responds to continuous improvements based on the studies' industrial property experience in 2009 and 2010.

In a first phase, patents were located using the international patent classification (IPC) related to biotechnology and Spanish ownership.

The data obtained was filtered in the Thompson and Marcanet databases.

Finally, to check, the public databases from the different offices were consulted: the Spanish Patent and Brand Office (OEPM), European Patent Office (EPO), United States Patent and Trademark Office (USPTO), Japan Patent Office (JPO) and finally in the World Intellectual Property Organization (WIPO).

623 publications of patent applications were identified along with 299 publications of patent concessions corresponding to 2011 held by organisations in the Spanish biotechnology sector.

Table 6 shows, in absolute terms, the breakdown of the 623 applications and 299 concessions, according to the scope of the protection (Spanish, European, American, Japanese or PCT patents) and the type of document (application or concession).

We should highlight the large number of inventions requested or conceded via the OEPM, with 476 documents and the PCT applications with 200 inventions far ahead of the European patents, followed by USPTO inventions with 90 documents. The Japanese office produced a remarkably low number of applications and concessions, 18 and 9 respectively.

Graph 11 shows the distribution of the applications depending on the patent office where they were requested. Patents processed via OEPM represent 37%, followed by PCT applications with 32%, EPO 16% and USPTO with 12%. Japanese applications are minimal, representing only 3%. Regarding the patents conceded (graph 12), the Spanish patents take first place with 81% compared to Japanese concessions (3%).



Graph 11. Distribution of patent applications depending on the patent office

Table 6. Number of applications and concessions from Spanish biotechnology entities (2011)

Patents published*	OEPM	EPO	USPTO	JPTO	PCT	TOTAL
Applications	233	100	72	18	200	623
Concessions	243	29	18	9		299
TOTAL	**476**	**129**	**90**	**27**	**200**	**922**

*OEPM, Spanish patent application and concessions; EPO, European applications and concessions; USPTO, American applications and concessions; JPTO, applications and concessions for Japanese patents and PCT, application via the PCT.

If we take into account the number of patent applications and concessions depending on the entity related to biotechnology in Spain (graph 13), it can be seen that there are 221 publications for patent applications where the holder is a Spanish company, and 74 publications of concessions.

Subsequently, there are the universities, with a total of 281 publications of applications and concessions of patents and the PROs (Pubic Research Organisations) with 218. The remaining requesting entities are foundations, public administrations, hospitals and individuals.

Analysing by type of publication (application or concession), 35% of biotechnology patent applications correspond to companies, 25% to universities and another 24% to PROs, as shown in graph 14.

Regarding concessions (graph 15), it stands out that 42% of the concessions correspond to universities and 25% to companies.



Graph 12. Distribution of patent concessions depending on the patent office



Graph 14. Distribution of patent applications by ownership



Graph 13. Ownership of publications of patent applications and concessions 2011



Graph 15. Distribution of patent concessions by ownership



Graph 16. Active companies in patent application and concession 2011

Taking into account the companies holding patents in 2011, we can highlight firstly the CIMA Biomedicine Project with 28 applications and 10 concessions. Then there is Lipotec with 10 applications and 5 concessions. The remaining companies can be seen in Graph 16.

Scientific production

ASEBIO carries out a study every year among its associated Spanish biotechnology companies and multinational research labs with headquarters in Spain regarding publications in high impact scientific journals.

This study does not compile the communications or posters in congresses or fairs nor chapters in books. Nor does this analysis include publications signed by research centres or by universities where no relation is quoted with studies for business projects.

During 2011, biotechnology companies have produced a total of 141 publications. These 141 represent a 6% increase on the previous year and are written by 22 biotechnology companies.

Regarding the companies with the highest number of publications, Pharmamar is once again first with 36, followed by BTImasD with 24, Merck Sharp & Dohme from Spain with 14, Noscira with 10 and Esteve with 9.

APPLICATIONS
CONCESSIONS

10



GRAPH 17. Number of scientific publications from ASEBIO-associated companies.
Source: ASEBIO

5

Healthcare or red biotechnology

The development of therapies for human health

ADVANCED THERAPIES

Advanced therapies, such as gene therapy, cell therapy and tissue engineering, offer new possibilities for treating human diseases. The boom currently experienced by advanced therapies throughout the world is set to promote measures for more training and adequate facilities for the services provided. Despite the fact that these gene, cell and tissue-based therapies are still at an early stage of development, they have already had a positive impact on the medical sector. Their potential is shown by the fact that there are currently more than 2,500 clinical trials registered throughout the world (www.clinicaltrials.gov). Of these, 1,600 are based on gene therapies. The inter-annual growth of cell therapy is also showing a remarkable upswing, increasing by 15% in the USA and 25% in Europe.

As published by Molecular Therapy, Spain is the leading country in Europe with regard to the number of advanced therapy clinical trials, with a total of 49, with particular mention of the mesenchymal stem cells, the haematopoietic cells and the dendritic cells. Spain is followed by Great Britain with 37 projects, Germany with 36 and the USA with 21. Spain is also leading the way with regard to the number of sponsors supporting and financing the advanced therapy clinical trials. A total number of 29 organisations support this research work, with particular mention of 15 academic institutions, 12 sponsor centres and 2 companies. Spain is followed by Germany with 25, Great Britain with 21 and the USA with 20.

CARDIOLOGY

The **Neuron Group** and the company **SuanFarma** signed an agency agreement for the implementation and marketing of a novel technology for the production of statins normally used to reduce the high levels of cholesterol, thereby reducing the risk of myocardial infarction and coronary death.

Sanifit concluded the pre-clinical trial of SNF472 for the treatment of cardiovascular disease in dialysis. The dossier includes animal models with kidney failure, in which the drug is shown to be more effective than competitor drugs, whilst also offering an excellent safety profile.

ONCOLOGY

Advancell has commenced the phase IIb clinical trials of its product ATH008 for the treatment of palmar-plantar erythrodysesthesia, known as hand-foot syndrome, a major secondary effect occurring in patients with cancer treated with chemotherapeutic agents such as capecitabine and other fluoropyrimidines, currently without treatment. A pilot study has already revealed some promising efficacy results. Advancell also announced some positive results for its Acadra (Acadesine) treatment in a Phase I/II clinical trial in a number of hospitals in Belgium, France and Spain, on patients with chronic lymphocytic leukaemia, resistant to current treatment. Following the administration of the treatment, patients showed a leukemic cell reduction of up to 50%. In the case of patients whose lymph nodes were affected at the start of the study, there was a 75% reduction in cancer cells after five doses.

GP Pharm has commenced a phase III clinical trial in the USA with Lutrate®3meses for the treatment of advanced prostrate cancer, the first controlled released drug. This is a hormone treatment to prevent the spread of the tumour in patients with advanced prostrate cancer. Furthermore, Lutrate was approved by the Spanish Agency for Medicines and Healthcare Products (AEMPS), a recognition that was extended to Germany, Italy, Greece and Portugal. GP Pharm also presented the findings of the phase II trial of Sarcodoxome®, a new liposomal formulation of doxorubicin hydrochloride for the treatment of advanced soft-tissue sarcoma.

INGENASA obtained recombinant proteins and monoclonal antibodies related to cancer biomarkers. These reagents are being used for "in vitro" and "in vivo" models to study lung cancer.

PharmaMar, a biopharmaceutical company which is part of the **Zeltia Group,** announced that phase II trials on Yondelis® were already being conducted on patients with advanced breast cancer and who have received at least two prior lines of treatment. Five hospitals from Belgium, France and Spain are taking part in the study. Likewise, PharmaMar announced the presentation of the overall survival data for the OVA-301 trial with Yondelis® + PLD for ovarian cancer at the 47th meeting of the American Society of Clinical Oncology (ASCO).

Furthermore, **Zeltia** reported that, following the completion of the phase I trial of PM01183, **PharmaMar** is to commence a phase II trial on metastatic cancer of the pancreas, directed at assessing its activity as a second line of treatment in terms of "overall survival", after six months of treatment in patients with this pathology.

Also in 2011, **PharmaMar** commenced the clinical development of its new marine-based anti-tumour drug PM060184 in the USA. This drug has shown a powerful anti-tumour activity in pre-clinical models and a favourable safety profile in toxicological studies in animals. As well as in the USA, the Phase I trials are also to be conducted in collaboration with hospitals in Spain and France, with the primary goal of identifying the dose limiting toxicities (DLT) and the recommended dose (RD). In addition, its pharmacokinetic profile will be determined and a preliminary assessment shall be made of its anti-tumour activity in patients. Yondelis, the first **PharmaMar** product to be marketed, was given eleven new marketing authorisations in eight countries. Four, in combination with Caelyx®, for the treatment of recurrent platinum sensitive ovarian cancer, in Belarus, Egypt, El Salvador and Honduras. The other seven, for the treatment of soft tissue sarcoma in Bahrain, Belarus, Canada, Egypt, El Salvador, Indonesia and Qatar. Yondelis® is currently authorised in 70 countries.

IUCT successfully completed its Eurostar DISC-SCREEN project, in a European consortium with SME in Finland and Romania, directed at obtaining new anti-cancer drugs.

Its principal achievements include a High Throughput Drug Discovery International Technology Platform. Based on high efficiency, this platform is able to prepare and biologically test new highly-complex chemical molecules. Other achievements include three patentable hits against breast cancer, nine patentable combinations with synergic effects against breast cancer, two patentable hits against prostate cancer, etc. The pre-clinical development phase of these products is set to start in 2012. Likewise, **IUCT** is part of the only healthcare project out of the seven projects awarded support in the INNPRONTA 2011 applications: "Comprehensive challenge against breast cancer, LIFE", seeking overall solutions for this disease from a diagnosis and treatment point of view, at a pharmaceutical and hospital level.

IUCT, LEITAT and the German SME, JPT Peptide TechnologiesGmbH (JPT) announced the creation of a joint venture for the co-development of an improved therapy against cancer, directed at developing new chemotherapy drugs that offer greater security and an improved efficacy profile.

Investigators at **Lipopharma** and the University of the Balearic Islands (UIB) have discovered a third basic requirement for a normal cell to become a tumour cell: it must have very low levels of sphingomyelin, one of the major components of normal cell membranes. **Lipopharma** obtained the Orphan Medicinal Product Designation from the EMA for Minerval® as a treatment for glioma. Minerval® is a novel investigational compound designed by the UIB and developed by **Lipopharma** for therapeutic use in cancer.

EntreChem, in collaboration with the Hospital of Valdecilla and the CIMA (Centre for Applied Medical Research), successfully tested its EC-70124 kinase inhibitor within a new strategy for glioblastoma, demonstrating activity in an orthotopic mouse model with patient cancer stem cells and with monitoring using advanced imaging techniques. The action mechanism is the inhibition of NF-kB, never described before in glioblastoma. Furthermore, with the collaboration of the NCI (National Cancer Institute, Bethesda, USA) **EntreChem** completed the DTP (Discovery Therapeutics Program) for the family of mithramycin analogs, with the conclusion that EC-8042 is one of the most potent molecules ever to be tested by this program, with a hollow fiber score of 66. This, together with the fact that EC-8042 is the least toxic mithralog of the family, makes it possible to substantially increase the therapeutic window with regard to mithramycin and has led to further collaborations with leading groups in the USA in the area of oncology.

NEUROSCIENCE

During 2011, **Noscira**, a company within the Zeltia Group, progressed in its Phase IIb Proof of Efficacy Trial with Nypta® (tideglusib), its first drug for the treatment of Alzheimer. This six month treatment study, performed on 309 randomized patients, was conducted in Spain, the United Kingdom, Germany, France and Finland. Preliminary results are expected by the end of 2012. Tideglusib has a novel action mechanism which, in experimental models, has shown some positive effects on the key pathological features of the disease.

Advancell and **Neurotec Pharma** commenced the Phase IIa clinical trial of NT-KO-003 on patients with multiple sclerosis. Pre-clinical trials have shown this drug to have anti-inflammatory and neuroprotective effects yet with no immunosuppression.

Neuron BioPharma published a scientific article in the Journal of Alzheimer's Disease in which Simvastatin is shown to be the best commercial statin for the prevention of neurodegeneration and that it has neuroprotective effects in animal models. The article also presented the progress made in the creation of a new experimental model to seek new anti-epileptic compounds through the use of the Zebrafish. Scientists from the **Centro de Investigación Médica Aplicada (CIMA - Centre for Applied Medical Research)** discovered the MMP-10 molecule, capable of dissolving stroke clots.

VACCINES

In 2011, RUTI, the first therapeutic vaccine against tuberculosis, developed by biotech company **Archivel Farma,** showed some positive immunological results in a Phase II clinical trial conducted in South Africa on 96 patients, half of which were HIV positive. The company expects to start the phase III trial in 2013, to be completed in 2015.

The HIVACAT program, a public - private international consortium of which **Esteve** is part, has identified a therapy that makes vaccines that have not previously worked in HIV+ patients, to be effective. This therapy is based on the growth hormone, which makes it possible to repair the immune system and could be used as a complement to a future HIV vaccine and also to improve the effectiveness of other already existing vaccines, for people with weak immune systems.

The **Ferrer Group** and Rovi joined forces to set up Alentia Biotech, a joint venture with headquarters in Granada and responsible for producing influenza vaccines for the Spanish and Portuguese markets. There are plans to construct a production plant in Granada.

DIGESTIVE

In February 2011 **Cellerix (now called Tigenix),** a leading company in cell therapy, presented some promising results for the IIa Phase trail of its drug Cx601, intended for the local treatment of complex perianal fistulas in patients with Crohn's disease. This is a product based on expanded adipose derived stem cells in adult tissue of allogeneic origin. This trial confirmed a good safety and efficacy profile in the patients assessed. On the other hand, the low immunogenicity confirmed in the tests conducted, provided some highly positive results, demonstrating the viability of the allogeneic platform.

OPHTHALMOLOGY

ProRetina Therapeutics, **GP Pharm** and BCN Peptides, agreed to form a consortium in order to develop formulations to vehicle drugs to the retina and to improve the patients' quality of life through the treatment of eye diseases such as retinitis pigmentosa and other types of retinal dystrophies.

Sylentis presented two studies at the World Glaucoma Congress 2011. These studies were based on its investigations with interfering RNA: the Phase I results with its more advanced product SYL040012 and the other study describing the 24 therapeutic targets for the treatment of glaucoma and optical hypertension using RNAi technology. Furthermore, it commenced Phase I trials with its new compound SYL1001 for the treatment of eye pain associated with dry eye syndrome. Additionally, Alnylam Pharmaceuticals granted **Sylentis** a non-exclusive licence option for a new therapeutic target within the InterfeRx™ program, which includes the R&D and marketing of an siRNA for the treatment of glaucoma. The project is currently in Phase I/II. The Spanish Medicinal and Healthcare Products Regulatory Agency granted **Sylentis** a pharmaceutical manufacturer's authorisation for investigational medicinal products.

BTI Biotechnology Institute, revealed the results of the study to assess the effectiveness of the application of PRGF®-Endoret® to ocular surface diseases that do not improve with other types of standard treatment (lubricants and steroids).

DERMATOLOGY

Digna Biotech recovered the rights to Disitertide (P144) for skin diseases. The market estimate for this medicine for cutaneous systemic sclerosis and localized scleroderma is more than 300 million Euros per annum. Digna Biotech is to share the potential revenue with ISDIN. The proof of concept in the Phase IIa study revealed some encouraging results in patients with systemic sclerosis. In view of these results, last year, the EMA provided advice to the company with regard to a protocol for the design of Phase IIb.

The Spanish Society of Community Pharmacy (Sefac), in collaboration with **Laboratorios Leti,** implemented the Atopic Dermatitis in Community Pharmacy (Dafac) project, which includes an in-depth epidemiological study of this disorder.

Ojer Pharma Laboratories started the clinical trials for a bio-adhesive gel to vehicle the antibiotic indicated for primary skin infections, such as impetigo, folliculitis and furuncles.

HEPATOLOGY

Digna Biotech announced that the Spanish Drug Agency (AEM) authorised the commencement of the first Phase I clinical trial with Cardiotrofina-I (CT-I) on healthy volunteers. Likewise, **CIMA** investigators demonstrated that CT-I is able to stimulate liver regeneration following a partial liver transplant, and also to protect the liver against ischemia - reperfusion injury. The EMA and the FDA have both granted CT-1 the Orphan Medicinal Product Designation for the prevention of ischemia - reperfusion injury asso-

ciated with the transplant of solid organs. Furthermore, the FDA has also granted CT-1 the Orphan Medicinal Product Designation for liver transplants.

The biotech company Hepacyl Therapeutics and the **CIMA** have signed an agreement for the Segovia-based company to conduct the pre-clinical and clinical investigation of the molecules discovered and patented by the Hepatology department of the **CIMA**.

RHEUMATOLOGY

Tigenix started the randomised recruitment for Phase IIa of the trial of its cell medicinal product for rheumatoid arthritis. It also received the green light to start Phase I of the Cx621 trial and to assess its safety (intra-lymphatic or intra-nodular administration of expanded allogeneic adipose stem cells) for the treatment of auto-immune diseases. The lymphatic route of administration is expected to offer considerable benefits due to the fact that the systemic effect of the cells occurs at the secondary lymph organs, the drainage lymph nodes and the spleen. **Tigenix** also announced the publication of some positive results for ChondroCelect® in the American Journal of Sports Medicine. This technique is based on the characterised chondrocyte implantation compared to the microfracture procedure for symptomatic cartilage defects of the knee and the study describes the clinical outcome after 5 years of the multi-centre prospective randomised trial to assess its safety and efficacy compared to the current microfracture technique.

New studies have demonstrated Plasma Rich in Growth Factors to be an effective treatment for knee osteoarthritis and also for corneal injuries that do not improve with traditional treatment. The Eduardo Anitua Foundation and **BTI Biotechnology Institute,** thus presented the latest advances in the treatment of knee osteoarthritis and eye injuries, thanks to the PRGF®-Endoret® application.

RARE OR MINORITY DISEASES

Digna Biotech and CIMA received funding for the Gene Therapy against Acute Intermittent Porphyria, as part of the EU FP7 Scheme for the Clinical Development of Orphan Drugs. Phase I/II was conducted in humans with the support of all the partners of AIPGENE.

IUCT received an award from the Fundació Mataró TV3 foundation, for its biomedical investigation project on myotonic dystrophy which proposes the identification and design of new molecules as future therapeutic agents through three combined strategies, including the design, synthesis and biological assessment of compounds.

Valentia Biopharma has obtained a patent for the exploitation of a new molecule for the treatment of myotonic dystrophy and is to start safety and efficacy tests on non-human models. The patented molecule discovered (abp1) is able to bind to the mutated gene, blocking the formation of a structure that hinders its correct expression.

NEW INFRASTRUCTURES, CERTIFICATES AND INNOVATIONS

Bionanoplus, a nano-biotech company opened its new facilities in Noain (Navarra), equipped with cutting-edge equipment to design and characterise nano-particulate systems applied to the pharmaceutical, cosmetics, agri-chemical and nutraceutical sectors. The company has also presented two patent applications covering its nano-encapsulation technology. As a result, **Bionanoplus** is already invoicing and developing products in collaboration with pharma companies.

In the Basque Country, **BIOEF, the Basque Foundation for Healthcare Research and Innovation,** has created three new units: O+Saik Tests for the co-ordination of Clinical Trials on Medicines and Healthcare Products in all the centres of the Osakidetza (Basque Healthcare Service); DEMOTEK, a Unit for the Demonstration of Innovative Healthcare Technologies and USITEC, Comprehensive Technology Transfer Services Unit.

In July 2011 the work commenced on the construction of the new plasma fractionation plant located at the industrial complex of **Grifols Engineering** (Parets del Vallès). The plant is to be equipped with twenty fully automatic process reactors and an automated line for the fusion of the plasma solution. The estimated investment of 20 million Euros is to create some 100 jobs and will be its firth plasma fractionation plant at a global level. **GP Pharm** was granted a Registration Certificate of Manufacturing Site by the Gulf Central Committee for the register of Drugs, valid for the next five years. The company is therefore able to produce medicinal products for Saudi Arabia, Kuwait, Bahrain, Qatar, The United Arab Emirates and the Sultanate of Oman.

In 2011, **3P Biopharmaceuticals** was the first Spanish CMO to receive GMP certification from the AEMPS (Spanish Agency for Medicines and Healthcare Products) and it extended the scope of its authorization as a manufacturer of active pharmaceutical ingredients. The certification, with a three-year validity, covers the following areas: the manufacture of commercial biological active substances, and those under research; the performance of quality controls; the batch release of drugs in research; and commercial drugs.

The **Granada Healthcare Technology Park** now has a new Animal Experimentation Unit, located at the Biomedical Research Centre of the University of Granada, making it possible to conduct cutting-edge biomedical research. The AEMPS has granted **Histocell** the Good Manufacturing Practices (GMP) certificate, required for the manufacture of advanced therapy biological products, thereby becoming a manufacturer and supplier of cells for clinical use and, more specifically, for the isolation and expansion of chondrocytes and mesenchymal stem cells. The **University of Navarra** is to open three new biomedical research centres, with 400 jobs. These centres will be focussed on Bioengineering, Neglected Diseases and Nutrition, with specific emphasis on Tissue Engineering, Biosensors, Bio-robotics, Imaging and Bio-computing.

Diagnostics products and services for human healthcare

The company **OWL** and the DEMOTEK Unit for the Demonstration of Innovative Technologies in Healthcare, are developing a project directed at assessing the diagnostic capacity and the predictive value of the diagnostic test for non-alcoholic fatty liver, through the use of a number of referral hospitals in the Osakidetza (Basque Healthcare Service), monitoring 200 patients. The service includes the possibility of extending the pilot trial to the healthcare systems in other European regions and which are currently collaborating with the Department of Health and Osakidetza.

In 2011, **INGENASA** developed a test to detect hydrolyzed gluten with the maximum sensitivity yet achieved (0,25 ppm).

Secugen presented its new gene test to predict the risk of suffering from Age-related Macular Degeneration (AMD), "Secugen AMD Test" which makes it possible to reliably and economically predict the probability of a person developing AMD.

AB-BIOTICS launched a new genetic analysis software version, Neurofarmagen®, able to predict the patient's response to the most common drugs for depression, schizophrenia, epilepsy and bipolar disorder. This new version includes the analysis of four new active ingredients, adding to the 35 already existing ones, and helps to reduce healthcare costs given the fact that it is ideal for patients who have not responded to a number of treatments, or who have experienced secondary effects with drugs or who, for a certain amount of time, have not benefited from the treatment.

Bioftalmik has developed an innovative, innocuous, biodegradable biomaterial which is applied to the vitreous to give a sharp on-screen image of the patient's retina. Also over the course of last year, it launched an on-line tool capable of managing orders for immunodiagnostic services, genetic and infectious diseases diagnostic services, and it has also developed a device to diagnose diseases through tears, including the monitoring of the evolution of the disease.

Brucellacapt®, by **Vircell**, gained recognition in scientific literature following a study on 211 patients in India, suspected of having brucellosis. The test results proved that the technique used was superior to other techniques. Furthermore, **Vircell** incorporated a new reference for the diagnosis of tularaemia in its immuno-chromatographic assay line; VIRapid® TULAREMIA (ref VR006), permitting the qualitative detection of total antibodies against Francisella Tularensis, in serum or plasma samples.

Biobide has developed a method which, using the Zebra fish model, measures the pharmacological efficacy of new drugs in the investigational phase, for the treatment of cancer. Specifically, the test makes it possible to detect the capacity of a compound to inhibit angiogenesis, a fundamental physiological process for the development of tumours in metastasis and involved in other pathologies such as diabetic retinopathy and psoriasis, amongst others.

CLART® EnteroBac is the new tool developed by **Genomica** which uses molecular biology techniques to diagnose the bacterial pathogens which cause infectious diarrhoea. In just five hours, it is possible to make a multi-diagnosis in one single essay, with no need for a prior stool culture or a sample pre-enrichment. Furthermore, starting directly from a blood culture, CLART® SeptiBac+ makes it possible to conduct a single multi-test for a wide range of Gram positive and fungi that cause sepsis. **Genomica**, also launched SAICLART® v1.0, its image processing software for microarrays. This company, which is part of the Zeltia Group, has obtained the marketing registrations for the CLART® products in Brazil, a milestone representing yet another step forward in its internationalization process.

Sistemas Genómicos created the diagnostic test to detect some of the principal cardiovascular genetic disorders, such as cardiomyopathies, channelopathies. Cardiogeneprofile is a highly innovative analysis model based on directed mass sequencing. Likewise, it developed GeneProfile®, a new mass gene sequencing method that makes it possible to identify new mutations associated with ovarian cancer and other hereditary tumours. **Biomedal** has studied the immunogenicity of pure varieties of oats, using T cells isolated from celiac patients. The results have made it possible to differentiate between those varieties of oats that are toxic to celiacs and other varieties that are potentially suitable, opening the way for the development of oat varieties that can be included in the gluten-free diet of celiacs.

Oryzon Genomics presented the results of what is to be its first own product on the market: GynEC-Dx. This is a new system for the early detection of uterine cancer, developed

together with Reig Jofré, and which is set to be launched in 2012. This product makes it possible to rule out the presence of a tumour in 97% of cases, based on a sample of uterine fluid taken by aspiration, thereby avoiding the need for biopsies and hysteroscopies. Furthermore, the company plans to launch a second product for the early diagnosis of bladder cancer, in Spain and Portugal.

GAIKER-IK4 has developed a portable test for the rapid detection of influenza. Point of Care, is a device that is highly sensitive in the automatic detection and typification of the various influenza viruses, including avian and swine flu, amongst others.

Proteomika signed a licensing agreement for seven antibodies of AbD Serotec, a division of MorphoSys, which it will implement in its Promonitor kits. For its part, AbD Serotec will receive royalties on product sales.

CICbioGUNE, **Owl Genomics,** MD Renal and Faes Farma patented a system to predict the hepatic toxicity of drugs, based on a set of molecules present in serum and able to detect and quantify hepatic toxicity non-invasively.

A research group attached to the **CIBERER** has published a genetic - molecular diagnostic protocol for the type 1 neurofibromatosis rare disease. Validated for excellent sensitivity (95%), it makes it possible to identify all types of variants making up the broad spectrum of mutations associated with this disease.

In 2011, **Pangaea Biotech** conducted 10,471 genetic tests and 3,116 check-ups for molecular pathology. These figures are a 40% increase on 2010. Likewise, it set in motion 20 internal R&D programs related to tumour cell technology to identify markers, pharmaco-genomics in lung cancer, nanotechnology, etc.

GENETADI Biotech has designed NeuroArray® a diagnostic test specifically intended for the neuro-paediatric medical sector and directed at identifying the genetic causes of idiopathic mental retardation and autistic spectrum disorders. This test is based on high-resolution Comparative Genomic Hybridization Technology (CGHT). Furthermore, with this technology, **GENETADI** has launched the Amnio-Chip®, an extended pre-natal diagnostic test that identifies 150 genetic syndromes in the amniotic fluid.

Biocomputing

The company **Era7** made one of the first functional annotations of the E.coli genome corresponding to the German outbreak. This was possible thanks to the "BG7" bacterial genome annotation method developed by its R&D&I department. The functional annotation is the step required to observe which genes and which functions are responsible for its pathogenicity and virulence.

Integromics announced a new SeqSolve ™ NGS software version, an advanced, intuitive solution for next-generation ultra-sequencing data analysis.

NorayBio took part in the European Bioledge project, directed at developing biocomputing platforms related to modelling in order to support the biotech application in the area of protein production.

Biomol-Informatics co-ordinated the INNPACT DIGEN-1K project entitled "Experimental Development of a Genetic Diagnostic System and the Identification of Pathogens through Genome Sequencing".

Animal Health

INGENASA in partnership with CISA-INIA, has developed the first test specifically designed to detect the antibodies for the African Swine Fever (ASF) virus, for direct use in the field. This is the first test that offers a reliable "on the spot" diagnosis in just 10 minutes.

Neiker-Tecnalia took part in the European Project AWIN Animal Welfare Indicators to improve the welfare of production animals. The basic objective was to design protocols to assess the welfare of sheep, goats, horses, donkeys and turkeys, with particular emphasis on determining any potential pain indicators in these species. The company also conducted a study on the epidemiology and diagnosis of infection for the Maedi Visn virus, in the various Spanish sheep farming systems.

Bionaturis acquired, through the University of Granada, the marketing rights of what would be the first prophylactic vaccine against gastro-intestinal parasitic infections in livestock farming. At the same time, it acquired the rights to a recombinant vaccine candidate for the prevention and treatment of canine visceral Leishmaniasis, developed by the López-Neyra Institute of Parasitology (CSIC).

6

Agrifood or green biotechnology

Agriculture

According to the "Annual Report on the global status of commercialised genetically modified crops in 2011" published by the International Service of the Acquisition of Agri-Biotech Applications (ISAAA), the global surface area with biotech crops reached 160 million hectares in 2011, representing an increase of 8% over the previous year, with 12 million more hectares planted.

Spain occupies the seventeenth position, with 97,326 hectares of corn crops resistant to Lepidopteran pests, one position less than last year despite having increased plantation by 20,751 hectares, 27% more than 2010 according to figures from the Ministry of Agriculture, Food and the Environment.

With regard to the developments by Spanish entities in 2011, investigators from the Basque Institute of Agricultural Research and Development, **Neiker-Tecnalia**, in collaboration with the University of the Basque Country, were able to find genetic material resistant to the pathologies known as "shoot wilting" and "resinous canker", thereby opening up many possibilities of using genetic improvements to develop trees that are not affected by these diseases.

Neiker-Tecnalia is leading a number of projects focused on developing new varieties of potatoes, and on improving existing ones, so that they are resistant to the effects of climate change, and on obtaining high quality starch by using new genetic improvement tools. It is also working on the development of new biotechnological tools for use in reforestation schemes.

Functional food

According to the latest study on innovation conducted by SymphonyIRI, the functional food market has remained stable over the last two years, achieving sales of 2,900 million Euros in October 2011, with a mass market share that is slightly above 7%, and sales up by 2% over the same period in 2010.

In this area, the European Patent Office (EPO) issued a favourable report on the international patent application filed for AB-LIFE, a functional ingredient of **AB-Biotics** which is able to reduce cholesterol levels by 14%, according to clinical studies conducted by the Puerta del Hierro Hospital in Madrid.



Graph 18 Global area of biotech crops. Source: Clive James, 2011

Within the framework of the CENIT-SENIFOOD project, and in partnership with the Institute of Agrochemistry and Food Technology of the **CSIC** (Spanish Council for Scientific Research) the company **Biopolis** has developed an effective probiotic for celiac disease. The probiotic has an anti-inflammatory response that opposes that exercised by the celiac disease and it also degrades the gluten peptides responsible for this pathology.

IUCT has achieved the first products obtained in fermentation processes that meet the desired functional expectations. Specifically, these are some new, high molecular weight expolysaccharides obtained through the fermentation of halophilic bacteria. One of the great advantages of these products is that they are not pathogenic, being based on the fermentation of extremophilic microorganism.

The Regional Government of Andalusia, the University of Granada (UGR) and the **Healthcare Technology Park (HTP)** are working in partnership to create food capable of improving health. The objective is that the HTP should provide the location, laboratories and machinery required, whilst the UGR provides the investigators and the Regional Government co-ordinates this public initiative directed at attracting private investment and involving the Andalusian Agrifood sector.

Laboratorios Leti launched BioMilk, a natural supplement that guarantees tolerance to milk and dairy products.

NEIKER-Tecnalia obtained nutritional biomolecules from algae, for use in the food sector (milk, bread, tuna, juices and vegetable purées).

Neuron, through its Innofood by Neuron brand, and Hacienda Señorío de Nevada, have started a joint investigation to seek autochthonous yeasts from Granada to enhance the unique properties of wine.

LAIMAT has developed new technologies for the microencapsulation of ingredients. For example, to facilitate the handling of dense and/or oily food ingredients, increasing stability during handling, transport, storage and against environmental factors.

The company **Alga Energy** launched ALGAEPISCIS and ALGAECARE, micro-algae with a high protein content and polyunsaturated fatty acids (PUFAs) type Omega 3, carotenoids, and with a high antioxidant power.

Technologies for food control and quality

Espadafor has developed a R&D&I project, in partnership with the Industrial Technology Development Centre (CDTI) and using the analysis tools of **Ingredientis Biotech** for the complete or partial replacement of natural colorants by their artificial equivalents, in the soft drinks manufactured by Espadafor.

The MoniQA Network of Excellence (Monitoring and Quality Assurance in the Food Supply Chain), which now comprises more than 500 international experts from a number of entities, including **GAIKER-IK4,** has the goal of harmonising, at a European level, the rapid analytical methods which, when integrated into Information and Communication Technologies (ICT), make it possible to guarantee and control food quality throughout the food chain, right from primary production up to the end consumer.

LAIMAT has created a new department to promote the development of its SEBIMAT line of sensors for the control of food safety. The first sensor developed is to quantify the levels of histamine in fish and is a considerable improvement on the performance of the usual analysis kits available on the market.

Investigators from the University of Jaen (UJA) have set in motion the design of a diagnostic kit based on molecular biomarkers. This will make it possible to have advance information on the changes occurring in an olive tree infected by Verticillium dahliae, responsible for the verticillium of the olive tree, and p. megasperma. **Biomedal** is to participate in the development and subsequent manufacture of the kit.

Additionally, **Biomedal** has launched GlutenTox Pro, a fast gluten detection kit for food, drink and surfaces, and which is particularly suitable for industrial kitchens, restaurants, school dining rooms, catering, etc.

For its part, **Biomar** launched a system for the detection of antibiotics in milk, a system which combines HPLC technology (high performance liquid chromatography) with MS/MS (mass spectrometry) and exponentially increases the sensitivity of the technique.

Bosques Naturales completed the test on black aphid control, through the use of naturally-sourced biocides, such as chrysanthemum flower extract or the essential oils of citrus fruits. Finally, Salvia Biotech has designed a service to detect the strain "0104H4" of the Enterobacteriaceae Escherichia coli, often related to food poisoning.


mL 0
±5%
50
100
300 mL
±5%
250
200
150

7

Industrial or white biotechnology

Biotechnology applications for energy production

With the incorporation of petrol stations selling e85 in the cities of Santiago de Compostela, Miranda de Ebro and Barcelona, there are now 21 petrol stations selling e85 in Spain. These three petrol stations sell a mixture of bioethanol and petrol at 5%, 10% and 85%, thanks to the investment made by **Abengoa Bioenergía.**

The Cenit I+DEA project headed by **Abengoa Bioenergía Nuevas Tecnologías (ABNT),** has been successfully completed in 4 years. The project involved a total of 25 companies and 27 research centres, and had a budget of more than 27 million Euros. The scope of the project included the complete bioethanol cycle, right from the production of raw material to biotechnology developments (energy crops and enzymes) and transformation technologies, including their use in combustion engines. The scientific and technological network of excellence generated by the consortium has given rise to a number of R&D projects at a national and European level, such as Cenit BioSos, 7PM LED, Cenit SOST-CO2, DemoE2, BIOCAT2ndOL, SORGOSWEET, etc.

Furthermore, **Abengoa** was the first company in Spain to implement the sustainability certification system for an agricultural production chain, Leonesa Astur de Piensos (Lesa) in compliance with the RBSA standard. This Standard, approved by the EC in July 2011, permits the marketing of biofuels certified as "sustainable" in all the Member States of the EU. Developed within the framework of the Directive to Promote Renewables, the RBSA Standard serves to demonstrate compliance with the requirements of this Directive, with regard to any raw material or production process, right from the agricultural production up to the marketing of the biofuel, including the industrial processing processes.

In 2012 **Repsol** signed an agreement with the company **Neuron Bio** to purchase a 50% holding in the company Neol Biosolutions, constituted through the segmentation of the bio-industrial division of Neuron Bio. The contribution of both companies will make it possible to accelerate the scaling up of the production process to obtain advanced biofuels, previously developed by Neuron. Neol is to continue to develop pioneering biotechnology throughout the world, for application to the energy sector, offering numerous synergies with the **Repsol** biofuel projects.

On the other hand, a Spanish consortium, headed by the technology company **AlgaEnergy** and which counts on the collaboration of the Ministry of Development, **CSIC**, AENA, **Repsol** and Iberia, is testing at an experimental plant of the Barajas Airport (Madrid) the production of biofuels from micro-algae crops.

The aim is to achieve the accelerated cultivation of two types of micro-algae (Anabaena and Murielopsis) which, based on their richness in fatty acids, are suitable to become the raw material for the production of bio-kerosene for aviation. The centre is to be dedicated to the research, experimentation and improvement of the technologies to harness C02, in this case coming from the Iberia reactors. **Repsol** is to transform the biomass oils obtained with the micro-algae into biofuel. Finally, Iberia is to test this in its planes and the initial results are expected to be available after a five year trial period.

At the end of 2011, **IUCT** commenced the 2g-biofuel project in partnership with the organic chemical centre "Costin D. Nenitescu", CCO and the company ICPAO Medias. 2g-biofuel is directed at obtaining the biofuel **IUCT**-S50 patented by **IUCT** through the available technical improvements, in addition to the construction of the first **IUCT**-S50 pilot plant around the year 2015.

Likewise, **IUCT** has developed a new product based on renewable energy sources, to be used as a biofuel for boilers, with improved properties compared to diesel and fuel oil (currently being used) and the commercial biofuels used today as an alternative. The most noteworthy properties include the fact that there is no need to pre-heat for ignition, as in the case of many of the above mentioned products.

NEIKER is working on some pioneering heating systems based on natural biomass sources and sustainable devices in the form of thermodynamic panels, which make it possible to control the greenhouse temperature in a more economical, environmentally-friendly way. In addition, these systems help increase the energy efficiency of the crops by up to 90%, meaning that only 10% of the energy generated is lost. This system is completed with a biomass boiler powered by a number of organic residues, such as almond shells, tree trimmings, or pellets - sawdust pellets, shavings and other scraps from the wood sector, in the form of pellets. This dual energy device is directed at making it possible to produce tomatoes and peppers all year round.

GAIKER-IK4, in partnership with Ekotek and Factor CO2, an Environmental Industry Cluster (Aclima), Transport and Logistics Cluster and Leia-Tecnalia, have developed a fuel life cycle analysis tool, which also offers the possibility of checking the environmental, social and economic impacts of these fuels on transport. The tool developed allows the managers of large transport fleets, fuel distributers and marketers, and the Administrations, to select the most sustainable biofuel.

Biofuel plants and centres

Abengoa Bioenergía Brazil has commenced the construction of a new mill at Fazenda São Luiz in Pirassununga. The project consists in the replacement of the present mill with a processing capacity of 620 TCH (tons of cane/hour) with a new one which has a capacity to grind 750 TCH (tons of cane/hour). Likewise, this substantial increase involves improving the evaporation system of the extracted juice, by installing 4 new evaporators and 7 new tubular heaters.

Furthermore, Abengoa is commencing the construction of a second-generation commercial-scale ethanol plant, located in Hugoton, Kansas. Abengoa was granted permission last September and immediately started the plant construction work. The construction period is expected to last some 24 months, during which time it is calculated that some 300 direct jobs will be created in the area. Once the plant has been completed, it is to have a production capacity of some 100 million litres per annum of clean, sustainable cellulosic ethanol, and is to create a further 65 jobs during the operating period.

Neuron BioIndustrial acquired a pilot fermentation plant which is to be used to scale-up the various processes under development. The plant makes it possible to cultivate micro-organisms in volumes of more than 400 litres/batch. In addition, the plant is also equipped with all the technologies required for biomass recovery and drying and the extraction and purification of the bio-products obtained. The pilot plant and other equipment is to be provisionally installed in the Technology Estate of Ogíjares, on a 380 m2 site. Its final location is to be the new Neuron Bio headquarters (currently under construction) at the **Health Science Technology Park of Granada.**

Bio-processes

Bosques Naturales is studying the application of the micro-propagation technique to a number of walnut tree species, a biotechnology technique used for plant reproduction. The key advantage of this system is that the plant obtained has the same genetic characteristics as the parent plant and it is therefore possible to propagate trees with desirable characteristics, from a forestry and industrial point of view.

The company **Clean Biotec** has concluded the "Sorbent" project, which is part of the Benefit scheme for the SME of the 7th Framework Program, directed at developing and validating a new bioremediation technique for soils contaminated with petroleum. With regard to the results obtained, particular mention should be given to the optimisation of processes and the obtaining of two microbial strains which are more active in the degradation of petroleum hydrocarbons.

GAIKER-IK4 and the Calcinor Group have developed a system for the re-use of waste water sludge, with sanitary guarantees.

Biopolymers and Bioplastics

The company **Neuron BioIndustrial** presented TriBioPlast®, an alternative in the production of bioplastics. These bioplastics (Polyhydroxyalkanoates) are produced from cultures, under specific conditions, from strains selected for their ability to produce and accumulate more than 50% of their dry weight in the form of bioplastics.

GAIKER-IK4 is taking part in an international project for the development of active containers with anti-microbial and anti-oxidant properties, headed by the Technology Institute of Sonora- Mexico. The goal is to extend the useful life of packaged food by preserving its original properties. The molecules are chitosan and astaxanthin, which are anti-microbial and anti-oxidant, respectively.

IUCT is developing a biomaterial with anti-oxidant and emulsifying properties for applications in the cosmetics industry, based on the anti-oxidant properties of the extremophilic microorganisms. These are new exopolysaccharide products obtained from halophyte bacteria present in highly saline conditions in Spain.

8

Financial environment

Among the major financial operations carried out during 2011 in the biotech sector, we should highlight **Cellerix** that achieved 18 million Euros, **AB Biotics** completing a capital increase of 4 million Euros at the end of the same year and the Zeltia Group company, **Noscira**, with a capital increase of 4 million Euros.

According to the latest data published by the Private Equity & Venture Capital Association (ASCRI), the volume of investments in the biotechnology sector has increased 16.8% on the previous year, going from 32.7 million Euros in 2010 to 38.2 million Euros in 2011. This contrasts with the overall data on investments made by the risk capital in any sector that drops to 8.21%. The number of operations in the biotech sector has also increased by 17.5%, going from 97 in 2010 to 114 operations in 2011.

The most outstanding merger of the year took place between **Tigenix** and **Cellerix**. The merger agreement was reached after increasing **Cellerix's** capital by 18 million Euros and after **Tigenix** managed 15 million Euros through a public share offer. With this operation, it was possible to combine the **Tigenix** product portfolio and their stem cell platform in pre-clinic phase with **Cellerix's** product portfolio and the platform based on allogeneic cells in clinical development.

In February 2011, a third biotech company made its debut on the market: EuroEspes based in Bergondo (La Coruña). At the start of 2012, the Andalusian company, **Bionaturis**, joined MAB, becoming the fourth company in the biotech sector listed on this market. The company's listing system worked through 'fixings', a system that fixes prices by converging offer and demand in two daily fixing periods. On the first day of listing, 26th January, shares rose 2.2%, to 2.30€ per share. With this start, Bionaturis wants to increase its sales five-fold and become a benchmark platform for developing bio-drugs.

Public financing. International programmes

European Union Framework Programme

Provisional results are shown below for Spanish participation in areas more directly related to biotechnology in the 7th Framework Programme (FP7) and fundamentally projects within the Health and BIO/KBBE programmes, the specific Cooperation area. There were a total of 26 biotechnology projects within the Health and Bio/KBBE areas with participation from Spanish entities. The funding

TABLE 7 Provisional results from Spanish participation in FP7 in the biotech sector. Source: CDTI

	Health areas				BIO/KBBE areas				TOTAL 2011			
Adjudication year: 2011	Activities		Subsidy		Activities		Subsidy		Activities		Subsidy	
Type of entity	No.	Led	Euros	%Total ES	No.	Led	Euros	%Total ES	No.	Led	Euros	%Total ES
PUBLIC ADMINISTRATION	1	0	694,903.00 €	7.6%	0	0	- €	0.0%	0	0	694,903.00 €	4.6%
ASSOCIATION	1	0	254,711.00 €		0	0	- €	0.0%	0	0	254,711.00 €	1.7%
RESEARCH ASSOCIATION	2	0	1,259,620.00 €	2.8%	1	1	477,988.00 €	7.8%	3	1	1,737,608.00 €	11.4%
INNOVATION AND TECHNOLOGY CENTRE	0	0		13.8%	2	1	733,555.00 €	12.0%	2	1	733,555.00 €	4.8%
PUBLIC RESEARCH CENTRE	2	0	1,161,892.00 €	0.0%	3	1	1,782,066.00 €	29.1%	5	1	2,943,958.00 €	19.3%
COMPANY	4	0	4,504,434.00 €	12.7%	5	0	1,521,687.00 €	24.8%	9	0	6,026,121.00 €	39.5%
UNIVERSITY	**2**	**0**	**1,260,200.00 €**	**49.3%**	**5**	**0**	**1,615,730.00 €**	**26.4%**	**7**	**0**	**2,875,930.00 €**	**18.8%**
TOTAL	**12**	**0**	**9,135,760.00 €**		**16**	**3**	**6,131,026.00 €**		**26**	**3**	**15,266,786.00 €**	

commitment for these 26 projects exceeds 15 million Euros. Compared to 2010 data, an increase has been seen in both the number of projects, going from 14 to 26, and the amount of the funding, from 5.6 million Euros to 15.2 million Euros. Business stockholding has also increased. Whilst there was only one company in the health area in 2010 and 3 in the Bio/KBBE area, by 2011 there were 4 in health and 5 in Bio/KBBE.

Public financing. National programmes

National Innovation Strategy Programmes E2i

INNPACTO programme: This aims to bring about cooperation projects among research organisms and companies to jointly carry out R&D&I projects that help to strengthen innovative work, mobilise private investment, generate employment and improve the country's technology balance. In 2011, a total of 38 INNPACTO projects were approved, in both the biotechnology area and strategic health and energy action. These projects mobilise a 66.7 million Euros R&D&I budget and funding of just over 50 million Euros. Comparing it with the previous year, the number of projects remains practically the same (34 projects in 2010), the budget has decreased from 72 to 66.7 million Euros and the amount of the funding has dropped from 57 to 50 million Euros.

INNPLANTA programme: This programme awards funding to facilitate set up or improvement of scientific-technological infrastructures intended for R&D&I activities, for entities set up or in the process of setting up in science and technology parks and to support purchasing scientific-technological equipment to carry out R&D&I activities by entities on science and technology parks.

INNOCASH programme: This programme identifies, assesses and matures technologies and R&D results generated, above all, by Public Research Centres, so that they can be transferred to the market via innovation projects boosted by industrial and financial investments.

INNCORPORA programme: This aims to support and reinforce contracting qualified staff to be able to stimulate knowledge and technology transfer to the production sector and promote business innovation.

INNPRONTA programme: This is aimed at financing major, strategic, integrated, industrial research projects, with large dimensions that allow new technologies to be developed in future technological areas with international economic and commercial projection.

In 2011, CDTI approved two INNPRONTA projects in the biotechnology field, committing 28 million Euros and 33 million Euros from the total budget. These two projects are called LIFE (improving health care for patients by applying and developing new techniques and products) and INCOMES (developing a standardised methodology to scientifically approve healthy and functional food and ingredients).

Programmes from the Centre for Industrial Technological Development (CDTI-MINECO)

Direct financing: Returnable or partially returnable funding.

In 2011, CDTI committed 48 million Euros by means of returnable and partially returnable funding with an interest rate of 0%, to R&D business initiatives (including individual R&D projects and individual operations resulting from Consortium projects, NEOTEC funding) related to the biotechnology field, independently of the application sector for the results obtained. The total investment mobilised by the projects supported by CDTI is 65 million Euros.

ASEBIO recommendations

ASEBIO has achieved one of the measures historically acclaimed by business owners: maintaining SME exemption from guarantees and endorsements, at least until 2013. In addition, ASEBIO considers that it is particularly important to increase Spanish representation in the biotech field in the different committees/areas of influence designing topics for the 7th Framework Programme and Horizon 2020, also boosting Spanish entities' access to European funding. Another field of work for ASEBIO involves promoting innovative public purchasing, along with the Ministry of the Economy and Competitiveness, CDTI and different Autonomous Communities. In this respect, ASEBIO reminds us of the need to make progress in other lines of promoting innovation from demand or creation of early technology demand programmes that combine the administration's medium term needs and allows the biotech sector to anticipate them. On the other hand, another priority aims to implant mechanisms that facilitate liquidity for fiscal loans generated by companies and allow them to be anticipated at the point when companies might most need financing, without having to wait for the company to turn a profit, as already seen in countries such as Great Britain, France and Ireland.

9

Internacionalization

The Spanish biotechnology sector is a young sector, existing for a mere 15 years. However, and as opposed to other production sectors in the Spanish economy, internationalization forms part of its DNA as the success of biotech companies depends to a large extent on their capacity to export their products, establish joint projects and technology exchange agreements and obtain international financing.

Since 2000, ASEBIO has been identifying priority factors for sector development plus inhibiting factors. In both sections, internationalization has gone from an aspect perceived as secondary to become a factor easing sector development (5th place in the ASEBIO index this year). In addition, it is no longer considered as one of the main inhibiting factors, although nowadays internationalization is perceived as a complex process to be developed.

Despite this perception, internationalization has been chosen by companies associated with ASEBIO as their main strategic priority for the third year in a row.

The data compiled in this Internationalization section comes from the Association's internal data and the annual survey on the sector's internationalization run among ASEBIO's members.



Graph 18. Evolution of Internationalization as a facilitating factor in the ASEBIO Index* (2000-2011). A higher score indicates a more favourable perception

ASEBIO 2011 Internationalization Survey

The survey's main conclusions on company internationalization during 2011 are given below, using the survey run by ASEBIO among its associates for the fourth year running.

86% of ASEBIO members carried out some kind of international activity in 2011, a similar figure to 2010 (88%).

Among the main international activities carried out, exporting products and/or services takes first place, with 58%, followed by alliances and collaboration in research (first place in 2010 with 70%) and participation in the 7th European Framework Programme.

Main international activities carried out by ASEBIO members in 2011 (% over the total answers obtained):

Exporting products/services 58%

Alliance/Research collaboration 42%

7th Framework Programme 42%

Licensing out 21%

Representation office 13%

Sales Offices 10%

Eureka/Iberoeka/Canadeka programme 10%

As in 2010, 50% of companies had a specific department or staff for internationalization, representing 18% of entities' total employees.

In 2011, the main destination countries for the associates' exports were once again European countries (mainly and in this order: France, Germany, United Kingdom, Italy, Switzerland, Portugal and Benelux) and USA. In addition, exports to Latin America (particularly Brazil and Argentina) and Asia (China, India and Japan) were higher than in previous years.

Regarding companies' priority markets in their internationalization strategy, Brazil, the Southern Cone and India are becoming more important, although the EU and USA remain more relevant.

90% of our members consider that the main obstacle to the internationalization process is a lack of economic resources, with scarce specific training in internationalization coming in a poor second.

Regarding activities related to internationalization, 71% of ASEBIO members estimate that partnering events are very useful or essential, followed by participation in fairs, direct sales assignments, BioSpain 2012 and training in internationalization. Among the training activities that would be the most interesting, we can mainly highlight market prospecting and international negotiation.

According to the survey, 90% of inexperienced companies name internationalization as their short term priority aim. Member companies that so far have not gone down this road state this is because they are still young companies preferring to consolidate their work in Spain before opening up to other markets. The types of activities preferred by these companies to be developed abroad in the future mainly involve exporting their products and/or services, followed by joint projects and/or alliances in research and technology transfer.

Finally, 78% of associates are aware of the activities and funding for internationalization promoted by ASEBIO and 61% have participated in some of them.

Implantation abroad

Another year on, ASEBIO associated companies continue their strong international expansion, boasting 90 subsidiaries, branches or offices of representation in 30 countries and 5 continents.

TABLE 9. International presence of ASEBIO associate companies by number of subsidiaries / branches / representation offices

Geographic Area	2010	2011	% Variation
European Union	29	37	28%
Africa	2	1	-50%
Asia/Pacific	11	11	=
North America	13	18	38%
Latin America	22	18	-18%
Middle East	4	5	25%

The geographic presence of ASEBIO associate companies abroad is concentrated in the EU (41% of the total), Latin America and USA (each 20% of the total). Asia/Pacific (12%), Middle East (6%) and Africa (1%) complete the list. We should highlight the significant increase in our companies' presence in two of the world's most important biotech sector markets: United Kingdom, where its presence has tripled going from three to nine companies and USA going from 13 to 18 companies set up in this market.

The list below includes the associated biotech companies and companies where they have a representation office / subsidiary / sales office.

Abengoa Bioenergía: USA, Brazil, France, Germany, Holland, United Kingdom

Alphasip: USA

Biokit: USA

Biotools: Brazil

BTI Institute: USA, Mexico, Portugal, Italy, Germany, United Kingdom

Esteve: Germany, China, USA, Italy, Mexico, Portugal, Sweden, Turkey

Eurosemillas: Poland, Turkey, China, Chile, Japan, Angola, USA

Genetadi: Mexico

Genetrix: Sweden

Genhelix: Japan

Grifols: Czech Republic, Germany, Argentina, Australia, Mexico, Colombia, Switzerland, Sweden, Singapore, Brazil, Chile, Slovakia, USA, France, Malaysia, Thailand, Italy, Japan, Poland, Portugal, United Kingdom.

Grupo Farmasierra: Portugal

Ingeniatrics: USA

Integromics: USA

Intelligent Pharma: Germany, United Kingdom, USA

Laboratorios Leti: Germany, Portugal

Lipopharma: USA

Neocodex: USA

Neuron Bph: USA

Neuroscience Technologies: United Kingdom

Noray Bio: Italy, France, United Kingdom

Pharmamar: USA

Probelte: Mexico, Dominican Republic, Brazil, Poland, Jordan

Progenika: USA, Mexico, UAE, United Kingdom

Sinoptia: USA, China

Suanfarma Biotech: USA, Venezuela, United Kingdom, Mexico, China, Colombia, Brazil

Thrombotargets: USA, United Kingdom.

International alliances

International alliances represent one of the most important aspects in internationalization for biotech companies. Through these alliances, the companies and institutions minimise the risk and access resources, knowledge and new technologies more easily.

31 ASEBIO companies and institutions (7% more than 2010) signed 48 international alliances in 2011, upholding the record of alliances attained the previous year. This statistic includes any type of formal agreement between at least one Spanish biotech company or Institution and any other international entity that implicates an explicit commitment to meeting all types of common objectives (R&D, production, sales, etc.).

86% of alliances are signed with companies/institutions from Europe (65% of the total) or North America (21% of the total). The remaining alliances are forged in Asia (13%) and Latin America (2%). These alliances featured companies from Andalusia (25%), Catalonia (23%), Madrid (19%), Basque Country (13%) and Navarra (8%).

ICEX Internationalization Plan for the Biotechnology Sector 2011

The Internationalization Plan mainly revolves around three lines of work: product, service or technology sales/licensing, technological collaboration with foreign partners and search for financing to make progress in the R&D&I process. The main instrument used is "partnering". The partnering system consists of using a computer tool to establish a contact book prior to developing the event.

Since 2009, the partnering events that have been included in the sector-based plan are specific for the biotech sector. In addition, the plan has compiled two complementary assignments to the sector's main event in Spain, BIOSPAIN, itself one of the seven largest biotechnology partnering events in the world.

Finally, the plan has been recently completed with the introduction of specific investor forums for the sector, such as BioEquity in Paris or Biotech Showcase in San Francisco.

All these actions have represented awarding over 250 travel grants since 2008, directly benefiting over 100 Spanish companies, many of them large and well prepared enough to work abroad.

The 2011 Internationalization Plan included the following activities, with a total of 100 travel grants for companies:

BIOPARTNERING NORTH AMERICA 2011: 27 Feb-3 Mar, Vancouver, Canada.

BIO EUROPE SPRING 2011: 14-16 Mar, Milan, Italy.

ILSI BIOMED 2011: 23-25 May, Tel-Aviv, Israel.

BIO EQUITY EUROPE 2011: 23-24 May, Paris, France.

BIOPHARM AMERICA 2011: 7-9 Sept, Boston, USA

BIO EUROPE 2011: 31 Oct-1 Nov Düsseldorf, Germany.

FORO ABU DHABI: 15-16 Nov, Abu Dhabi, UAE

BIO INTERNATIONAL CONVENTION 2011: 27-30 Jun, Washington, USA.

17TH TECHNOLOGY SUMMIT & TECHNOLOGY PLATFORM: 22-24 Nov, New Delhi, India.

INTERNATIONAL INTER-COMPANY: This ASEBIO project (2009-2011) supported by CDTI within the National R&D Internationalization Programme. The aim of the project was to promote the Eureka/Eurostar programme, the first of its kind dedicated exclusively to European SMEs to boost collaboration for research and innovation, promoting participation from biotech companies.

APPENDIX 1:
WHO'S WHO? ASEBIO MEMBERS

Business Partners

3P Biopharmaceuticals

Dámaso Molero
General Manager
dmolero@3pbio.com

Adress: Polígono Mocholí, C/ Mocholí nº 2 Noain - Navarra

Phone: 34 948 346 480
www.3pbio.com

3P Biopharmaceuticals is a Contract Manufacturing Organization (CMO), specialized in the development and manufacture of biologics and cell therapy products for pre clinical and clinical trials and commercial stages.

GMP certified by the AEMPS (Spanish Medicines and Sanitary Products Agency): API for clinical trials and commercial. QC and release of medicinal products for clinical trials and commercial.

Our main services are: Manufacture of biologics. Proteins.

Recombinant proteins, native proteins, monoclonal antibodies, fusion proteins.

Vaccines. Biosimilars.

Another biological molecules: Peptides, Lipds, Carbohidrates, Complex molecules, Manufacture of cell therapy products.

Advanced Therapy Medicinal Products: Cell therapy products. Tissue engineered products.

Intermediate products: Cell culture media. Biomaterials (scaffolds or membranes).

Target areas for futures collaborations/alliances:

- Development and manufacture of biological molecules for therapeutic, diagnostic, esthetical and other industrial uses.
- Participation in collaborative National and European Projects.
- Development and manufacture of biosimilars.
- Development of industrial processes.
- Development of bioproduction technologies and platforms.

AB BIOTICS S.A.

Miquel Angel Bonachera / Sergi Audivert. CFO
info@ab-biotics.com

Address: Parc Cientific i Tecnologic Universitat de Girona. Edifici Jaume Casademont B8 C/ Pic de Peguera, 15 – 17003 - GIRONA

Phone: 34 902 903 844
www.ab-biotics.com/

Research, development, protection and distribution of our own biotechnological solutions, makinga contribution to improve people health and wellbeing.

AB-Biotics has three business divisions:

FUNCTIONAL INGREDIENTES develops probiotics and other nutraceuticals for the pharmaceutical and food sectors. Among them AB-FORTIS (cognitive development of children) AB-LIFE (improvement of cardiovascular health) and AB-I3.1 (a probiotic for IBD/IBS).

AB-GENOTYPING develops genetic analyses for conducting pharmacogenetic studies. One of them is Neurofarmagen, already in the market. It is a DNA chip that enables the assessment of the patient's predisposition to respond to the drugs most widely used in treating depression, schizophrenia, bipolar disorders or epilepsy.

R+D PARTNERING offers the pharmaceutical and food industries the comprehensive management of research projects, based on obtaining unique, patentable biotechnological solutions with high added value.

AB-BIOTICS is interested in developing biotechnological products for human health. Our main objectives are functional genomics and nutraceuticals. We are always open to set up synergic partnerships with other companies in order to jointly develop new solutions.

ABBOTT LABORATORIES, S.A.

Address: Avenida de Burgos, 91 Madrid - Madrid

Phone: 34 91 337 5200
www.abbott.es

All that concerning or linked to pharmaceutical products, nutritional, diagnostic, molecular diagnostic, vascular devices, diabetes, optics.

Import, buying and selling, export, manufacture, production, transformation, operation, distribution, and marketing retail of any type of raw materials, products and chemical preparations, diagnostic products, veterinary products, biological products, pharmaceutical products, including any pharmaceutical specialty, foodstuffs products, dietary products, cosmetic products, hospital specialty products, produced or semi produced, and others in general, concerning healthcare.

ABENGOA BIOENERGIA

Abengoa Bioenergy

abengoabioenergy@abengoa.com

Address: Paseo de la Castellana, 31 - 3 Planta Madrid – Madrid

Phone: 34 91 319 70 70
www.abengoa.com

Abengoa Bioenergy is a biotechnological company that contributes to sustainable development through the production of cheap sugars from starch and sugarcane. By means of fermentative processes that make possible a net reduction of contaminating emissions, Abengoa Bioenergy currently places on the market transportation fuels obtained from renewable resources.

The mission of Abengoa Bioenergy consists of:

- Contributing to the sustainable development of the fuel and biochemical market by means of green technologies that reduce carbon emissions.
- Develop innovative technological solutions through continuous investment in R&D.
- Create value for our shareholders.
- Contribute to the personal and professional development of our employees through continuous training and the establishment and monitoring of individual development plans and goals.

Abengoa Bioenergy is a leader in the development of new technologies for the production of biofuels and other bioproducts through biotechnology and sustainability of raw materials, thus devoting a large amount of resources to research work.

The activities of the company are included in the following main areas:

Procurement of raw material: Abengoa Bioenergía has managed to acquire great experience in procurement and appropriate logistical handling of raw materials, thus ensuring the supply of all plants of the business group.

Production: Bioethanol is produced in the plants of Europe and United States from cereal grains. As a co-product, the so-called DDGS, whose high protein content makes it suitable as livestock feed, is obtained.

Trading: AB Trading, devoted to the worldwide trading and export of our products, owns offices in Rotterdam (The Netherlands), St. Louis (USA) and São Paulo (Brazil).

New technologies: Abengoa Bioenergy in-house engineers and scientists, working together with research centers, universities and other industrial partners, develop innovative processes to increase ethanol yield from starch, improve quality of co-products and develop the technology of lignocellulosic biomass for production of bioethanol and other bioproducts through biotechnology. As a part of its business strategy, it develops and registers the Company's intellectual property rights in order to provide technology to third- parties under management agreements.

AD.TECH IBÉRICA

Ad-Tech Ibérica, S.L.

Address: Avda. Camino de lo Cortao, 6-8 nave 22 28700. Madrid Madrid

Phone: 34 911 960 845
www.ad-techiberica.com

Ad-Tech Iberica specializes in the sale and representation of machinery and process solutions for Pharmaceutical sterile production and Biotechnology Production at all scales.

With a highly specialized sales staff, we collaborate with clients in the development of processes, selection and sizing of equipment, and optimizing return on investments.

AD TECH IBERICA, offers with a specialized sales staff, customer support before, during, and after the sales of equipments and machinery. Consulting for equipment selection.

- Isolators and containment systems.
- Fermenters from 5L.
- Industrial and Laboratory Freeze-Dryers.
- Filling Machines for Vials / Ampoules / prefilled syringes.
- Sterilization Tunnel.
- Autoclaves and low temperature sterilizaction.
- Washing of Vials / Ampoules.
- Labeling Machine for Vials / Ampoules.
- Water Distillers and Pure Steam Generators, Reverse osmosis, CIP, SIP.
- Supplies of vials, ampoules, stoppers.
- Laminar Flow custom made, portable, ATEX.
- Maintenance Services.

Advanced Medical Projects

Antonio Molina. CEO
amolina@advmedprojects.com

Address: Edif. TecnoAlcalá, Av. Punto Com 2, Campus Univ. 28805 Madrid

Phone: 34 91-8305950
www.advmedprojects.com

Development and commercialisation of orphan drugs against rare diseases caused by accelerated aging and DNA instability caused by low telomerase actibity.

Products:
A) Family of peptides able to increase telomerase activity in senescent cells or prone to become tumoral due to DNA instability.
B) GesTelMir peptide going into clinical trials against dyskeratpsis congenital.

C) Complete premium antiaging cosmetics line under GSE24-2 commercial name, based on telomerase activating peptides. 100% of the profit is reinvested on the biomedic R+D.

Advancell Advanced In Vitro Cell Technologies, S.A.

Clara Campàs-Moya
General Director
advancell@advancell.net

Address: Parc Cientific Barcelona, Baldiri i Reixac 10. CP 08028 Barcelona - Barcelona

Phone: 34 93.403.45.45
www.advancell.net

Advancell, founded in 2001, is an innovative biotechnology company that addresses patients' unmet medical needs and well-being by developing value-added products need in oncology, dermatology and CNS.

Advancell mission is to build a portfolio of high value pharmaceutical products based on its enabling nanomedicine technology and from in-licensing of promising pre-clinical candidates that we develop to clinical proof of concept. Advancell has two business units. Advancell Nanosystems is the R&D unit where we develop preclinical opportunities based on our proprietary nanomedicine technology which may enhance bioavailability or open previously unattainable delivery routes and possibly new indications for certain drug products. Advancell Therapeutics is the clinical development unit.
Currently, Advancell has the following programs in clinical development:

- Nanomedicines for the use in psoriasis (licensed to ISDIN).
- Acadra (Acadesina) Chronic lymphocytic leukaemia and multiple myeloma.
- Topical treatment of hand foot syndrome (ATH008),
- An oral treatment for multiple sclerosis (ATH012).
- Ciclostopic-Vet for the treatment of canine atopic dermatitis.

In addition, we pursue a series of preclinical opportunities. The business unit that develops and commercializes in vitro cellular models has been spinned out into a new company called Readycell S.L.
Interest areas for futures colaborations/alliances:
Collaborations with the objective to apply the nanosystem technology to change or enhance the administration of drugs in various administration routes (dermal, oral or nasal). In-licensing of preclinical programs in oncology, dermatology or CNS. We prioritize proyects with the following criteria. Repositioning of known molecules into new used Orphan drugs. New chemical entities with clear in vivo evidence of security and efficacy.

ALGAENERGY, S.A.

Augusto Rodríguez-Villa.
President
info@algaenergy.es

Address: Avda. de Europa, 19 – Parque Empresarial "La Moraleja" Alcobendas MADRID

Phone: 34 91 490 2020
www.algaenergy.es

ALGAENERGY, founded in 2007, is a technology based company working in the microalgae biotechnology sector. It has been promoted and is managed by a group of entrepreneurs and scientists with solid financial backing and extensive experience.

The company is backed by IBERDROLA, world leader in renewable energy, and Spain's largest oil company REPSOL, as shareholders and technology partners.

With substantial R&D programmes, ALGAENERGY is linked to some of the most recognised international microalgae research centres and universities. ALGAENERGY's mission also includes the exploitation of the enormous talent and ability available in Spain within this area of science and expertise.

ALGAENERGY is already selling products from microalgae for aquaculture, under its brand name ALGAEPISCIS, and is also investigating the application of microalgae in pharmaceuticals, nutraceuticals, cosmetics and animal feed.

The company's ultimate goal is the production of biofuels from certain microalgae and cyanobacteria in a commercially viable way, promising alternative as its production may use waste water, brackish or marine, does not compete with agricultural land, production is high and sustainable and its main nutrient is CO2 thus contributing to improving the environment.

ALGENEX (Alternative Gene Expression S.L.)

José Luis Cabero, CEO
direccion@algenex.com

Address: Centro Empresarial – Parque Científico y Tecnológico de la UPM Campus de Montegancedo 28223. Pozuelo de Alarcón - MADRID

Phone: 34 91 452 49 41
www.algenex.com

Algenex develops and commercializes remarkably productive baculovirus-based technologies for the production of high quality recombinant proteins. It also manufactures difficult-to-produce, recombinant proteins for diagnostic products and vaccines, some of them immunologically potentiated by a proprietary adjuvant molecule. Algenex aims to demonstrate the regulatory and commercial feasibility of the its innovative technologies by developing and licensing its first animal vaccine.

Two technology platforms are the foundation of ALGENEX:

Top-Bac® - A proprietary expression cassette composed by several virus-derived regulatory elements that, when incorporated into the genome of a baculovirus vector, improves to unprecedented levels the productivity and quality of recombinant proteins produced by insect cells; and IBES® - Based on the use of insect larvae as disposable, living biofactories that in combination with Top-Bac® lead to record productivities for a baculovirus-based expression system. This technology, pioneered by Algenex in Europe, allows for a rapid and linear scaling-up process; increases success with proteins difficult to express; and dramatically reduces the capital investment with respect to conventional bioreactor-based technologies.

Algenex´s key business lines are: 1) licensing its proprietary technology platforms to produce recombinant proteins, whether for investigational or commercial purposes; 2) co-development of vaccines with suitable partners; and 3) contract manufacturing to supply diagnostic reagents and/or assisting in their development.

Aliad Conocimiento y Salud

comunicacion@aliad.es

Address: c/ Arándiga 18C 28023 Madrid

Phone: 34 91 357 15 50
www.aliad.es

Aliad (www.aliad.es) is a training and consulting company specialized in private healthcare. We are leaders in services to private healthcare in Spain with 11 years of history. Our mission is to contribute to the improvement of health services by supporting organizations and professionals. We have international experience, because we are partner of the EFQM for Private Healthcare and work closely with EFQM in health areas since 2003.

We have 456 references and work actually with more than 300 clinics and hospitals in Spain.

We are very focused on business excellence and quality improvement systems, and we have developed three Programmes for our clients: SEP-Sanidad Excelente Privada (Excellent Private Health Care), Confianza (Patient Safety) and Mercurio (Data Protection). Also we conduct research studies on Private Healthcare and many innovation projects, both in management and training; We have partnerships with leading Universities, Professional Associations and Scientific Societies and we elaborate with them training and R+D projects.

With respect to training experience, we have more than 275 courses and we have trained over 70,000 health professionals. Our belief in active training has supported professional development and business projects, patient care, competence, equality, and many others. Our training design and strategy are monitored by a Commitee of Customers, all of them Human Resources managers, Care managers and doctors coming from hospitals, clinics and Scientific Societies.

Allinky Biopharma

Miguel Vega. CEO
lab@allinky.com

Address: C/Faraday 7. Campus de Cantoblanco Madrid

M Phone: 34 618060829
www.allinky.com

Allinky Biopharma is focused on the discovery and development of small molecule drugs for the treatment of chronic inflammatory conditions, age-related degenerative diseases and cancer

Scientific and clinical research have shown that sustained oxidative stress, chronic inflammatory condition and progression cell missignalling are key factors in diseases such as Alzheimer's, ictus, rheumatoid arthritis, osteoarthritis, diabetes type II, atherosclerosis and certain types of cancer. Allinky develops novel therapeutics capable of modulating abnormal cell-molecular signals behind these diseases and thus contributing to restore normal cell-gene expression. Therefore, Allinky seeks to become a well-known player in the application of molecular-based medicine to fight prevalent diseases.

Alma Consulting Group España

Marta Orueta/Juan Antonio Costa. Marketing and Communication Responsible / Sales and Marketing Manager
morueta@almacg.com
jacosta@almacg.com

Address: Edificio Sollube Plaza Carlos Trías Bertrán nº7. 28020 MADRID

Phone: 34 91 575 03 01
www.almacg.es

Our mission is to identify and obtain financing and savings for our customers.

We contribute to our clients competitiveness through measurable actions.

Professionals of ALMA Consulting Group work day by day to boost your growth through Innovation, providing the resources you need to finance your Research and Development potential, with a constant commitment for optimisation and security.

Areas of expertise: Innovation Financing. Propety Tax. Overhead Expenses: telecoms, electricity, office cleaning, travels, etc.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: We create a long-term partnership with our customers in order to provide an outstanding support to improve their results.

Amgen, S.A

Juan Carlos Esteban. Corporate Communication
jesteban@amgen.com

Address: World Trade Center Barcelona.Muelle Barcelona Edificio Sur, 8ª planta Barcelona

Phone: 34 936 001 900
www.amgen.es

To serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.

PRODUCTS: Oncology and hematology treatments. Amgen is developing research programs in nephrology, hematology, oncology, inflammatory diseases, metabolism and neuroscience.

Araclon Biotech, S.L.

Guillermo de Vilchez Lafuente.
Managing Director
gdevilchez@araclon.com

Address: Paseo de la Independencia, nº 30, 2º A 50004 Zaragoza

Phone: 34 976 796 562
www.araclon.com

Archivel Farma, S.L.

Olga Rue. Chief Executive
Officerarchivel@archivel-farma.com

Address: C/ Fogars de Tordera, 61 Badalona - Barcelona

Phone: 34 934 972 456
www.archivelfarma.com

Discovery and initial clinical development of novel pharmaceutical agents of biological nature.

Products:

RUTI®, poly-antigenic vaccine made of fragments from Mycobacterium tuberculosis, detoxified, and formulated with liposomes. RUTI® is in phase II of clinical development for the prevention of active tuberculosis in individuals with latent tuberculosis infection (therapeutic use). RUTI® is as well under evaluation for its use in the treatment of active tuberculosis and in other therapeutic areas.

Areas of interest to future collaborations:

Prevention and treatment of tuberculosis with biological agents. Diseases or pathological conditions that could benefit from immunomodulatory treatments.

ASCIDEA COMPUTATIONAL BIOLOGY SOLUTIONS, S.L.

Albert Mascarell Creus.
CEO
amascarell@ascidea.com

Address: C/ Almogavers 165. 08018 Barcelona Barcelona

Phone: 34 935516280
www.ascidea.com

aScidea is a technology-based company that provides scientific services based on bioinformatics tools and advanced computing.

We offer complete solutions in the field of the omics (genomics, proteomics, transcriptomics), with access to the best experimental platforms (microarrays, deep sequencing NGS) in order to obtain high quality genetic data, and a wide variety of bioinformatic data analyses to obtain comprehensive results.

aScidea is committed to quality and cost efficiency, so we offer consulting services to optimize the design, management and implementation of projects in the area of genomics research and pharmaceutical and biotechnology companies.

In aScidea we believe that the democratization of the genetic information will lead to a healthier and more prosperous society.

1. Obtaining genetic profiles with different complexity, using the most innovative and proven platforms: Massive sequencing. Roche 454 GS FLX. Roche 454 GS Junior. Illumina HiSeq2000. Illumina MiSeq. Ion Torrent PGM. Microarrays. Affymetrix platforms. Agilent platforms. Illumina Arrays

   We also obtain genetic profiles with reduced performance technologies such as qRT-PCR, SNPlex or DigitalPCR.

2. Bioinformatics Data Analyses: We offer several pre-configured packages for the most common studies in the market. We also customize any bioinformatic and/or biostatistician analysis to fullfil the specific needs of our customers.

3. Custom Software Design: In aScidea we know that the Software-as-a-Service is not always the ultimate solution for computerized solutions. Therefore, we provide our IT department to design and implement innovative solutions, packaged on a software format with optional services of maintenance, warranty and after-sales.

4. Scientific and technical consulting: We are aware that time is money, and therefore innovative projects must be cost-effective for companies or research institutions.

Bayer CropScience SA NV

David Andrés. EU Registration Manager
david.andres@bayer.com

Address: J.E. Mommaertslaan 14 Diegem - Diegem

Phone: 34 +32 9 243 04 68 www.bayercropscience.com

BioScience.

Vegetable seeds.

Seeds for agricultural crops (e.g. cotton, canola, rice, soybean).

Trait development and commercialization.

Bayer BioScience is the part of Bayer CropSciene that develops crop seeds with enhanced yield and quality properties for the benefit of agriculture, food and fiber manufacturers, consumers and the environment.

Bayer BioScience employs modern breeding methods including plant biotechnology for this. The individual seed varieties are adapted to the requirements of the relevant markets, and guarantee high quality.

Our work is focused on improving the plant properties, for example their optimized performance under the most varied of environmental conditions.

We therefore create sustainable, plant-based solutions for agriculture.

BICG, Business Innovation Consulting Group

Alejandra Martínez
Manager
alejandra.martinez@bicg.com

Address: Calle Molina 17 28029. Madrid MADRID

Phone: 34 913141331
www.bicg.com

R&D and consultancy company specialized in designing and implementing new ways of working strategies in organizations as well as designing knowledge environments. Structured innovation through ways of working strategies and professionals of the company.

We provide services to organizations to help them to solve complex challenges either strategic, operational and organizational that have an impact in the way they work and in developing knowledge environments (inspiring places to work, to research, to collaborate, to innovate, to learn, etc.). We understand by ways of working all these apparently not connected activities that have an impact in how, when, where and with whom work is done. We integrate different disciplines: work organisation, processes, use of Information and Communication technologies, architecture and spaces, etc. to design innovating strategies. These strategies allow organisations to be more competitive, productive and flexible, more sustainable (spending less for more) and ready to respond to changes our society is constantly facing.

Biobide, S.L.

Idoia Ruiz de Azua.
General Manager
ruizdeazua@biobide.es

Address: Paseo Mikeletegi, 58 - Donostia-San Sebastián - Guipúzcoa

Phone: 34 943 309 360
www.biobide.es

Biobide is a biotech company that aims to help our customers worldwide developing taylor-made solutions to maximize R+D productivity and minimizing risks in the Drug Discovery process, integrating zebrafish animal model with innovative tools, adding value to their R+D+i mainly in the preclinical area (toxicology, safety and efficacy).

PRODUCTS: Capabilities for taylor-made solutions. Target validation. Transgenesis and disease model generation. Customized assay

TOXICITY: Specific toxicity Assays. Cardiotoxicity: Cardiotox assay. Teratogenesis: Teratox assay. Ototoxicity: Ototox assay. Hepatotoxicity: Hepatotox assay. General toxicity Assays: Acutetox assay.

EFFICACY: Oncology: Angiogenesis inhibition assay. CNS/Neurodegeneratives: Alzheimer assays.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Collaboration agreement with pharmaceutical and biotechnology companies with the aim of developing assays, increasing its value by means of this synergy collaboration.

Company policy consists on setting up agreements with agents that possess quality research capacity and undertake applied research projects complementary to our company's activities, maximizing therefore the investment on all fronts.

BIOCHEMIZE SL

Jaume Mir. CEO
jmir@biochemize.com

Address: Av. de la Innovació 2 08225 Terrassa BARCELONA

Mobile Phone: 34 686441120 www.biochemize.com

Biochemize uses the platform of the microbial fermentation and biocatalysis for the design of bioprocesses at industrial level, and for the enzymatic screening upon active principles and high value molecules.

Biochemize designs, optimizes and scales-up bioprocesses at industrial level, based in the use opf enzymes and/or microorganisms (wild or recombinantly obtained) for the production of high value molecules, with competitive advantages related with standard chemical synthesis methods.

Biochemize also develops enzymatic screening procedures upon an specific molecule, for the evaluation for the obtention of derivated structures which can suppose higher or different activity, with competitive advantages related with combinatory chemistry methods.

Biodescon

Carlos Roldán. Consultant
croldan@biodescon.es

Address: C/ Mallorca, 273 Principal 2º 08008. Barcelona - Barcelona

Phone: 34 934 876 927
www.biodescon.es

Services and innovative products for infection prevention and hygiene

Our aim is to become the trusted sorce regarding the prevention of biological infections and hygiene of products, facilities and customers, offering, in Spain, innovative products or services suitable for various industries: pharmaceuticals, research, health, food, emergency services, hospitality, public services and transportation

Bioftalmik

Jon Careaga.
Executive Director
jon.careaga@bioftalmik.com

Address: Parque Tecnológico de Bizkaia, ED. 800 - 2ª planta Derio - Bizkaia

Phone: 34 944.069.659
www.bioftalmik.com

Our main objective is to design and develop diagnostic, prognostic and therapeutic systems for eye diseases and Biodevices for ophthalmic surgery.

SERVICES: Integral R&D platform Diagnostic tests Clinical trials

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Our strategy clearly promotes scientific, technical and clinical collaboration and all its manifestations as the most effective ways to innovate. Our main areas of interest are: Ophthalmology, therapy, diagnostic, prognostic, cell culture, molecular biology, proteins, drug development and drug delivery.

Biogen Idec Ibérica, S.L.

Guido Decap Carrasco.
VP & Managing Director
guido.decap@biogenidec.com

Address: Paseo de la Castellana, 41 - 2º. Madrid

Phone: 34 91 310 7110
www.biogenidec.es

VISION: With passion, purpose and partnerships, we transform scientific discoveries into advances in human healthcare. MISSION: We create new standards of care in neurology, oncology and immunology through our pioneering research, our global development, manufacturing and commercial capabilities. CORE VALUES: Courageous Innovation. Quality, Integrity, Honesty. Team as a Source of Strength. Commitment to Those We Serve Growth, Transformation and Renewal. Consistent with our core values, we as individuals and as a corporation are dedicated to creative and constructive growth, transformation and renewal as a source of inspiration and vitality. Stating your corporate principles is one thing; At Biogen Idec, we live these principles every day. They are the soul of the company.

PRODUCTS: With our stated mission to create new standards of care for unmet medical needs, Biogen Idec is focused on five therapeutic areas: Neurology, Immunology, Oncology, Cardiopulmonary and Hemophilia. These are areas in which we have both proven expertise and products in our pipeline that we believe can lead to first-in-class or best-in-class molecules. Within each area, we have selected targets based on both biology and the pathophysiology of disease. TYSABRI® (natalizumab) is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. AVONEX® (Interferon beta-1a) has the most treatment experience for relapsing forms of MS worldwide, with more than 135,000 patients on therapy. It is used worldwide as a treatment for relapsing forms of MS to slow the progression of disability and reduce relapses.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: At Biogen Idec, we believe strongly in the value of successful partnerships, and we do everything we can to make them work. If your company is in the later stages of development, Biogen Idec can provide a wealth of resources to help successfully commercialize your product. Our approach to partnerships is driven by two core principles that promote success: respect and flexibility. We are interested in partnerships in our core therapeutic areas, which include neurology, oncology and immunology. In addition, we welcome products in acute care, including cardiovascular, hemophilia, infectious disease, and other products used in a hospital environment. We also have active programs in hemophilia research and development. In fact, we are open to partnerships in additional therapeutic areas that lend themselves to a specialty biopharma business model.

Bioibérica S.A.

Roger Sabata. Business Development Manager
rsabata@bioiberica.com

Address: Plaza Francesc Maciá, 7 – 8ªplanta
08029 Barcelona

Phone: 34 93 490 49 08
www.bioiberica.com

Bioibérica S.A. is a Spanish biotech company established in 1975. Its main activities are the Pharmaceutical Division and the manufacturing of API.

Since its foundation in 1975, Bioiberica have specialized in the research, manufacture and marketing of biomolecules for the pharmaceutical, veterinary and agricultural industries.

Bioiberica's commitment to science and technology and its extensive knowledge of the field have consolidated its leadership as producers of Glycosaminoglycans (Mucopolysaccharides), in particular Heparin, Chondroitin Sulfate, Hyaluronic Acid and Glucosamine, as well as other active ingredients such as Amino Acids, Characterised Peptides and Hydrolysed Proteins.

Interest fields: Strategic alliances in Osteoarthritis management, Intestinal Health and Plant Stress Management.

Bioingenium, s.l.

ybezares@bioingenium.net

Address: Edifici Hèlix Parc Científic de Barcelona Baldiri Reixac 15-21 08028 BARCELONA

Phone: 34 93.402.02.40 www.bioingenium.net

Biokit, S.A.

Pau Planas. Quality Assurance Manager
pau.planas@biokit.com

Address: Can Malé, Lliçà d´Amunt Barcelona

Phone: 34 93 860 90 00
www.biokit.com

Development, production and commercialization of immunoassays for the clinical diagnostics (IVD) market.

PRODUCTS: Serology reagents for the diagnosis of infectious diseases and for the detection of plasma proteins. Manual assays (latex agglutination, hemoagglutination, immunochromatography), ELISA assays and assays for automatic platforms (immunoturbidimetry and chemiluminiscence).

OEM services: Contract development and manufacturing of immunoassays for clinical chemistry, immunochemistry and coagulation applications. Raw materials: Polyclonal and monoclonal antibodies. High-quality natural and recombinant antigens.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: New clinical biomarkers with high diagnostics potential, apt to be detected through the use of high sensitivity immunoassays. OEM immunoassay opportunities.

BIOMAR Microbial Technologies, S.A.

Dr. Arturo Ayats Pérez. Vicepresident. Dr. Antonio Fernández Medarde. CEO
info@ibiomar.com

Address: Parque Tecnológico de León. Calle D, Parcela M-10, 4 Armunia León

Phone: 34 987 84 92 00
www.biomar.com

Biomar is a Biotechnological company specializing in Marine Microbiology and the Chemistry of Natural Products. Biomar develops its own drug candidates in a variety of therapeutic areas. In parallel with the pharmaceutical sector, projects are under way since 2006 in a variety of industrial sectors such as Bio-energy and Agro-food areas. The quest for medicinal products in the area of human health has been our main aim since the very origin of the company. The collection of compounds and their great chemical diversity, as well as our network of collaborators specializing in different pathologies, allow us to embark on projects ranging from cancer to neurodegenerative, infectious or autoimmune diseases. Other hand, we are working on natural extracts with anti-fungal activities against pathogenic fungi of the skin and on natural extracts as whiteners, antioxidants, anti-acne and anti-wrinkle products.

The food production area comprises several Biomar compounds in a very advanced stage of development, compounds that will help to increase the productivity of agriculture and the food processing industry: Natural preservatives, sweeteners, etc., in food processing, and high-performing biopesticides and fertilizers, including some that are about to be marketed world-wide. Biomar has now selected several candidates from microalgae in order to obtain fatty acids that are transformed into biodiesel; and sugars/proteins that can be used for feeding humans and animals. It is a key project for Biomar in terms to reduce the impact of current energy processes.

PRODUCTS: OUR LIBRARIES are the beginning of all our research projects due to Biomar has the world´s largest collection of marine micro-organism. We are making extraordinary advances in a wide variety of fields due to its bio diversity and presence of novel compounds.

SERVICES: BIOMAR is an expert in the development of production methods to obtain compounds with high purity is at the heart of this line of work. Fermentating and downstream processing have been developed in our plant for more than 50 compounds. Besides, our fermentating capacity of 30, 300, 3000 liters.

BioMarin Europe Ltd. Sucursal en España

Tiago Osório de Barros. Country Manager IBERIA
tbarros@bmrn.com

Address: Comp. Inm. Emp. Miniparc I, Edificio B-Planta 1ª Oficina 4, C/ Azalea s/n, Urbanización "El Soto" CP 28109 Alcobendas Madrid

Phone: 34 800 808 508
www.biomarin.com

BioMarin seeks to develop product candidates that:

Address currently unmet medical needs.

Suggest a clear-cut development profile.

Provide an opportunity to be first-to-market .

Long description.

PRODUCTS:

Naglazyme, Aldurazyme, Kuvan

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Metabolic Diseases.

Enzyme Replacement Therapies .

Biomaslinic, S.L.

José Prados Osuna. CEO
biomaslinic@biomaslinic.es

Address: Parque Metropolitano, Industrial y Tecnológico. C/ Juncalillo, 64. Escúzar - Granada

Phone: 34 958 35 78 08
www.biomaslinic.es

Manufacture and supplier, acknowledgement and aplications of Maslinic Acid and Hidroxitirosol.

PRODUCTS: Animal growth promoter, nutraceutics, functional foods and antiinflamatory indications.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Maslinic acid has demonstrated a high selective apoptotic capacity over tumoral cells, based in the description of its route of activity.

The experiments in vivohave been developed having a great success.

Now Biomaslinic S.L. is working about its potential pharmaceutical application.

So collaboration is needed to carry on different studies along the different phases of investigation, and also alliances to advance its development and marketing.

Biomedal, S.L.

Ángel Cebolla Ramírez. General Manager
acebolla@biomedal.com

Address: Avda. Américo Vespucio, 5-4. Planta 1, módulo 12 Sevilla - Sevilla

Phone: 34 954 081 276
www.biomedal.com

To develop new, innovating technologies for the progress of post- genomic research and the efficient industrial production of new biomolecules that are useful for society.

Biomedal S.L is a biotechnology company whose mission is to develop and commercialize new technologies, services and products for research, bioindustry and diagnostics.

Biomedal enhances the talent of its team with the collaboration of an outstanding and growing network of international scientists and technologists, and directs its efforts to satisfy its customers.

The company develops its activities in two areas:

Biomedal Life Sciences and Biomedal Diagnostics

Biomedal Life Science

R&D contracts, DNA synthesis, peptide and protein production, antibodies, protein expression and purification systems, kits for molecular biology, affinity chromatography, strains, plasmids, etc.

Biomedal Diagnostics. Health related bioanalitic systems, detection of immunological diseases markers, food safety products such as Glutentox, and Oleotest, food analysis etc

Biomol-Informatics

DR.PAULINO GÓMEZ-PUERTAS. Scientific Advisor
bioinfo@bioinfo.es

Address: C/ Faraday, 7. Campus Universidad Autónoma de Madrid - Cantoblanco. Madrid - MADRID

Phone: 34 647 504 634
www.biomol-informatics.com

BIOMOL-INFORMATICS offers consulting services on Bioinformatics in areas of research, diagnostics and pharmaceutical industry. Located in the campus of the Autonomous University of Madrid, the company is specialist in Rational Drug Design using 3D computational simulation, Molecular Dynamics of macromolecules and Data Analysis of "Next-Generation DNA Sequencing (NGS)".

SERVICES: "In silico" analysis and prediction of new drugs activity on 3D models of proteins and in molecular dynamics techniques applied to docking of compounds. Data Analysis of "Next-Generation DNA Sequencing (NGS)": human genome, cancer-related mutations, hereditary illnesses

AREAS OF INTEREST TO FUTURE COLLABORATIONS: "In silico" design of anti-obesity drugs. Molecular dynamics simulation of polymerization and depolymerization processes of bacterial septum protein FtsZ: "in silico" design of antimicrobials. Collaborative project 7FP - EU. Data Analysis of "Next-Generation DNA Sequencing (NGS)".

Bionanoplus, S.L.

Eduardo González de Salamanca Gª.Business Development Director
egsalamanca@bionanoplus.om

Address: Pol. Ind. Mocholi Plaza CEIN, 5 nave B14 – NOAIN - NAVARRA

Phone: 34 948103926
www.bionanoplus.com

Bionanoplus is a bio-nano-pharmaceutical company aimed to the development of nano-formulation and nano and micro delivery technologies. We provide solutions to overcome formulation and delivery problems for Pharma, Cosmetic, Agrifood and plant healthcare industries based on our proprietary technology. Our technology is based on GRAS or food-grade substances with no organic solvents and easy to scale.

Bionanoplus applies nanotechnology to solve formulation and processing problems in the pharmaceutical industry, cosmetics, agro-food and plant healthcare. We developed our own technology and patents. We are a specialist in polymeric nanoparticles. We develop R&D for third parties, product co-development and our own pharmaceutical products portfolio based on well known out of patent molecules increasing their safety and benefits.

Our technology platform allows us to develop tailored solutions to specific problems using or adapting our self assembling nanoparticles (Nano G201, Cap G201, SNAP,...). We developed bio-adhesive nanoparticles and delivery systems based on in-situ self assembling nanoparticles for controlled release of the substance of interest.

BIONATURIS

Victor Infante. CEO
Info@bionaturis.com

Address: Av. Desarrollo Tecnológico 11. CP 11591 Jerez de la Frontera - Cádiz

Phone: 34 856 818 424
www.bionaturis.com

BIONATURIS is a specialty biopharmaceutical company that develops and manufactures a new generation of more affordable biopharmaceutical products by means of FLYLIFE. FLYLIFE is a revolutionary Plug&Play system for producing tailor-made biologics at industrial scale. The easiest and quickest way to manufacture local batches of new generation vaccines or antibodies

Products: Bionaturis is focused on clinical-stage developing of highly cost-effective biological APIs for unmet diseases, especially in the field of second generation vaccines for human and animal health

Services: Bionaturis acts as CDMO developing and manufacturing biological APIs by means of its FLYLIFE platform, in compliance with cGMP standards.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Second generation vaccines; Virus-Like Particles; recombinant antigens; biological downstream; out-licensing of early stage -preclinical or phase I- leads; oral delivery systems for protein-based vaccines

BIONCOTECH THERAPEUTICS, S.L.

Elena Caballero Castellote
Project department
ecaballero@bioncotech.com

Address: C/ Catedrático Agustín Escardino, 9 – Parc Científic UV Paterna - Valencia

Phone: 34 961109955
www.bioncotech.com

Bioncotech Therapeutics is a biopharmaceutical company focused on the development of new anticancer and autoimmune therapies.

Bioncotech Therapeutics is a biopharmaceutical company based in the Scientific Parc of University of Valencia that counts with the support of the Spanish National Cancer Institute (CNIO) and Instituto Empresa. We are currently finalizing the pre-clinical phase of our first compound, BO-110, a selective activator of autophagy and apoptosis, designed for the treatment of cancers which, due to their aggressiveness and lack of effective treatments, are included in the concept of orphan oncological diseases. In addition, we are developing a new concept of therapy aimed at the selective inhibition of reactive T cells to mitigate or prevent autoimmune diseases for which currently available treatments are ineffective or have highly toxic profiles.

Bionet Ingeniería

Enrique López. Head of Chemical Engineering
enrique.lopez@bionet.com

Address: Av. Azul 2.11.2 - Parque Tecnológico Fuente Alamo Fuente Alamo - Murcia

Phone: 34 902 170 704
www.bionet.com

To provide engineering services and turnkey construction of process package units for the biotech industry (fermentation, downstream, purification, isolation...). Our commitment to our clients means that we offer an integrated service for the whole project life cycle; from lab to industrial facilities and process start up.

PRODUCTS: Lab to Market Engineering [L2M]. From process development at lab-scale we offer: Feasibility studies. Industrialization and scale-up studies. Turnkey construction of pilot plants. Pilot plant testing. Project management of biotech investments: Basic and detailed engineering. Project management or turnkey construction of industrial facilities. Commissioning and start up according to GMPs

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Technology centres and R&D departments with new processes that want to add value to the Process Technology Package through a viability study, from an engineering point of view, considering existing / potential investors. New industrial investment projects and facilities that want to introduce a new process / product or that simply want to revamp an existing one. Technology centres that can collaborate in process optimization and troubleshooting.

BIONURE FARMA, S.L.

Alberto G. Zamora. CEO
info@bionure.com

Address: BALDIRI REIXAC, 15 Barcelona - Barcelona

Phone: 34 931258607 Mobile Phone: 34 620857779
www.bionure.com

Bionure is a spin-off from the Hospital Clinic of Barcelona-IDIBAPS (Institut de Investigació August Pi i Sunyer) and the CSIC (Spanish National research Council) that was born in 2009 with the aim of developing new therapies for neurological diseases Neurodegenerative diseases are sanitary priority in advanced countries because of its high frequency, social and sanitary costs and the lack of curative therapies. In particular, current treatments for MS are immunomodulatory drugs (modulate the body immune system) that decrease the frequency of relapses and hold up its progression, but they are only partially effective and have many side effects. The aim of Bionure is developing neuroprotective drugs working as eurotrophins agonists (such as NGF, BDNF, NT 3/4) by targeting their receptors. At present, there are no neuroprotective drugs in the market, so it represents a new approach for the treatment of brain and retina diseases using a new mechanism of action in a well known pathway avoiding high selectivity for preventing sideeffects and covering common pathways for neuroprotection. Neuroprotective activity in vitro and beneficial in vitro effects (in animal models for MS) have been already demonstrated from 9 molecules protected by 3 patents filed to the European Office and licensed to Bionure. From those molecules, G79 has been identified as the candidate for its development as neuroprotective therapy for MS, Glaucoma and other nervous system diseases. At present, Bionure has obtained in vitro and in vivo a proof of concept for treatment with G79 in models for MS, Glaucoma, Parkinson, and is currently completing studies for Alzheimer, Amyotrophic lateral sclerosis (ALS), Senile macular degeneration and Retinitis pigmentosa. The aims of Bionure are complete G79 preclinical development for indications of MS and Glaucoma and seek agreements with other companies to license or co-develop G79 for indications of other neurodegenerative diseases.

Biopolis, S.L.

Daniel Ramón Vidal. Director General
biopolis@biopolis.es

Address: C/ Catedrático Agustín Ecardino, 9. Parque Científico Univ. de Valencia - edificio 2. CP 46980 Paterna Valencia

Phone: 34 963 160 299
www.biopolis.es

The main objectives of Biopolis S.L. are to design, produce and purify microorganisms (bacteria, yeasts and filamentous fungi), microbial metabolites: high-value by-products (enzymes, proteins and nucleic acids) following classical fermentation methods and metabolic engineering design.

PRODUCTS AND SERVICES

- Probiotics and functional ingredients
- Functional and technological validation trials
- Use of animal model C. elegans for Alzheimer candidate screening, obesity, diabetes, aging, microbial infection testing
- Revaluation of waste and subproducts
- Purification of proteins
- Custom design and selection of microbial strains/valuable biochemical compounds
- Process design, development and production of microorganisms and derivatives
- Production of new generation biofuels and biopolymers
- Metagenomic and metabolomic analysis.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Biopolis S.L. offers its services both to industries, such as the food and feed sector, agrochemical, chemistry, pharmaceutical and environment, as well as to public and private research centers. Finding customers and collaborators: License for probiotics commercialization. For contract manufacturing of microbial strains or specific industrial-microbiology-derived compounds. For contract R&D using proprietary biological model (C. elegans), sequencing (454 Roche, Ion Torrent), metagenomics, metabolomics and nutrigenetics tools.

Biosearch S.A.

Mónica Olivares Martín.
Research Manager
molivares@biosearchlife.com

Address: Camino de Purchil, 66. CP 18004 Granada

Phone: 34 91 380 29 73
www.biosearchlife.com

Company dedicated to research, development and commercialization of new products based on natural ingredients with health benefits .

PRODUCTS: Vegetable, lipid and probiotic extracts. Exclusive product development. Technical and legal consultants. Regulatory affairs. Stability studies.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Development of new bio active ingredients based on vegetable, lipid and probiotics extracts and their application in the pharmaceutical, food and cosmetic industries.

Bioserentia

Jorge Arenas-Vidal
Director
jarenas@bioserentia.com

Address: C / Alcántara, nº 11- 3C Madrid. Madrid

Phone: 34 914 311 970
www.bioserentia.com

Partner with companies, entrepreneurs, investors, governments to create and accelerate Ventures in Life Sciences.

SERVICES: Corporate Strategy, Strategic Investments in Life Sciences R&D Strategy and Management Fund Raising BioEntrepreneurship Platform BioBusiness Incubation & Acceleration Interim Management Commercial, Sales & Operational Support.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: HEALTH: Oncology, Rheumatoid Arthritis, Wound Healing, Transplantation, Cellular Therapies, Vaccines, Pharmacogenomics, Nutrigenomics. Personalized Medicine, Convergent Technologies. ENERGY: biomass optimization, biorefineries strategy and mplementation.

Biot

Agustín Lasserrot
General Director
direccion@biot.es

Address: Av.Innovación 1. Edificio BIC. Parque Tecnológico Ciencias de la Salud. Armilla. Granada

Phone: 34 958 750 618
www.biot.es

BIOT is a Biotech Enterprise group focus on innovation and R&D in Microbiology. Goals are achieved from the interaction between different BIOT Companies and Research Groups from Universities, Research Institutes and other Companies as well. BIOT develops reliable solutions, products and metholodogies based on microorganisms in the areas of agro-food, enviromental and bioenergy production

PRODUCTS: Selected strains of high biotechnological interest for different industrial sectors: Probiotics. Biofuel. producers: methane, ethanol and biodiesel. Bioplastic producers. Soil and water decontamination. Enzimes and biomolecules from microorganisms of high industrial interest. Genetic constructions for improving microbiological processes

SERVICES: Selection, isolation, quantification and identification of microorganisms using biochemistry and genetics techniques. Genetic Engineering Service of microorganisms. Analysis of microbial communities in terrestrial and aquatic ecosystems. Design and conservation of microbiological resources and culture collections of biotechnological interest. Consulting and advice in the field of Microbiology. Innovation, R&D Project Performing and Management.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Renewable energies production. Remainders. Biofuel production. Residual, industrial and urban water purification. Bioremediation. Functional food and nutrition-health. New active biomolecules. Nourishing industry. Security and microbiological control. Projects of I+D+i in cooperation

Biotherapix Molecular Medicines S.L.U.

Juan Sebastián Ruiz. Institutional Relations Director
jsruiz@genetrix.es

Address: Pza de la Encina, 10-11. Núcleo 1, 3ª Planta. Tres Cantos - Madrid

Phone: 34 91 806 30 89
www.biotherapix.com

Biotherapix Molecular Medicines S.L.U. is a company belonging to Genetrix Group, which specializes in generating high affinity biological molecules to treat inflammatory diseases. . *Programmes under way: - New generation of anti-inflammatory drugs - specifically chemokine receptor antagonists (Diakinas®). - Platform for generating and selecting (screening) human monoclonal antibodies for therapeutic and diagnostic purposes.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Molecular therapy Protein biology Protein production and purification systems Development of therapeutic antibodies Inflammation Infectious diseases

Biotools B&M Labs, S.A.

Carmen Tomás- Verdera Alba. Chief Communications Officer
ctomas@biotools.eu

Address: Valle de Tobalina 52, nave 43 Madrid - Madrid

Phone: 34 917100074
www.biotools.eu

Research, development and manufacture of recombinant enzymes and other tools for molecular biology. Development of new technologies for molecular diagnostics and biomedical research. Comprehensive, fast, simple, robust, automatable and competitive diagnostic solutions, based on internationally patented proprietary technologies and reagents from the company.

PRODUCTS: Recombinant enzymes, nucleic acid purification systems and other reagents for molecular biology. "Ready-to-use" Molecular diagnostic Kits based on Gelification Technology (one tube-one reaction)

SERVICES: Services for design, stabilization and automation of nucleic acid amplification reactions. Services for the development of comprehensive automatable solutions for molecular diagnostics.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Technology transfer: Transfer of Biotools Gelification Technology for the stabilization in a single tube all necessary reagents to perform an amplification reaction. This technology has been licensed to the Brazilian Public Health System, and it has been implemented in Brazilian blood banks for the detection of HIV and HCV among blood donors.

Bosques Naturales, S.A.

Ricardo Licea. Biotechnology Coordinator
ricardolicea@bosquesnaturales.com

Address: Avda de la Vega, 1. Edificio 3 Alcobendas Madrid

Phone: 34 91 360 42 00
www.bosquesnaturales.com

Promotion and maintenance of fine wood forestry plantations.

This activity has a triple function: Sustainability, Productivity and Innovation.

Bosques Naturales is a company leading research and development which applies vegetal biotechnology and intensive agronomic techniques to its production processes. Its lines of research in forestry biotechnology are oriented to genetic characterization of vegetal material in order to improve the volume and quality of wood.

PRODUCTS: Plantations of high economic value trees using selected vegetal material which is reproduced "in vitro".

The company has a Vegetal Tissue Growth Unit which provides its own germplasm bank.

SERVICES: Bosques Naturales covers all the growth and maintenance costs of the trees during the twenty or twenty-five years which their productive cycle lasts

BTI Biotechnology Institute

Dr. Eduardo Anitua Aldecoa. Scientific Affairs Manager eduardoanitua@eduardoanitua.com

Address: C/ Jacinto Quincoces, 39, CP 1007 – Vitoria - Álava

Phone: 34 945 160 652
www.bti-implant.es / www.prgf.es / www.institutoeduardoanitua.com

Research and development of new product, new materials and new processes for biological material obtaining through several technologies some of them related to Regenerative Therapies.

PRODUCTS: Design and manufacture of dental implants, prosthetic components and surgical instruments, Bioactivatable surface for implantology. Technology development for tissue regeneration using Plasma Rich in Growth Factors (PRGF). Educational material and courses development, and its diffusion. Diagnostic software

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Tissue engineering, bone regeneration,regenerative therapies

Canvax Biotech S.L.

Elier Paz Rojas. Managing Director e.paz@dominion.es

Address: CL Alcalde Velasco Navarro 10, 5-Izq Córdoba - Córdoba

Phone: 34 957 420870
www.dominion.es

The search for antigens for vaccines

PRODUCTS: Own technology for the identification of antigens inducing T CD4+ and CD8+ response.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Vaccine sector, model animals for protection against infections

Celgene Institute of Translational Research Europe (CITRE)

David Villalba. Senior Manager Operations dvillalba@celgene.com

Address: Parque Científico y Tecnológico Cartuja 93 C/Isaac Newton 4 Sevilla - Sevilla

Phone: 34 955 001 705
www.celgene.com

CITRE®, the Celgene Institute of Translational Research Europe, is a focal point for advanced biomedical research including regenerative medicine, personalized medicine and cellular therapies.

CITRE® consists of five departments - tumor biobanking, bioinformatics, placental stem cells, epigenetics and cell signaling. They will be supported by five services - cell culture, cytometry, electronic microscopy, genomics and proteomics, organized around a Central Unit for Translational Medical Research.

Located in Seville, Spain, CITRE® grows out of a shared vision between Celgene and the government of Andalusia to provide a bridge between the discoveries of basic research and their application in addressing the needs of modern medicine

Clean Biotec S.L.L.

Nathalie Beaucourt.
nathalie@clean-biotec.com

Address: San José de Calasanz 11 La Rioja - Logroño

Phone: 34 941238261
www.clean-biotec.com

Find solutions to resolve environmental pollution problems using clean, sustainable and economical technologies. Improve the natural regulation capacity of ecosystems to reduce environmental impacts. New ways of natural and controlled systems for waste elimination and recycling . Ecodiagnostics. Environmental audit reports. Waste assesment projects. Paleobotanic studies. Implantation and control of biomonitoring networks. Phytoremediation and Bioremediation. R & D biorremediation projects. Restoration of degraded lands. Reseach and improvement of new phyto and bioremediators.

Microorganism research from extreme environments to use in bioremediation and other biotechnological applications.

Interest areas for futures colaborations/alliances: Environmental microbiology. Bioremediation. Biomonitoring. Metagenomics.

CYTOGNOS, S.L

Fernando Martín de Lara.
Director Financiero
fmartin@cytognos.com

Address: Polígono "La Serna", Nave 9. 37900 Santa Marta de Tormes - Salamanca

Phone: 923125067
www.cytognos.com

Cytognos S.L. is a biotechnology company based in Salamanca (Spain) dedicated to the design and development of new reagents, software and techniques that provide innovative solutions in the flow cytometry field. Our aim is to offer complete solutions in the diagnosis of haematological diseases by flow cytometry.

Products: Cytognos markets a large number of single, double and triple antibodies against human antigens and isotype controls, reagents to study cell cycle and DNA content (multiple myeloma, acute lymphoblastic Cell B Leukemia, Non-Hodgkin's Lymphoma Cell B ,Bladder Cancer screening), multicolor Kits for the study of lymphocyte subpopulations, monitoring of multiple myeloma and screening of Paroxysmal Nocturnal Hemoglobinuria.

We have also developed systems for absolute cell counting and the erythrocyte lysing solution Quicklysis.

Another Cytognos´ product is the flow cytometry Analysis Data Software INFINICYT, one of the most powerful and complete software worldwide, supported by the EC within the VI Frammework Programme.

Areas of interest for future collaborations: Cytognos is always open to possible collaborations, both in the development of new joint projects, and in the commercial exploitation of new methods. The main areas of interest are those related to Oncology, Immunology and Hematology.

Digna Biotech, S.L.

Núria Safont.
Communications officer
nsafont@dignabiotech.com

Address: Avda. Pio XII, 22. Oficina 2. 31008 Pamplona - Navarra

Phone: 34 91 185 25 10
www.dignabiotech.com

A biotechnological company focused on developing new drugs from CIMA (Center of Applied Medical Research) of the University of Navarra. The goal of the company is to develop the patented products to clinical proof-of-concept and to forge partnerships with other biopharmaceutical companies in order to complete clinical development and commercial launch.

DIGNA BIOTECH has an extensive pipeline for several diseases in Hepatology, Gene therapy, Oncology and Cardiovascular developed so far. Three products are already in clinical phase (Cardiotrophin-1; Inferferon alfa 5, Disitertide (P144)) It is expected a new product reaching clinical trials every year.

RARE DISEASES: Escleroderma (morphea and systemic sclerosis): Disitertide (P144). Isquemia / Reperfusion in solid organ transplant: CT-1 (cytokine). Acute intermittent porphyria: Viral vector adeno-associated for the deficiency of porphobilinogen deaminase (PBGD)

ONCOLOGY: Melanoma: P17 and Disitertide (P144). Actinic Queratosis: Disitertide (P144). Skin cancer: Disitertide (P144). Bone metastasis: P17. Therapeutic vaccine: EDA-HPVE7. Oncologic adjuvant: P17.

OFTALMOLOGY: Macular degeneration: P17 and Disitertide (P144)

HEPATOLOGY: Hepatitis C: IFNa5. Hepatic resection: CT-1 (cytokine).

NERVOUS CENTRAL SYSTEM: Multiple sclerosis: MTA (small molecule). Alzheimer: 4PBA (4-phenylbutyrate)

ALLIANCES: CT-1: Hepatic indications are alliance to Biotecnol y Genentech. Porfiria Viral Vector: Licensed to AMT. Alliance with AMT to search and development for treatments based in viral vector for gene therapy.

INTEREST: Therapeutic vaccines, oncology, nervous central system diseases

Diomune S.L.

Carolina Egea. CEO
cegea@diomune.com

Address: C/ Santiago Grisolía Nº2. CP 28760 Tres Cantos - Madrid

Phone: 34 91 806 46 56
www.diomune.com

Diomune is a biotech company specialized in research and development of new immunology treatments oriented to human and animal health areas in infectious, inflammatory and autoimmune diseases. The three main lines of business of the company are to develop a veterinary drug to cure canine leishmaniasis, research and develop a drug to treat sepsis in humans and seek licensing agreements for the use of an innovative immunomodulatory compound as an adjuvant for vaccines. Thanks to our experience, Diomune SL offers other research groups and companies a range of products and services of high complexity.

PRODUCTS/SERVICES: Murine models of sepsis (LPS, E. coli, CLP), Leishmaniasis, models with and without adjuvant vaccine or with and without subsequent treatment, inflammatory models (rheumatoid arthritis, psoriasis, asthma, acute inflammation by carrageenan peritonitis by thioglycolate), Cancer colon associated with ulcerative models, metabolic syndrome and obesity, hepatic cirrhosis, and so on.

Validations: Microbiological tests, determination of glucose, lactic acid, cell proliferation, apoptosis, cytokines in culture supernatant and serum, monitoring of cell populations by flow cytometry, antibody titers, study of the Th1/Th2 balance, and so on. Variety of cell types available.

Diomune uses the latest advances in Molecular Biology, Immunology and Research to meet the technological demands of enterprises: servicios@diomune.com

INTEREST AREAS: Our main interest for future collaboration focuses on the implementation of licensing agreements or joint ventures, with other companies with greater capacity than ours, to develop clinical trials for sepsis and septic shock in human phases with our drug (which has been shown excellent results in animal models). Also, we would like to contact other companies who develop and/or market vaccines that seek new adjuvants to enhance their action. Our major interest in collaboration is Vaccine Development. Diomune has a potential immunomodulator able to direct immune responses to be used as vaccine adjuvant. We are looking forward to find partners interested in using them as adjuvant in their vaccines or as immunomodulator in Immune-based diseases.

Draconis Pharma,S.L.

Jordi Vilar. Sales & Business Development Manager
jvilar@draconispharma.com

Address: Av. Cami Reial, 51-57 / Pol. Ind Riera de Caldes - Palau-solità i Plegamans. Barcelona

Phone: 34 902 565 092
www.draconispharma.com

Draconis Pharma is a biotechnology company focused on providing scientific and technological services to pharmaceutical and biotechnology companies, aimed at supporting drug discovery at different stages of research, such as target validation, hit-finding, hit-to-lead and lead optimization towards the release of a robust and well-characterized preclinical candidate.

Draconis offers services and has expertise in the following areas: Medicinal chemistry. Analytical chemistry. Cell-based assays. In-vivo efficacy. ADME & PK. Toxicity & Safety. Quality assurance. Integrated service.

Draconis Pharma also dedicates part of its resources to the discovery and development of innovative drugs for the treatment of inflammatory, autoimmune, allergy or pain disorders. Currently, Draconis is collaborating in two independent drug discovery programs, Neogenius Pharma and Dendria, focused on the identification of innovative molecules to treat inflammatory pain and neuroinflammatory diseases respectively.

EntreChem, S.L.

Francisco Morís.
Co-founder & CEO
info@entrechem.com

Address: Edificio Científico Tecnológico, Campus "El Cristo" Oviedo - Asturias

Phone: 34 985 259021
www.entrechem.com

Our objective is the discovery and development of bioactive new chemical entities (NCEs) from m icrobial natural products. We generate novel analogs by combinatorial biosynthesis of the corresponding metabolic pathways, identify the most promising candidates and advanced the preclinical development until demostration of efficacy "in vivo".

PRODUCTS: EntreChem offers genetic engineering for identification and manipulation of metabolic pathways from bacterial natural products of interest in the pharmaceutical (antibiotics, antitumorals, antifungals) and agro (insecticides, herbicides) sectors. EntreChem offers enantiopure products for medicinal chemistry and services of applied biocatalysis, as well as custom synthesis of optically pure compounds.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Discovery and developmente of new drugs from natural products by genetic engineering and biocatalysis. Antibiotic and antitumoral activity assays (cellular and biochemical), target identification. Early preclinical in vivostudies (efficacy, PK). Bioprocess scale-up

ERA Biotech

Sr. Lieven De Smedt. Director General info@erabiotech.com
Address: Parc Científic de Barcelona. Baldiri i Reixac, 15-21 Barcelona - Barcelona

Phone: 34 934 034 773 www.erabiotech.com

Era7 Information Technologies, S.L.

Eduardo Pareja-Tallo.
Director General
epareja@era7.com

Address: BIC Granada Avda. de la Innovación 1 Parque Tec. Ciencias de la Salud 18100 Armilla - Granada

Phone: 34 958 256 771
M Phone: 34 655 660 448
www.era7.com

To help biotech companies and organizations in the biomedical field to take advantage of Information Technologies for a better information and knowledge management. With this objective in mind we design and provide advanced software solutions specially based on Internet technologies.

PRODUCTS: Palinsight Pro : software for DNA palindromicity analysis and representation. Livera7 : Software specially designed to manage and held real time virtual Congresses and workshops.

SERVICES: Services of Knowledge Expression. Services of custom software development of Web applications, intranets, Web platforms and bioinformatics workflows automation. Bioinformatics and biosciences consultancy services.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Bioinformatics software development. Participation in R&D and innovation projects including participation in the EU VII Framework Program. Agreements for marketing and distribution of our services and products.

Esteve

Dr. Eduard Valentí.
Regulatory Affairs Director & Pharmaceutical Quality Head
evalenti@esteve.es

Address: Av. Mare de Déu de Montserrat, 221 Barcelona - Barcelona

Phone: 34 93 446 60 00
www.esteve.com

ESTEVE is a private, fully integrated International Group that pursues innovation and excellence in the pharmaceutical-chemical industry, while maintaining its dedication to the promotion of health for the benefit of society.

R&D: ESTEVE invests significantly in R&D, focused in analgesia. Its lead program is a Sigma-1 receptor antagonist for neuropathic pain.

ESTEVE is a diversified company marketing a wide range of ethical and OTC pharmaceutical products, vaccines, generics, products for veterinary use and it manufactures APIs.

ESTEVE has also established strategic alliances, ISDIN for dermatological products and ESTEVE-TEIJIN-HEALTHCARE in home respiratory therapy.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: ESTEVE is open to evaluating new opportunities for collaboration, especially in the area of analgesia.

Eurosemillas, S.A.

José Pellicer. Development Manager
eurosemillas@
eurosemillas.com

Address: Pº de la Victoria, 31 1º A Córdoba - Córdoba

Phone: 34 957-421732
www.eurosemillas.com

To be a company of reference in the farming world, committed to agricultural development in the geographical areas where it is present.

PRODUCTS: Select seeds CottonGrain: cotton grain animal feed Cotton fibre Oleaginous oils Development of licences for various plants: Fruit trees. Strawberry. Citrus fruits. Raspberry Others: avocado pears, asparagus, etc.

SERVICES: Farming news portal http://terraagraria.es Development of an electronic commerce platform.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Select seeds Genetic improvement Biotechnology Development of plant varieties Farming portal Extraction of vegetable oils and cotton fibre.

Ferrer inCode, S.L.

Jordi Puig. General Manager
jordi.puig@ferrerincode.com

Address: Diagonal, 549
08029. Barcelona - Barcelona

Phone: 34 93 600 37 00
www.ferrerincode.com

Ferrer inCode's goal is to offer personalized medicine services that make it easier for health professionals to make decisions on disease prevention. In so doing, it contributes to the improvement of the therapeutic targets of treatment and consequently on the quality of life of patients whose pathologies, such as cardiovascular and oncological diseases, have a major impact on the health system.

Ferrer inCode's services are based mainly on the latest genomic, proteomic technologies.

CardioinCode®, DNA-Chip analyzes more than 111 genes to determine the risk to suffer a cardiovascular event in patients with moderate risk and will identify the altered signaling pathways with cardiovascular significance for the patient.

Sudd inCode ® DNA-Chip determines the risk to suffer sudden death identifying more than 50 genes associated to arrhythmic congenital syndrome and cardiomyopathys.

Nutrichip®, DNA-chip for apply nutrigenetics and nutrigenomics to personalize the diet and to identify the genetic causes of the obesity.

MammaPrint® measures the expression of a ser of 70 genes which means that patients can classified as having low or high risk of relapse so that adjuvant chemotherapy is delivered only to those patients who really need it.

CancerType® uses a gene expression analysis comprising 92 genes and can locates the primary tumor among 54 different types of tumors.

ADTect® evaluation of the genetic profile of 96 genes which help diagnose an illness of he central nervous system. This provides the doctor with a practical, less invasive and quick methodology.

Ferrer Internacional S.A.

Dr. Andrés G. Fernández.
Innovation in Biotechnology, Head
agfernandez@ferrergrupo.com

Address: Avda. Diagonal 549; 5ª planta 08029.
Barcelona - Barcelona

Phone: 34 936.003.867
www.ferrergrupo.com

FERRER is a private pharmaceutical group that works for the wellbeing of society through the promotion of health.

FERRER Grupo, formed by more than 50 companies, has a direct presence in 26 countries and its products are present in more than 90 territories.

FERRER is characterized by the diversification of its business covering drug prescription, vaccines, molecular diagnostics, OTC and food additives.

FERRER maintains a high investment in R&D of new therapies, having a specific area dedicated to the collaborative research and focused on biotechnology projects originated in the Academy or biotech companies.

FERRER has research centres in Spain, Germany and India. FERRER internal R&D investigates new drugs in the field of antimicrobials and sleep disorders. It also develops projects under the "polypill" concept to facilitate treatment compliance and the rationalization of costs for the health systems.

The area of Innovation in Biotechnology identifies, promotes and develops therapeutic and diagnostic projects in collaboration with external groups. Projects, based on cutting-edge technology platforms, provide high added value therapeutic solutions in fields such as CNS, cardiovascular, oncology, infectious diseases, dermatology, ophthalmology and gastroenterology

Gadea Biopharma, S.L.U.

José Luis Barredo.
Biotechnology Director
joseluis.barredo@gadea.com

Address: Parque Tecnológico de León, Edificio Usos Comunes, Oficinas 101-102 24009 León

Phone: 34 983 54 82 72
www.gadea.com

Gadea Grupo Farmacéutico, S.L. is an independent Spanish group of affiliated companies dedicated to the development, production and commercialization of active pharmaceutical ingredients (APIs) and finished forms, as well as chemical and galenic process development. It is formed by the following companies: (I) Crystal Pharma, S.A.U., dedicated to the development, production and commercialization of APIs, and specialized in steroids, sterile steroids, and high potency products. (II) Gadea Biopharma, S.L.U., dedicated to lyophilization and aseptic filling of APIs under the highest quality requirements, and to the development of biotechnological processes for the bioconversion of vegetal raw materials to precursors of steroids. (III) Cyndea Pharma, S.L., company shared at 50% by Cinfa and Gadea. (IV) Hunan Norchem, Ltd. Chinese company 67% owned by Gadea.

Gadea Biopharma, S.L.U. works in the biotechnological field on the selection of microorganisms, and development and scale-up of different processes of fermentation for the production of APIs, mainly precursors of steroids. These precursors are used by Crystal Pharma, S.A.U. for the chemical synthesis of different kinds of commercial steroids. Additionally, it offers services to other companies for strain improvement and development of fermentation processes.

Moreover, Gadea Biopharma, S.L.U. is very active in the pharmaceutical field, focusing its activities on aseptic filling of Vials, Prefilled Syringes and Eyedrops. Expertise in suspensions and freeze drying, APIs and Vials.. It works on the development of new APIs and offer services to other companies

Gendiag

Margarita Garrido.
Associate CEO
margarita.garrido@gendiag.com

Address: Juan de Sada, 32 Barcelona - Barcelona

Phone: 34 93 509 32 33
www.gendiag.com

GENDIAG's objective is to facilitate the application of personalized medicine by providing diagnostic services for disease predisposition, early diagnosis, prognosis and drug-response prediction. These area based mainly in genomics, proteomics, metabolomics and bioinformatics technology.

GENDIAG creates alliances with investigators, research institutes, biotech and or pharmaceutical companies for the development of their project on a faster and efficient manner. GENDIAG wants to involucrate to the investigator in the development of the project and to share with him the benefits of the marketing when the idea turns into product.

The products developed by Gendiag and marketed by Ferrer inCode are: CardioinCode®), DNA-Chip analyzes more than 111 genes to determine the risk to suffer a cardiovascular event in patients with moderate risk and will identify the altered signaling pathways with cardiovascular significance for the patient.

Sudd inCode ®) DNA-Chip determines the risk to suffer sudden death identifying more than 50 genes associated to arrhythmic congenital syndrome and cardiomyopathys.

Nutrichip®, DNA-chip for apply nutrigenetics and nutrigenomics to personalize the diet and to identify the genetic causes of the obesity.

Trombo inCode® DNA-Chip for genotyping polymorphisms in genes involved in hereditary thrombophilia.This tool will incorporate the genetic tests that are currently performed individually and sequentially in order to find a genetic alteration.

Gendiag is currently leading new developments in Oncology, Neurology and Hepathology areas

GENETADI Biotech

José Luis Castrillo. CEO
info@genetadi.com

Address: Parque Tecnológico de Bizkaia. Edificio 502 Derio Vizcaya

Phone: 34 944044343
www.genetadi.com

Genetadi Biotech is a company that develops new human genetic diagnosis kits specialized in the gynecology, pediatric and oncology biomedical sectors. Our company is integrating its projects of research and development in Systems Biology applying the most modern techniques developed after human genome sequencing.

PRODUCTS: AMNIOCHIP & NEONATAL-ONE

SERVICES: Prenatal and neonatal testing by aCGH microarrays

Cytogenetic and molecular genetics services

Analytical metabolic services by mass spectrometry (MS/MS).

Human genomic NGS services

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Nanodiagnostics

Single-molecule DNA sequencing

Human genomic analysis (Bioinformatics)

Genetrix, S.L.

Juan Sebastián Ruiz. Institutional Relations Director
jsruiz@genetrix.es

Address: Pza de la Encina, 10-11. Núcleo 1, 3ª Planta. Tres Cantos - Madrid

Phone: 34 91 806 30 89
www.genetrix.es

Genetrix, created to promote entrepreneurial leaders in the biotechnology sector, is a group of companies aimed at generating value from using the results of academic and clinical research for the benefit of society.

SERVICES: Genetrix is constantly working to bring together the outcomes arising from different scientific disciplines, by setting up and maintaining collaborations of a varied nature with public research centres, technological centres, public and private hospitals and pharmaceutical and biotech enterprises. This collaborative spirit is one of the features that most identifies the Genetrix Groups and its has proven to be of great value in making this ambitious business project a reality. The Group is working on the creation of biotech initiatives assessing, designing and executing business plans in the life sciences field. The rapid evolution of the Genetrix Group is the direct result of the excellent quality of the work carried out by its professionals and the special concept held by its development team of the biotech business. The groups speed of development is also underpinned by the selection of staff from a scientific and business background, in the keeping up of the links and collaboration with a variety of groups and the appointment of professionals of the highest level onto its management team.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Biotechnology Life Sciences Scientific applications for medical purposes Investment in biotechnology .

Gennova Scientific, S.L.

Carmen Pérez. CEO
carmen@gennovalab.com

Address: C/ Vides, 24 TOMARES. Sevilla

Phone: 34 95 4150767
www.gennova-europe.com

Gennova Scientific is an international Biotechnology company in the life sciences and clinical diagnosis field. It is integrated in a business corporation committed to the development of new products and advanced technologies.

Our goal is to provide the highest quality in the production of innovative antibodies for in vitro diagnostic as well as the development of new products combining Nanotechnology and antibodies as an implement for the clinical diagnosis. Gennova is certified ISO9001:2008 e ISO13485:2004.

Gennova is mainly focused in the production of antibodies and ancillary reagents for Immunohistochemistry (IHC) and Histopathology Special Stains Kits.

We are interested in the improvement of multiple staining antibodies tests, optimization of antibodies production from Hybridomas, Histology, research&development and quality control.

New lines of development are Flow Cytometry along with Nanotechnology particles to improve the detection through antibodies. Also the design of DNA and RNA diagnosis probes for in situ hybridization applied to diagnosis and diseases monitoring

GENOMICA S.A.U

Rosario Cospedal
General Manager
rcospedal@genomica.es

Address: C/ ALCARRIA 7, Pol. Ind. Coslada, CP 28823 MADRID - MADRID

Phone: 34 916748990
www.genomica.es

GENOMICA S.A.U. is the first Spanish company focused on molecular diagnostics that also have an extensive experience in the analysis of Genetic Identification. Founded in 1990, it is located in the Community of Madrid and it is 100% owned by Zeltia. Our mission is to improve current methods of molecular diagnosis and genetic identification using reliable and automatic tools, according to the highest quality standards.

GENOMICA designs, manufactures and markets, nationally and internationally, molecular diagnostics applications (IVD) based on the amplification and subsequent detection of genetic material on its innovative CLART ® platform, which is a combination of low-density arrays and a colorimetric reader, that includes a specific software for its analysis, developed for this purpose (SAICLART ®).

To date market lines addressed are two: diagnosis of infectious diseases and pharmacogenomics related to cancer. This last one is based in the detection of human gene mutations associated with factors determining tumor response to therapy.

In the area of Genetic Identification, GENOMICA performs forensic genetic identification, parentage testing, "turnkey" projects for laboratories for analysis of genetic fingerprinting and population-based databases.

COLLABORATION INTERESTS: Marketing of diagnostics products mainly in Middle East,Eastern Europe and Asia. Inlicensing: Diagnostic systems in oncology and molecular microbiology. OEM opportunity in both markets.Outlicensing: Technology transfer and staff training on DNA genetic fingerprinting.

Genzyme, S.L.

Fernando Royo. CEO
genzymespain@genzyme.com

Address: Lanzarote, 2 San Sebastián de los Reyes - Madrid

Phone: 34 91 659 16 70
www.genzyme.com

The discovery and development of innovating products and services for serious pathologies, with special attention to rare diseases. *Genzyme S.L. is a subsidiary of Genzyme Corporation through Genzyme BV in Naarden (The Netherlands), dedicated to the development and introduction of therapeutic solutions for unresolved medical problems.

PRODUCTS: Lisosomal Storage Diseases: Gaucher, Fabry, Hurler and Pompe diseases. Hyperphosphatemia in chronic renal disease. Oncohemathology. Articular Viscosupplementation. Prevention of surgical adhesions. Biomaterials. Immunological disorders. Neurodegenerative diseases. Cellular therapies.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Rare diseases/Orphan drugs.

Renal disease. Oncology / Transplant

GH GENHELIX S.A.

David Marcos del Blanco.
Director of Corporate Strategy
dmb@genhelix.com

Address: Parque Tecnologico de Leon. C/ Julia Morros S/N 24009 Armunia - Leon

Phone: 34 987 219558
www.genhelix.com

Genhelix applies the highest standards of quality and the most advanced technology in protein production.

Our main asset, nonetheless, is our top-class staff which has a long tradition in top-class companies such as Lonza, Genentech, GSK etc.

Our main services include:

- Process Development; Preclinical, Clinical and Commercial Manufacturing under contract Monoclonal Antibodies) and other biologics as well as biosimilars.
- Scale-up, engineering and validation batches.
- cGMP manufacturing fully documented (20, 50, 200, 600 and 3 x 2000 l FULLY DISPOSABLE).
- Dossiers for main regulatory authorities (FDA, EMA, MHLW of Japan etc.)

Our partnering initiatives are focused on establishing collaborative relationships in the fields of:

- Monoclonal Antibodies and other recombinant proteins from Preclinical to Commercial scale.
- biosimilars (follow-on biologics) to reinforce our current projects in this area

Gilead Sciences, S.L.

Maria Rio
General Manager
ma.recepcion@gilead.com

Address: C/ VIA DE LOS POBLADOS , 3 .CRISTALIA EDIFICIO 7/8 , PLANTA 6ª Madrid Madrid

Phone: 34 91 378 98 30
www.gilead.com

Investigate, Develop and commercialize innovative drugs in therapeutics areas with uncover needs, with the objective to improve curation and surveillance rates in patients with severe infectious diseases.

PRODUCTS: HIV :VIREAD(Tenofovir disoproxil). EMTRIVA(Emtricitabina). TRUVADA(Tenofovir disoproxil y emtricitabina en un solo comprimido). ATRIPLA(Tenofovir disoproxil, emtricitabina & efavirenz ,one pill, once a day)

HEPATITIS B :HEPSERA (Adefovir dipivoxil), VIREAD (Tenofovir disoproxil)

ANTIFUNGAL : AMBISOME(Anfotericina B liposomica)

Glen Biotech S.L.

Berenice Güerri Agulló
Manager
b.guerri@glenbiotech.es

Address: Colegio Mayor. Ctra. San Vicente – Alicante s/n. CP 03690 San Vicente del Raspeig. Alicante -

M Phone: 34 633 034 536
www.glenbiotech.es

Glen Biotech is a spin-off from the University of Alicante (UA). Our mission is to develop innovative and sustainable solutions for problems linked to agricultural and landscape sector.

The main business line is the development and commercialization of biological control agents against pests, specifically against palm tree pests. In the future, we will expand our activities to other fields such as plant sample analysis for the detection of crop pathogens, search for secondary metabolites with biological activity, etc.

GP-PHARM, S.A.

Isabel Bazán
Assistant CEO
ibazan@gp-pharm.com

Address: P.I. Camí Ral. Isaac Peral, 17 Gavà - Barcelona

Phone: 34 93 638 80 00
www.gp-pharm.com

Research, development, manufacture and commercialization of Injectable products for the areas of Oncology, Nervous Central System, Cardiology and Urology. Based on two Drug Delivery Technological Platforms (Micro- nanspheres and Liposomes)

PRODUCTS: Development and Contract Manufacturing services based on the two Drug Delivery Platforms of injectable drugs (Micro- Nanspheres and Liposomes). Products in phase of commercialization or register (Octeotride-Irinotecan-Leuprolide-Oxaliplatino-Gemcitabina). RD Projects in different phases of development (Oncology-CNS-Cardiovascular)

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Utilization of our Delivery Systems for development new molecules or for improvement of current molecules that already have lost patent. Alliances with pharmaceutical companies to take our products to the Market (USA, Japan, China, India). Alliances with pharmaceutical companies to do joint development of GP-Pharm's projects. Manufacture and Development for pharmaceutical companies in our Laboratories and Manufacturing Plant

GRADOCELL,SL

Rossana García
rgarcia@gradocell.com

Address: Santiago Grisolía, 2 Parque Científico de Madrid Tres Cantos Madrid

M Phone: 34 664429569
www.gradocell.com

Gradocell is a consulting and CRO (Contract Research Organization) Spanish, founded in 2010, offering advisory services (technical and documentary) and training standards (GMP, GLP and GCP) in the field of advanced therapies (cell therapy , gene and tissue engineering) and Innovative Medicines and the preparation of necessary documents and monitoring of clinical trials in this area of biotechnology.

Our objective is to become the reference consulting company and CRO in Spain, and we are directed to companies and laboratories interested in implanting quality in both research and products belonging to advanced therapies.

Gradocell services are focused on consulting and helping our clients in their process to obtain and implement autorization regarding Cell Therapy regulations. We also give advice in documentation and procedures for addressing these guidelines. At Gradocell we can offer:

- GMP for advanced therapy laboratories.
- Preparation of audits and inspections by regulatory agencies.
- Specialized technical consulting in cell therapy processes.
- Consulting and elllaboration of documents for clinical trials in advanced therapies (IMPD, researcher manual, etc.) and monitoring of clinical trials in advanced therapies.

We advise and train your staff in all levels of the process: documentation, facilities, validations, etc. Our training offer in specialized in the preparation of: Quality managers, Manufacturing managers, Production technicians, Quality control managers, Quality control manager, Qualified person.

Grifols Engineering S.A.

Esperanza Guisado Moya.
VP Government and Public Affairs esperanza.guisado@grifols.com

Address: Avda. Fuentemar, 31. CP 28823 Coslada - Madrid

Phone: 34 91 748 12 08
www.grifolsengineering.com

Grifols Engineering is a company specialized in biotech and sterile manufacturing processes. Grifols Engineering offers consultancy and engineering services and also machinery development for the biotech industry (Ultrafiltration units, Filtration Skids, fermentors, CIP's, etc...) We have the know-how to design projects and specific machinery which comply with the European health authorities and the US FDA.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Biotechnology

Technological applications for medical purposes

Grupo Farmasierra

Tomás Olleros. President
tomas@farmasierra.com

Address: Carretera de Irún, Km, 26,200 San Sebastian de los Reyes - Madrid

Phone: 34 916 570 659
www.farmasierra.com

Pharmaceutical group of companies specialised in Research & Development, Manufacturing, Distribution and Marketing of Medicines, Food Supplements and Cosmetics operating at national and international level.

PRODUCTS:

Gynaecology: Remifemin, Carbocal 600 mg, Carbocal D, Carbocal D Masticable, Tricolam, Flucosil gel.
Paediatrics: Calcio 20 emulsión, Calcio 20 complex, Calcio 20 Fuerte, Aminoveinte, Trofalgón, Trilombrin,
Urology: Prosturol
Generics: Acetilcisteina,
Pain & Inflamation: Ibuprofeno Farmasierra 5% gel, Ibuprofeno Fermasierra 50 mg/g gel mentolado, Astefor, Ibustick
Central Nervous System: Sinequan
Antiinfectives: Terramicina, Terra-Cortril,
Línea 20: Ferro 20, Multivitamínico Farmasierra
Food Supplements: Bifibran, Lactospore, Omega 3, Visdon, Nutrobal, Aceite de Onagra Cosmetics

AREAS OF INTEREST TO FUTURE COLLABORATIONS:
In terms of services GRUPO FARMASIERRA offers:

- Technological Development and High Tech Contract Manufacturing Services
- Research & Development
- Manufacturing of investigational Medicinal Products (IMP)
- Licences out
- Licences in
- Warehousing and Distribution Contract Services

Hamamatsu Photonics

David Castrillo.
Manager Director
dcastrillo@hamamatsu.es

Address: C. Argenters, 4 edif 2. 08290 Cerdanyola del Vallés (Barcelona)

Phone: 935824430
www.hamamatsu.es

Hamamatsu Photonics; a global company with over 50 years' expertise in the manufacture of optoelectronic components. The company's corporate philosophy stresses the advancement of Photonics through extensive research and yields innovative, high quality products for a wide variety of applications. Hamamatsu Covers the whole spectrum and reaches up to single photon detection. Hamamatsu manufactures from components like photodiodes or CCDs to big systems such as cameras and HTS, for enduser application or specially custom designs to cover our customer´s needs.

Products:

- Components: Photodiodes, Photomultipliers, CCD, CMOS, Cameras for fluorescence and luminescence imaging.
- Systems: HTS, slide scanner, microscopy imaging, spectroscopy, lifetime analysis.
- Customized products. Detectors that can include optics, filters, electronics and mechanics to fullfill customer´s applications.

Our interest area is to become a partner when photons has to be detected.

Histocell, S.L.

Julio Font. CEO
info@histocell.com

Address: Parque Tecnológico de Bizkaia, Edificio 800, 2ª planta Derio Bizkaia

Phone: 34 94 656 79 00
www.histocell.com

Histocell Works in Tissue Engineering and Cell Therapy to develop innovative products for regenerative medicine. Histocell facilities include a 65m2 certified clean room for GMP production of Cell Therapy medicaments, and several laboratories for quality control and R&D. Histocell works with differentiated adult stem cells obtained from adipose tissue.

SERVICES: Cell Therapy medicaments.

Divided in three main lines: GMP production of adult mesenchymal stem cells from adipose tissue and chondrocytes. Development of new Cell Therapy medicaments. Development of biomaterials for regenerative medicine.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Open new research lines to provide solutions to lacks in regenerative medicine and cell therapy, in addition to providing products that facilitate testing tasks in the pharmaceutical and cosmetic sectors. Its interest is directed to research groups with expertise in the field of new biomaterials

Human Genome Sciences Spain, S.L.

Javier Barceló.
Country Manager
javier_barcelo@hgsi.com

Address: Avenida de Burgos 17, 2º Dcha. 28036 MADRID

Phone: 34 91 768 2247
www.hgsi.com

Human Genome Sciences Incorporated is a publicly traded company (Nasdaq HGSI) founded in 1992 in Rockville (Maryland, USA), by Dr. William Haseltine. By 1999, it was the first company in the world to place a genomic-based drug into clinical trials.

The company currently has two commercialized products: Benlysta® for the treatment of SLE and Raxibacumab for inhalation anthrax, and is developing a strong pipeline of early- to mid-stage investigational drugs in immunology and oncology.

Once HGS confirmed the strong potential of Benlysta® (belimumab) for the treatment of systemic lupus it signed a Co-Development and Commercialization Agreement with GSK to complete the phase 3 trials and commercialize Benlysta®

Over the next five years, Human Genome Sciences will emerge as a leading biopharmaceutical company known for generating innovative medicines that make a real difference in patient's lives.

The therapeutic areas of HGS are autoinmune deseases and Oncology, and now in research in more areas:

BENLYSTA - Systemic Lupus - Marketed

Raxibacumab - Inhalation Anthrax - Phase 3

Mapatumumab - Cancer - Phase 2

BENLYSTA – Vasculitis - Phase 1

BENLYSTA - Active Lupus Nephritis - Phase 1

HGS1036 – Cancer - Phase 1

Igen Biotech, S.L.

David Segarra de la Peña.
Managing Director
igen@igenbiotech.com

Address: Gustavo Fernández Balbuena, 11 Madrid

Phone: 34 91 510 29 99
www.igenbiotech.com

IGEN Biotech is a privately owned company focused on R&D in the biomedical field. Its aim is to put into practice biomedical research and development and bring it to the market as products and services. Its main field is development of new diagnostic methods, drugs and other therapeutic methods, focusing on the use of genomic, proteomic and cell therapy.

• Genomic DNA extraction kit for low cell concentration samples.

• Aptamers search and selection by SELEX Method.

• Specific R&D services in molecular biology, cell biology, experimental surgery and medicine and proteomics areas.

• Development of a growth factor for Parkinson's treatment.

• Drug-screening based on aptamers for ischemic stroke treatment and diagnostics.

Interest areas for futures colaborations/alliances:

• Companies interested in aptamers development and application.

• Public R&D Centres, Foundations, Universities and research groups interested in technology transfer and implementation.

• CMO's and CRO's with experience in clinical trials.

• European partners related with aptamers development.

ImmunNovative Developments

Josep Lluís Falcó. CEO
jlfalco@immunnovative.com

Address: Parc Científic de Barcelona. Biooincubadora PCB-Santander Baldiri Reixac 4-8. CP 08028 BARCELONA - BARCELONA

Phone: 34 934031945
www.immunnovative.com

Technological platform based in the development of new biological for the treatment, diagnosis and prevention of immune-based inflammatory disorders.

ImmunNovative-01: treatment of bacterial sepsis.

ImmunNovative-02: treatment of fungal sepsis.

Interest areas for futures colaborations/alliances:

• Biotechnology

• Sepsis

• Proteins

• GMP Development

• Regulatory

Immunostep, S. L

D. Ricardo Jara Acevedo.
CEO
rjara@immunostep.com

Address: Cancer Research Center of Salamanca Campus Miguel de Unamuno Avda. Universidad de Coimbra s/n. CP 37007 Salamanca

Phone: 34 923 29 48 27
www.immunostep.com

IMMUNOSTEP is a Biotech company focused in the proteomic area that research, develop, produce and market reagents and technologies both for research and diagnostics based on techniques such as Flow Cytometry, Proteomic Arrays or Multiplex Technology.

Our product areas include human and mouse cell immunophenotyping, human recombinant proteins, apoptosis, cytokines and growth factors, cell-cycle analysis, detection and quantification proteins.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

IMMUNOSTEP has its own research and diagnostics product development, production and quality control capabilities both for research nd diagnosis products (EN ISO 13485:2003/AC:2007, Health License to Manufacture IVD).

We have a multidisciplinary program, which includes the production of antibodies, recombinant proteins and different protein array formats for the development of technologies, solutions and diagnostic kits in vitro.

At present we have in our pipeline, developments related to hematological malignancies, respiratory and other illnesses.

Ingeclima, S.L.

Natalia Goya
ingeclima@ingeclima.com

Address: Dr. Díaz Emparanza, 39 A 48002. Bilbao Bilbao

Phone: 34 944 424 800
www.ingeclima.com

Our aim is to provide the best technological solutions complying with our customers needs in order to achieve a profitable exchange. We want to strengthen and improve by means of the excellence of our actions, exceed our customers expectations and adapt skillfully to changes in our environment.

INGECLIMA, ALBIAN GROUP member and 25 years experience company, is made up of a team of professionals specialized in turnkey projects for pharmaceutical, biotechnological, veterinary, and other related industries.

We provide solutions for all those who need to developed their production activities in controlled contamination atmospheres. (Reproduction and cellular handling, advanced therapies, biosafety).

We stay close to our customers since the initial idea of a new plant or production area to the validation, qualification and approval by regulating agencies.

Our aim is to provide suitable sensible and skilfull solution to optimize our clients in vestments.

Ingeniatrics

Joaquín Gómez Moya.
joaquin.gomez@ingeniatrics.com

Address: Camino Mozárabe 41 Camas - SEVILLA

Phone: 34 954 081 214
www.ingeniatrics.com

Ingeniatrics, Microencapsulation for you: Drug Delivery, Functional Nutrition and Chemicals microencapsulation products and services specialists.

Development, Scaled-up Process Validation, Transference & In-plant Manufacturing of particles at micro and nano scale for applications in Pharma, Biotech, Chemistry and Nutrition.

3 Pilot-plants, Whiteroom, Flow Spray-Dryer.

Wide range of sizes and materials.

LOW FOCUSING® One step microencapsulation by gentle proprietary technology producing small & homogeneous droplets.

Size and morphology control.

FLOW BLURRING® Production of sprays of extremely fine droplets with the lowest energy consumption.

NE-4 High throughput nebulizer for microparticles generation: nanoclays, lixiviates treatment..

IngredientiS Biotech S.L.U.

Jesús Jiménez López. CEO
jesusjimenez@ingredientisbiotech.es

Address: Avda. de la Innovación 1. Edificio BIC. Parque Tecnológico de la Salud Armilla - GRANADA

Phone: 34 958 750 985 / 628 735 741
www.ingredientisbiotech.es

Ingredientis Biotech is a biotechnology company dedicated to the discovery and development of bioactive ingredients with effects on obesity, cardiovascular disease and diabetes, for functional food industries and dietetics.

PRODUCTS:

- Discovery of Active Ingredients
- Product Development
- Nutrition and Health
- Use of Byproduct

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Discovery of bioactive compounds. Nutritional evaluation of bioactive compounds and functional foods. Developing products, processes and technology to food. Membrane separation technologies, microencapsulation, solubilization and controlled release of nutrients and bioactive compounds.

Inmunología y Genética Aplicada, S.A. INGENASA

Antonio Sanz Fernández
ajsanz@ingenasa.es

Address: Hermanos García Noblejas, 39. 8º Madrid

Phone: 34 913 680 501
www.ingenasa.es

Research, development, production and commercialisation of biotech products for animal health care.

PRODUCTS: Serologic diagnosis assays. Molecular diagnosis assays. Second generation vaccines.

SERVICES: Protein expression, monoclonal antibodies.

Institut Univ. de Ciència i Tecnología, S.A. (IUCT)

Angeles Molina. Manager of the Business Projects Dept.
Iuct.sales@iuct.com

Address: C/ Alvarez de Castro, 63 Mollet - Barcelona

Phone: 34 93 579 34 32
www.iuct.com

IUCT is a High-Tech Company for the discovery, creation, develop and exploitation new knowledge to be transferred or licensed to Chemical, Pharmaceutical, Biotechnology and other synergic industries. This knowledge is gained through a Pipeline of new products, processes and Technologies created in house, as well as a collection of technology and knowledge transfer services.

The misión of IUCT is to generate new Technologies, products and processes such as Pharmaceuticals, Chemicals, Fine Chemicals, Biotechnology products and Biofuels in order of being applied industrially in sectors.

To support this mission, IUCT has also created the Knowledge Capital Fund, which has been designed to invest and add value in the creation or growth of innovative companies related to the chemical, pharmaceutical, biotechnology and other synergic industries.

The company has 4 business activitits

1. Transfer Know-how and patents: Pipeline, from we remark: i. Chemical libraries to evaluate their pharmacological activity or Hits aimed to therapeutic areas such as inflammation, asthma, rhinitis, migraine, Parkinson Disease, Cocaine addiction treatment, Cancer and viral disease; ii. Second generation Biofuels; iii. "Green Solvents"; iv. "Green Chemicals Products"; v. APIs. Contract Research. Proprietary Technology Platforms for use in industrial Projects.

2. Technological Services: Multiple Analysis in different areas making in any of our laboratories of synthesis, physic-chemical and microbiology analysis. Pharmaceutical, nutraceutical and cosmetic production, Pharmaceutical Pilot Plant (GMP). Consultancy and Technical audit.

3. Knowledge transfer and scientific and technical training: Open training. Customized training in a Wide number of areas of scientific knowledge. Conferences, Seminars, Workshops and Congresses.

4. Joint Venture Empresarials: Spin off of IUCT proprietary Technologies. Joint Venture with consolidated business. Investment young technology companies through knowledge capital found.

Areas of interest to future collaborations: Pharmaceutical, biopharmaceutical and cosmetic sector. Chemical industry and fine chemical. Food industry. Environmental/ Health at work.

Instituto de Medicina Genómica (IMEGEN)

Ana Martínez Hortigüela
anam.hortiguela@imegen.es

Address: C/ Catedrático Agustín Escardino, 9 Paterna - VALENCIA

Phone: 34 963 212 340
www.imegen.es

Development of diagnostic tests based on genetic and genomic analysis, focused on the detection of hereditary disorders. Design and production of sets of analysis based on molecular biology techniques, for the diagnosis of human diseases. Promotion of alliances and collaborations public - private.

SERVICES:

- Services of molecular diagnostic
- Sets of molecular analysis of human pathologies
- Research Projects in genomic

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Diseases of hereditary transmission
- Oncology
- Farmacogenomics
- Next generation sequencing

Instituto Internacional de Flebología IIDF

Juan Cabrera. Chairman
juancabrera@iidf.es

Address: Dirección C/ Recogidas, 24 Portal B Bajo - 18002. Granada - Granada

Phone: 34 958253581
M Phone: 34 630951225
www.iidf.es

The Institute specializes in providing scientific and medical services related to sclerosing microfoam, the best and most advanced means for the removal of a large vein area. The mission of the International Institute of Phlebology.

IIDF is to offer the highest possible level of excellence in its research and in the transmission and innovative marketing of its achievements on behalf of the scientific community, healthcare and society in general.

The International Institute of Phlebology has set itself the following strategic objectives:

- Becoming in a reference center in Europe in promoting and conducting research, development and innovation in its field.
- Being a pioneer in translational research of new pharmaceutical vectors in biotechnology and gene therapy.
- Having a separate building that serves as headquarters in Granada's Health-Siciences Technology Park. Focus research effort in immediately applicable lines as nonsurgical treatment of hemorrhoids and varicocele.

Integromics, S.L.

Jose Maria Carazo
PhD. Principal Founder
carazo@integromics.com

Address: Avda. de la Innovación, 1 Armilla - Granada

Phone: 34 958 750 627
www.integromics.com

To provide the market with up to date knowledge on IT solutions in the field of life sciences and particularly in genomics and proteomics.

SERVICES:

- The development and marketing of software for genomic and proteomic data management, analysis and mining.
- Professional services relating to these products.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

The development and commercialisation of software for genomics, proteomics and related sectors.

Intelligent Pharma S.L.

Anna Serra. Business Development
aserra@
intelligentpharma.com

Address: Torre I, Planta 6. Parc Científic de Barcelona, c/Baldiri Reixac, 4-8 Barcelona - Barcelona

Phone: 34 934034551

www.intelligentpharma.com

Our mission is to be the preferred partner of the pharmaceutical and biotech industry in the computational side of the drug discovery research. By using our in silico tools, we can enhance their efficiency and productivity. Our final goal is to help our clients in reducing the time-to-market, the costs and the risks of the biomedical research.

We offer the best in silico services for drug discovery. Among our services we include hit identification, hit-to-lead optimization, identification of mechanisms of action, ADME/Tox prediction, etc.

We also offer advanced solutions based on scientific software for companies and institutions working on life sciences research, as electronic laboratory notebooks or animal facilities management systems.

AREAS OF INTEREST FOR COLLABORATIONS:
At Intelligent Pharma we are very opened to collaborations with private companies and academic research institutions. Our main areas of interest are drug discovery and personalized medicine

Janus Developments

Natàlia Ferrer. Head of administration nferrer@janusdevelopments.com

Address: PCB, Baldiri Reixac, 10 Barcelona

Phone: 34 934031351
www.janusdevelopments.com

JANUS DEVELOPMENT SL is a company specializing in the management of transitional stages of biomedical projects with a mission to transform knowledge into economic value and biomedical social.

JANUS has acquired licensing patent rights over 11 technologies for their early stage development and has worked with various hospitals, public research centers, foundations and private companies to define development plans for their technologies.

Interest areas for futures colaborations/alliances: JANUS, as areas of interest are all those companies, universities, hospitals ... with the need of our services, either to develop some technology to provide a counseling service.

Kymos Pharma Services, S.L.

Lara Ferrer
Marketing Manager
lferrer@kymos.es

Address: BALDIRI REIXAC, 10. 08028 Barcelona -

Phone: 34 934020280
www.kymos.es

Kymos is a Contract Research Organization specialised in analysis for the pharmaceutical, fine chemicals, biotechnology and veterinary sectors. Our facilities, are located, at the Parc Científic de Barcelona Ever since its establishment Kymos have created a wide network of contacts of a large variety; the main objectives of such network are to enlarge the list of our services, to establish synergies, to update and widen our knowledge and make our company known, with the aid of the best allies in each case.. We have also privileged access to the Parc Científic's equipments.

Our services support our customers as far as research, development, registration and marketing of their products is concerned, which enables them to speed up their projects, optimise internal resources and facilitate their approach to an advanced analytical technology. Our technical team's analytical specialisation is high, and are widely acquainted with regulatory aspects required for designing and carrying out the studies. We ensure the quality of the studies carried out which are performed in accordance with internationally accepted quality standards (GLP/GMP). We offer a complete range of services. We are ready to act on all aspects of drug development requiring analysis: synthesis, pharmacokinetics, toxicology, metabolism, galenic pharmacy, clinics, quality control and manufacturing.

Labgenetics, S.L.

www.labgenetics.com.es

Jorge Puente Prieto
General Manager
jorge.puente@labgenetics.com.es

Address: C/ Poeta Rafael Morales, 2. 2ª Planta. San Sebastián de los Reyes - Madrid

Phone: 34 91 659 22 98

To carry out highly accurate and decisive genetic tests within a minimum response period. To apply the most advanced techniques to identify alterations in the DNA sequence related to the onset of the most prevalent hereditary diseases in Europe. To consolidate as the Reference Centre in Forensic Genetics and Human Genetic Identification Tests.

PRODUCTS: Forensic Genetics: Paternity testing, parentage (kinship) analysis and genetic identification (DNA fingerprinting) from any biological traces. Reference Centre in complex kinship testing and complex Forensic sample analysis. Detection of biological fluids (semen, blood and saliva) Clinical Genetics: Molecular Diagnostics of more than 250 hereditary diseases. Personalized Genetic Diagnostic Service ("A la carte" Diagnostic) to comprise rare diseases. Prenatal Genetic Diagnostic, including the fast aneuploidy screening by QF-PCR, and Preimplantational Genetic Diagnostic (PGD) to select genetically healthy embryos. Technology Transfer: Set up and start up of Molecular Biology turn-keylaboratories, focused on human genetic analysis. The designed projects are highly flexible and are adjusted to the petitioner requirements. Scientific Advisory Services: Interpretation of expert reports based on DNA evidences in civil legal and penal procedures. Assistance to legal procedures as judicial experts to ratify specialist's reports based on DNA evidences. Theoretical and practical training in Forensic Genetics and Genetic Diagnostic techniques to professionals, private individuals, companies, laboratories and research teams.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Development of new Molecular Diagnostic techniques. Projects of Forensic Genetics and Genetic Diagnostic training. Development and distribution of new Molecular Diagnostic Kits.

Laboratorios Alpha San Ignacio Pharma S.L. (AlphaSIP)

Miguel Roncales. DIRECTOR
mroncales@alphasip

Address: Calle María de Luna 11, Nave 13. CP 50018 – ZARAGOZA

Phone: 34 976 512 887
www..alphasip.es

AlphaSIP's main goal is to develop benchmark medical diagnostic devices to contribute to the improvement of the international healthcare system and foster advances towards personalized medicine

AlphaSIP is mainly focused in the Haematology sector to provide a medical diagnosis tools capable of detecting thrombosis risk.

Laboratorios LETI, S.L. Unipersonal

Ellen Caldwell. BU Director, Immunology and Vaccines for Global Health
ecaldwell@leti.com

Address: Gran Via de les Corts Catalanes, 184. 7º 1ª, CP 08038 Barcelona

Phone: 34 933 945 350
www.leti.com

The company's objective is to contribute to sustainable improvements in heath and well-being, paying special attention to prevention, early diagnosis and treatment of personal healthcare. Having innovative, patented products is a key objective of LETI. The company dedicates to research and development between 8 and 10% of its turnover.

The company is focused in four areas—allergy,dermatolgy, diagnostics, and vaccines.

The Allergy Unit specialises in the production of allergenic extracts for in vivo diagnosis and etiological treatment of allergies.The Dermatology and Personal Healthcare Unit (DPH) is focused on the manufacturing of skincare and other, personal healthcare products. The Diagnostics Unit specialises in in vitro diagnosis and culture media for assisted reproduction. The Vaccine Unit is focused on the development of vaccines for the prevention of leishmaniasis.

AREAS OF INTEREST FOR FUTURE COLLABORATIONS:

Laboratorios LETI isinterested in inresearch and developmentcollaboration in theareas of diagnostics, vaccines, and therapiesrelatedtoallergy, dermatology, immunology and leishmanisis. In addition to research and development, the company is interested in expanding access of our products to international markets.

Laboratorios Ojer Pharma

Carlos González Ojer. Managing Director
cgonzalez@ojerpharma.com

Address: Sancho El Mayor nº 2, 1º izquierda Pamplona - Navarra

Phone: 34 948281776
www.ojerpharma.com

Ojer Pharma is a spin-off company of the University of Navarra that aims at developing a pipeline of innovative dermatological medicines with a national and international scope. Due to its tight collaboration with prestigious research centres from the public sector (Service of Development of Medicines, SDM, of the University of Barcelona) and the private sector (Center for Applied Pharmacobiology Research, CIFA, and the University Hospital of the University of Navarra, CUN), the company has direct access to cutting edge findings in medicine development, which allows us to provide our clients with more effective dermatological solutions.

Ojer Pharma Laboratories is the centre of a whole collaboration system in which it leads the major part of the research and development process. Our laboratory seeks for partners interested in co-developing dermatological drugs and willing to in-license its products.

Ojer Pharma's products portfolio consists of a wide set of innovative dermatological medicines for common dermatological diseases. The aim of our medicines is the simultaneous treatment of aetiological and symptomatological aspects of skin conditions, contributing to reduce both illness permanence and consumption of multiple products. The company is specialized in skin infections, dermatitis and pressure ulcers.

Laboratorios Rubió

labrubio@laboratoriosrubio.com

Address: c/ Industria 29 – Pol. Ind. Comte de Sert Castellbisbal - Barcelona

Phone: 34 93 772 25 09
www.laboratoriosrubio.com

Laboratorios Rubió S.A. is a Specialty Pharmaceutical Company manufacturer of finished and bulk pharmaceutical products, 100% privately owned. Its main focus is in manufacturing and / or commercializing medical products for diseases of low incidence / prevalence in the therapeutic areas of CNS, Rheumatology, Nephrology, Urology, Gynecology and Oncology-Radiotherapy. Rubió is a leading company in ADHD in Spain and has a significant presence in rheumatoid arthritis, lupus and chronic kidney disease.

Its main focus is the manufacture and / or marketing of specialty/products for diseases of low incidence/prevalence in the therapeutic areas of CNS, Rheumatology, Nephrology, Urology, Gynecology and Oncology-Radiotherapy.

It has a well established export business and licenses-out, export agreements for its main strategic products: Rubifen, Rubifen-SR, Dolquine, Resincalcio, Resinsodio and Resincolestiramina, Reutenox.

Rubio is present in over 40 countries and actively seeking new customers and markets as a strategic business and export.

Laboratoris Sanifit, S.L.

Bernat Isern Amengual. Scientific Director
laboratoris@sanifit.com

Address: PARC BIT. Ctra. Valldemossa, km 7.4. Edificio 17 - D3 Palma de Mallorca

Phone: 34 871 70 30 62
www.sanifit.com

Laboratoris Sanifit is a biotechnology company dedicated to the research and development of health products and to transferring this research for the benefit of society.

Sanifit´s work focuses on research and development of innovative drugs and products for the treatment and/or prevention of diseases, mainly in the cardiovascular, renal, osteoporosis and dental fields.

PRODUCTS:
SNF-471: experimental drug in preclinical phase indicated for the treatment of cardiovascular calcifications.
SNF-472: experimental drug in preclinical phase indicated for the treatment of coronary calcification in end stage renal disease patients.
SNF-571: experimental drug in preclinical phase for the treatment of calcic renal lithiasis.
SNF-671: experimental drug in preclinical phase for the treatment of osteoporosis.
ASB-01: consumer health products for the treatment of dental calculi.
Patents granted.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Drugs and other products in the following areas: Urology. Cardiology. Dermatology. R+D of new drugs.

Laimat Soluciones Científico Técnicas, S.L.

Josefina Pedrajas. Director
fpedrajas@laimat.com

Address: Parque Tecnológico Ciencias de la Salud de Granada, Avda. Innovación 1, Armilla - Granada

Phone: 34 958 750 951 / 858 100 141
www.laimat.com

Reach: Applied investigation for the development of new products for the biotechnological, agro food, pharmaceutical and chemical industries.

Mission: Contribute to improve society's health and welfare, participating in the development of new products for pharmaceutical and agro food industries, by applied investigation using physic-chemical particles properties Knowledge.

R&D:
- Microencapsulation of active ingredients for new materials, intelligent textiles and food.
- Development of electrochemical sensors with applications in food security, toxicology and diseases diagnosis.
- Services as external R&D department for companies from the agro food, pharmaceutical and chemical sectors.
- Provides solutions to physicochemical problems: Solubility, Stability, Formulation, Microencapsulation.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:
R&D Projects, in Health, Nanotechnology and Biotechnology areas:
- Microencapsulation and controlled delivery of drugs
- Adaptation of a new analytical technology for determination of toxics and early diagnosis. Provides: portability, quickness, sensitiveness, selectivity and easy use.
- By-products revaluation
- Polymorphs determination
- Physicochemical characterization of biopolymers
- Solubility
- Stability control

Life Length

Stephen J. Matlin. CEO
info@lifelength.com

Address: C/ Agustín de Betancourt, 21 – 8º. 28003 Madrid - Madrid

Phone: 34 91 3956368
www.lifelength.com

Life Length, a spin-off of the Spanish National Cancer Research Center, is the world's only company able to measure critically short telomeres, a crucial biomarker test for measuring biological age for the public and providing telomere measurements services for drug development and clinical trials to the pharma / biotech industry.

Life Length, a life sciences company founded in 2010 to commercially exploit Telomere Analysis Technology (TAT) developed by Dr. Maria Blasco, Chief Scientific Advisor of Life Length and Director of Spanish National Cancer Research Centre, provides testing services to pharmaceutical and biotech industries for drug R&D and clinical trials, as well as to the general public through physicians and clinics interested in telomere indicators of biological age and overall health. Life Length is the first company offering such precise testing. The founding partners are the Botin Foundation, Dr. Blasco and Matlin Associates.

Life Science Praxis, S.L.

Laurence Mickalonis. President and Senior partner
laurence.mickalonis@lifesciencepraxis.com

Address: Av. Diagonal 468, 6ta 08006. Barcelona - Barcelona

M Phone: 34 610545732
www.lifesciencepraxis.com

Our mission, at Life Science Praxis, is to enable life sciences companies to maximize the value of their innovation by empowering bioscience with market insight.

We aim to help innovators:

- Maximizing the innovation Core Market Value, at the intersection of science, market and product and
- Differentiating a Technology Platform and/or Product throughout the development continuum up to launch
- In order to enhance their success chances in fundraising and/or exit strategy.

Our core services are:
Develop the Innovation DNA for a scientific platform, Define and assess Core Target Markets and Core Market Value, Develop and adapt optimal Target Product Profiles at the intersection of Science, Product and Market, Define and adapt Positioning, Value Proposition, Story board and Key messages that maximizes the innovation potential, Develop and support development or launch roadmaps and exit strategies, Collect Market Insight with diversified market research techniques to drive business decisions. We have experience in many therapeutic classes, particularly in oncology, immunology and rare diseases

Lipopharma Therapeutics

Vicenç Tur. CEO
v.tur@lipopharma.com

Address: Ctra. de Valldemossa, Km. 7,4. Parc BIT. Incubadora de Empresas de Base Tecnológica. Edificio 17- 2º piso. Módulo C-8 Palma de Mallorca

Phone: 34 971439 886
www.lipopharma.com

Lipopharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and initial clinical development of a new generation of medicines associated with a novel therapeutic approach: Membrane Lipid Therapy (MLT).

PRODUCTS: Minerval®, a Ras/MAP Kinase pathway inhibitor, is showing very high efficacy with no toxicity in several types of cancer, clearly outperforming approved drugs. A promising MLT based pipeline is also being consolidated, with potential applications in CNS (Alzheimer's Disease), cancer, inflammation or Spinal Cord Injury.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Lipopharma is seeking new partnerships and collaborations with pharmaceutical companies in order to complete the clinical development for Minerval® in cancer. We are also interested in R&D collaboration agreements to further advance our new MLT based products in attractive areas such as AD, inflammation, cardiovascular diseases or Spinal Cord Injury

Lonza Biologics Porriño, S.L.

Luis Sánchez Ureña
Site Manager
lonzaporrino@lonza.com

Address: La Relba, s/n
Porriño - Pontevedra

Phone: 34 986 344 060
www.lonza.com

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture.

Lonza Biologics Porriño is a manufacturing site from Lonza Group, which belongs to the Lonza Custom Manufacturing - Biologics (LCMB) division, a which offers comprehensive multi-product recombinant protein manufacturing services to the biotechnology and pharmaceutical sectors.

It also provides advanced analytical services for the characterization of proteins and manufacturing process support for the biotechnology industry.

Master Diagnostica, S.L.

Juan Jiménez Rodriguez
Manager
juan.jimenez@vitroweb.com

Address: Avda. Constitución, 20 Ofic. 208-209 Granada

Phone: 34 958 271 449
www.masterdiagnostica.com

Design, development and commercialization of systems for molecular and immunohistochemical diagnostic in oncology and infectious diseases.

PRODUCTS: Antibodies and detection systems for immunohistochemistry. Kits for molecular analysis of gene rearrangements in lymphomas. Kits for screening and genotyping of human papillomavirus by PCR. Kits for molecular diagnostic of zoonotic bacteria Kits for mutational analysis of tumoral genes.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Molecular diagnostic in infectious pathology. Mutational analysis of genes involved in pharmacogenetic and inherited cancer.

Merck S.L.

Marta Gállego
Dpto. Comunicación
comunicacion@merck.es

Address: C / María de Molina, 40. C.P.28006
MADRID

Phone: 34 917454400
www.merck.es

Merck is the pharmaceutical and chemical company with more tradition in the world, with origins in 1668. Merck seeks business success with a formula based on values and generate economic value. Our strategy is supported on three concepts that define Merck's strategy: Sustain, Change and Grow.

Merck is concentrated in two business segments: pharmaceuticals and chemicals. All activity of the company is organized into four Divisions: Merck Serono and Merck Consumer Health Care (pharmaceutical) and Performance Materials and Merck Millipore (chemical).

Interest areas for futures colaborations/alliances:

The Merck Serono division aims to provide innovative solutions to patients. We are specialized in the treatment of cancer, neurological diseases, infertility, hormonal and metabolic disorders, cardiovascular disease and other diseases with significant unmet medical needs, such as phenylketonuria. And we continue investigating to provide patients with therapeutic advances in our actual business

Merck, Sharp & Dohme de España, S.A. (MSD)

Carmen López-Lavid
Communication Director
carmen_lopez_lavid@merck.com

Address: Josefa Valcárcel, 38 Madrid

Phone: 34 91 321 06 00
www.msd.es

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. MSD

PRODUCTS:

MSD pipeline has over 20 promising late-stage candidates spanning the stages of life, and we have a presence in more than 100 countries around the world, including emerging markets. MSD also publishes unbiased health information as a non-profit service. To visit MSD pipeline: http://www.merck.com/research/pipeline/home.html?WT.svl=content

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Scientific discovery and development have always been the cornerstones of our company. Today, we conduct research in a broad range of therapeutic categories including cardiovascular disease, infectious diseases, vaccines, cancer, neurology and womens health. And, to help achieve our goal of saving and improving lives around the world, we are expanding our capabilities in new areas, such as biologics.

Miltenyi Biotec

Iván Alvarez-Sierra
Country Manager
macs@miltenyibiotec.es

Address: Ciudad de la Imagen. C / Luis Buñuel, nº 2
Pozuelo de Alarcón - Madrid

Phone: 34 91 512 12 90
www.miltenyibiotec.com

Miltenyi Biotec develops, produces, and markets state-of-the-art products and services for cell separation, cell analysis, cell culture, molecular biology, and clinical research applications.

PRODUCTS:

- MACS® Technology for Cell Separation.
- AutoMACS"
- CliniMACS®.
- Microarrays & Bioinformatics.
- Adsorbers for Therapeutic Apheresis.

Minoryx Therapeutics

Marc Martinell. CEO
mmartinell@minoryx.com

Address: TecnoCampus Mataró-Maresme, Av. Ernest Lluch 32, TCM2
08302. Mataró - Barcelona

Phone: 34 937021975
www.minoryx.com

At Minoryx, we are committed to finding novel treatments for life threatening rare diseases.

We prioritize pediatric diseases and we are currently focused on neurometabolic diseases of genetic origin.

Minoryx develops a new generation of small molecule drugs named pharmacological chaperones, which are the most promising approach to treat genetic diseases affecting the central nervous system.

As a complementary approach, Minoryx also progress repositioning-based projects.

Monsanto Agricultura España, S.L.

Jaime Costa
jaime.costa@monsanto.com

Address: Avenida de Burgos, 17 Madrid

Phone: 34 913 432 701
www.monsanto.es

To attend the world's food needs.
To conserve natural resources.
To protect the environment.
To serve our customers and our shareholders.

PRODUCTS: Monsanto is a group of companies whose activity is aimed at the development and improvement of agriculture and the food sector. Over the last 30 years Monsanto has been focusing in research, development and commercialization activities for agriculture and it has concentrated its aims on providing sustainable agricultural systems, beneficial for farmers all over the world.

Monsanto is committed to developing safe technologies and products that are beneficial for both farmers and consumers.

Our most outstanding products are our herbicides from the Roundup range and the Dekalb brand seeds. For further information on our products go to: http://monsanto.es/monsantoes/productos.html

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Plant Biotechnology
- Conservation agriculture
- Biofuels.

Myriad Genetics España, S.L.U

Felis Iglesias
Country Manager Iberia
iberia@myriad.com

Address: Calle Calendula Nº93 , Miniparc III , ED.K , PB 28109. El Soto de la Moraleja. Alcobendas - MADRID

Phone: 34 910916946
www.myriad.com

The promotion, development and commercialization of solutions, services, products and treatments for disease prevention and analysis, identification and evaluation of risks associated with any disease or prognosis of the disease in patients.

Predictive Medicine:

- BRACAnalysis: Testing for Hereditary Breast and Ovarian Cancer (HBOC) Syndrome.
- COLARIS: Testing for Lynch Syndrome (HNPCC).
- COLARIS AP: Testing for Adenomatous Polyposis Syndrome (FAP, AFAP, MAP).
- MELARIS: Testing for Hereditary Melanoma.
- PANEXIA: Testing for Hereditary Pancreatic Cancer.

Personalized Medicine:

- OnDose (US): Testing for 5-FU Dose Optimization.
- PREZEON: Testing for PTEN Status.
- TheraGuide(US): Testing to guide 5-FU related chemotherapy.
- Prognostic Medicine:
- Prolaris: Testing for Prostate Cancer Aggressiveness

NANOIMMUNOTECH

Rubén Santos Martínez de Laguna. Control Manager
rubensantos@nanoimmnunotech.es

Address: Plaza Fernando Conde Montero Ríos, 9. 36201 Vigo - Pontevedra

Phone: 886302070
www.nanoimmunotech.es

Nanoimmunotech is a spanish company in the Nanobiotechnology sector.

The core business is the "Functionalization and Characterization of nanoparticles, along with the appropriate advice, prior to their use in different applications."

Vision: To become a world reference in the Functionalization and Characterization of "nanoscale systems"

Mission: nanoimmunotech commitment is to offer products and services that comprehensively cover market characterization and functionalization of nanoparticles, in the Biotechnology and Health sectors.

The company is based on the following business areas:

1. The core business of nanoimmunotech is the product portfolio based on the nitzipper® technology. This technology consists in two strategies for the multifunctionalization of nanomaterials. nanoimmunotech also offer personalized development projects, for the conjugation of different nanoparticles, biomolecules or drugs, depending on the needs of the customer.

2. Biological (in vivo and in vitro) and physicochemical characterization of nanoparticles and products using nanotechnology. Giving support to very different customers (pharmaceutics, cosmetics, diagnostics, agrifood market, etc.) so they can design better and safer products.

nanoMyP

Angel Valero Navarro.
Product and Marketing Managing Director
avalero@nanomyp.com

Address: Edificio BIC-Granada, lab 121 Parque Tecnológico de la Salud. Avda. Innovación, 1 18100 Armilla - Granada

Phone: 34 958637114
www.nanomyp.com

Our mission is to provide high-tech products that satisfy the most demanding needs of our customers, through the generation and supply of smart materials "on demand" with physicochemical properties fully customizable.

We base our competitiveness in the constant innovation of our products. That is why our main pillars are the training and empowerment in the creativity of our research team.

NanoMyP® vision is to be the national and international reference in the design and supply of smart materials based on nanotechnology and functional materials "on demand".

For each problem, a solution ... and nanoMyP® products are this solution.

NanoMyP® is a Spin Off company of the UGR which is specialized on the design and synthesis of polymeric and hybrid nano and microparticles, polymers and copolymers, and smart materials with tailored physicochemical properties to customer needs.

NanoMyP ® supplies: molecularly imprinted polymers (MIPs); Polymers of cyclodextrins; Polymeric nano and microparticles functionalized with OH, COOH, NH2, tertiary amines, pyridine, epoxide, Cl ...; Silica microparticles for biomolecules immobilization; and inert or functionalized (OH or NH2) magnetic particles.

In addition we offer our R&D Department to develop those materials you need for your business (materials "on demand").

NATAC BIOTECH S.L.

José Carlos Quintela
Chief Scientific Officer
natac@natac.es

Address: Parque Científico de Madrid. C/ Faraday 7. 28049 Madrid - Madrid

Phone: 34 91 827 64 70
www.natac.es

Natac is a biotechnology company dedicated to the investigation, development, manufacturing and commercialisation of healthy ingredients for their application in functional foods and food supplements as well as active pharmaceutical ingredients of natural origin, namely plant extracts and functional lipids. Also, Natac makes available to its clients a range of services aimed at placing the final product in the different sale channels.

Vision: To become a world reference company which through scientific knowledge, applies the benefits of nature to improving life quality.

Mission: To transfer, through strategic alliances, the scientific knowledge to industrial projects which generate value and contribute to improving health and quality of life.

OUR COMPETITIVE ADVANTAGE

- Knowledge of the key markets for functional ingredients.
- We are specialists in combining basic research, applied research, innovation and transferring knowledge to the market (SCIENCE TO MARKET).
- Ability and strength of a large company with the flexibility, agility and personal service of a small company.
- Research and development team of highly qualified professionals with wide experience in the development of new functional ingredients and scientific documentation to support health claims in functional foods.
- Potential to develop technological and commercial barriers with our proprietary products.
- Markets: APIs, nutraceuticals, functional food, animal feed and cosmetic.
- We have a wide range of proprietary products developed in different health areas. Please, visit our website.

NEOL BIOSOLUTIONS SA

Javier Velasco. CEO
info@neuronbio.com

Address: Avda de la Innovación 1, 18100 Armilla - GRANADA

Phone: 34 958 750 598
www.neolbio.com

Neol is focused on the discovery and development of industrial bioprocesses in the biofuels and chemical markets. Neol´s main goal is to provide efficient and environmentally-friendly solutions to the industry.
Neol owns a wide microbial collection and a highly qualified team that created Microbiotools by Neol, a technological platform that enables the development of bioprocesses up to industrial scale.
MicroBiOil®is a technology platform to produce second-generation biofuels from microbial oils. Via the use of specific micro-organisms, renewable feedstocks or industrial by-products are metabolized as the sole carbon source to obtain an oily biomass. Due to its fatty-acid composition these oils are suitable to be used as raw materials to produce biodiesel, renewable diesel or biokerosene. All processes and micro-organisms used have been fully developed by Neol and are protected by world-wide patents.
Neol is also at the development stage of a procedure for producing bioplastics from industrial by-products and renewable feedstocks (Tribioplast®). Such process is based on the cultivation of PHA over-producing strains isolated and developed by Neol.

Neuron Bio

Javier Velasco. CEO
info@neuronbio.com

Address: Avda de la Innovación 1, 18100 Armilla - GRANADA

Phone: 34 958 750 598
www.neuronbio.com

Neuron Bio specializes in the development of biosolutions for the pharmaceutical and agro-food industries via its divisions: BioPharma, Bioservices and Innofood by Neuron.

Long description: The Neuron BioPharma research division is devoted to the discovery and assessment of pharmaceuticals and nutraceuticals to treat and combat neurodegenerative illnesses such as Alzheimer's disease.

Neuron Bioservices division offers in vitro and in vivo assays for the discovery and evaluation of drug candidates.

Innofood by Neuron offers a versatile team with wide experience in the development of complete R&D+i projects for the agro-food industry.

Neuroscience Technologies, S.L.

Dra. Cristina Quiles
Director
cquiles@nsc-tec.com

Address: Parc Cientific,- Edifici Hélix. C/ Baldiri Reixac, 15-21 Barcelona

Phone: 34 93 402 01 64
www.nsc-tec.com

Research on the mechanisms of neuropathic pain. Development of new therapeutic drugs.

PRODUCTS: New drugs for neuropathic pain treatment.

SERVICES:
- Studies on patients with neuropathic pain.
- Studies on experimental models of axonal hyperexcitability.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:
- Development of new drugs targeting axonal hyperexcitability.
- Development of diagnostic devices for neuropathic pain.

NEUROTEC PHARMA SL

Marco Pugliese. CEO
marcopugliese@
neurotec-pharma.com

Address: c/Baldiri Reixac 15, Edifici Hèlix, Bioincubadora PCB-Santander Barcelona - Barcelona

Phone: 34 93 518 99 08
www.neurotec-pharma.com

Neurotec Pharma SL is a spin-off from the University of Barcelona founded in 2006 and based in the Bioincubator PCB-Santander, Science Park of Barcelona, Spain. The business model of the company is based on reprofiling, preclinical and clinical development of drugs to treat central nervous system (CNS) diseases that occur with inflammation and neurodegeneration such as Stroke, Alzheimer's disease (AD), Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). Neurotec Pharma is part of the BioRegion of Catalonia, member of Biocat network, founder member of CataloniaBio, and member of Asebio.

The team of Neurotec has an extensive experience in CNS research and we are developing our therapeutic proposals by using in vitro tools and accepted animal models of CNS diseases. Currently, in collaboration with the company Advancell, Neurotec is performing a Clinical Phase IIa trial in 13 Spanish and German hospitals to test the efficacy and safety of the compound NT-KO-003 in 105 patients with relapsing-remitting MS (Study NEUROADVAN). In parallel, Neurotec is completing the preclinical tests of an oral treatment for ALS with the purpose to enter in clinical phase in early 2013.

Newbiotechnic, S.A.

Evangelina Naranjo
enaranjo@nbt.es

Address: Paseo de Bollullos de la Mitación, 6 - PIBO Bollullos de la Mitación - Sevilla

Phone: 34 955 776 710
M Phone: 34 615 612 828
www.nbt.es

To identify, protect and commercialise microbiological and molecular tools with an immediate, practical application in the farming and agrifoodstuffs sector, which are safer for the consumer and more respectful with the environment.

Founded in 1999, NBT is an R&D company in farming and agrifoodstuff biotechnology, with three business areas: 1) Biological control agents 2) Gene technology for improving crops and 3)Molecular diagnostics services. It has genomics and phytopathology laboratories and a pre-industrial production plant and a HR team, including six people with PhDs. With a technological portfolio of over 20 patents and a research network of 45 groups at world level, NBT is a pioneer in the development and registration of biofungicides and leader in molecular phytopathology.

PRODUCTS: Biological Control Agents (biofungicides, bioinsecticides).Tools for plant improvement by genetic transformation.

SERVICES: Genomic and Bio-IT services. Phytopathological diagnostics. Agrifoodstuff diagnostic. Veterinary diagnostics. Human genetic diagnostics.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: The development of microbiological products for crop protection. Submerged fermentation technology and product recuperation. Co-development/ distribution of natural products for agriculture (microbiological products, plant extracts, organic extracts, etc.). Development of diagnostic genetic tests for farming, aquaculture, veterinary and food product applications. The development of concept tests in plant genetic transformation.

NIMGENETIS, GENÓMICA Y MEDICINA, SL

Beatriz Maroto
R+D Manager
bmaroto@nimgenetics.com

Address: C/ Faraday, 7. Parque Científico de Madrid Cantoblanco - MADRID

Phone: 34 91 8047760
www.nimgenetics.com

NIMGENETICS is a biomedical technology company dedicated to the research, development and innovation of last generation products (DNA biochips) to be used in genetic diagnosis of clinical and research samples.

Our main goals are:

To ease, in an efficient way, medical professionals´ access to the latest scientific advances in genomic tools such as Array-CGH for the improvement of health care at all stages, prevention, prognostic characterization and diagnostic reliability.

To offer researchers and research services, in addition to an extensive range of genomic tools, a personalized customer service that goes from the design and selection of the most appropriate platform, up to a complete biocomputer analysis.

The company is right now focused on three main areas:

- Own design of Diagnostic Biochips to be used for prenatal diagnosis (KaryoNIM® Prenatal 15K, KaryoNIM® Prenatal 60K), postnatal diagnosis (KaryoNIM® Constitutional 60K, KaryoNIM® Constitutional 180K), oncologic diagnosis (OncoNIM-CD Cancer Diagnostics, OncoNIM-CF Cáncer Familiar) and stem cells (KaryoNIM® Stem Cells)
- Services of Genetic Diagnosis based on our bichips, we provide our clients with a genetic report for the medical specialist to help in the diagnostic and management of their patients. This is possible because NIMGenetics is the only Spanish company authorized by the Community of Madrid's Health Department as an Analitical Diagnostics Centre with Genetic Unit, specialized in biochips.
- Services of consulting and development of genomic research, with an specialized service for the biomedical community in R&D institutes.

Noray Bioinformatics, S.L.U. (NORAYBIO)

Marta Acilu
General Manager
info@noraybio.com

Address: Parque Tecnológico de Bizkaia, 801 A - 2º Derio Bizkaia

Phone: 34 944 036 998
www.noraybio.com

Supports the life science sector.Aims to meet the needs of work in all aspects of the biosciences.

Animal research centres.

Biobanks.

Centres for assisted reproduction.

Laboratories and research units.

Pharmaceutical industry.

PRODUCTS: AniBio , NorayBanks, Fivisoft, NorayLIMS, NorayLab, Noraymet.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

NorayBio looks for strategic alliances and partnerships to continue the internationalization of its products and the company by opening branch offices abroad.

Noray Biosciences Group (Noray BG)

Julio Font. President
info@noraybg.com

Address: Parque Tecnológico de Bizkaia. Edificio 801-A. 2ª planta Derio - Bizkaia

Phone: 34 94 403 69 98
www.noraybg.com

Noray BG is a holding group focussed on Biosciences, whose mission is to manage and integrate the companies in the Biosciences sector to enhance their access to the market and their internationalization. NorayBio is currently composed by two companies: Histocell and NorayBio.

SERVICES: Noray BG is a holding dedicated to the management of its companies (NorayBio and Histocell, at the moment), in different fields like strategic management, business development, internationalization, financial management and human resources.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Noray BGs strategy for the near future is based on the continuous growth by means of collaboration agreements with other companies and institutions, development of new innovative products and acquisition or merger with new firms, everything done with the firm idea of motivating the expansion throughout the European and international market

Noscira, S.A.

Belén Sopesén Veramendi, PhD. Managing Director (CEO)
bsopesen@noscira.com

Address: Avda. de la Industria, 52 Tres Cantos - Madrid

Phone: 34 91 806 11 30
www.noscira.com

To research, develop and commercialise innovative drugs for the treatment and prevention of diseases of the Nervous System with unmet medical needs, especially focused on Alzheimer's disease (AD).

Noscira's main aim is to develop a treatment capable of modifying the neurodegenerative process of AD, which is able to slow down or halt its progressive course and bring about cognitive and functional improvement of patients.

Products:

- Tideglusib, only GSK-3 inhibitor in clinical development, in phase II for AD (as Nypta®).
- GSK-3 inhibitors programme for AD, in earlier stages of development.
- New targets programme.

Areas of interest for future collaborations/alliances: Noscira is currently in the process of negotiating a license for tideglusib for all countries, maintaining certain rights in Europe.

Additionally, Noscira may consider setting up specific collaboration agreements with the aim of co-developing any of their lines of research or compounds within the Nervous System field

Omnia Molecular, S.L.

RG Klingmann. CEO
rklingmann@omniamol.com

Address: C / Baldiri Reixac 15-21, PCB - Helix Building. 08028 Barcelona

Phone: 34 93 402 01 58
www.omniamol.com

Omnia Molecular Ltd. (Omnia) leverages proprietary technology to rapidly design first-in-class antibiotics targeted at difficult-to-treat hospital infections. Lead compounds are optimized and proven effective in animal models before being presented as candidates for co-development with pharma industry partners.

Omnia's platform applies a completely new approach to the selection and optimization of pharmacological compounds. Our proprietary platform is based on a validated molecular target of universal distribution and is currently being used to develop compounds against MRSA (Methicillin-resistant Staphylococcus aureus), a bacterium responsible for several difficult-to-treat infections in hospital. Our technology combines cellular assays that simultaneously evaluate compounds for several pharmacological parameters, thus accelerating and improving current methods for the discovery and development of anti-infective drugs. The resulting compounds are pharmacologically optimized and proven effective in a mouse model of infection.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:
We are seeking a co-development partner for our lead program against MRSA. The partner should be have the capacity to contribute the resources and expertise to move the selected drug candidate from IND through clinical trials.

One Way Liver Genomics, SL. (OWL)

Julián Sánchez. CEO
jsanchez@owlmetabolomics.com

Address: Parque Tecnológico de Bizkaia, Edif 502, pl 0 48160 Derio - Vizcaya

Phone: 34 94 431 85 40
www.owlmetabolomics.com

OWL is a biotechnology company with the mission to identify biomarkers and therapeutic targets in the field of high prevalence diseases. Its technological platform offers metabolomics and lipidomics services to Pharma, Biotech companies and Research Centers.

The company is focused in the area of human health, with pioneering applications in the international scientific arena, and its goal is to identify, validate, patent and commercialize diagnosis and/or prognosis systems, as well as therapeutic targets.

PRODUCTS AND SERVICES:

To consolidate the developments of OWL as a technology-based company, an innovative line of development has been developed, Metabolomics, which allows opening diagnostics to the massive identification of specific biomarkers for a given pathology. Currently there are two business lines:

In vitro serum based Non Alcoholic Fatty Liver Disease (NAFLD) diagnosis test..

Metabolomics and lipidomics services to pharmaceutical, biotechnology companies and research centers in key areas such as biomarkers discovery, clinical studies, diagnostics and toxicology.

AREAS OF INTEREST TO FUTURE COLLABORATIONS

- 1. OWL is applying its know-how in metabolomics to be used in other pathologies for both the diagnosis and prognosis within the framework of the personalized medicine.
- 2. Currently OWL is developing new research in hepatic diseases and other high prevalence diseases such as Multiple Sclerosis and CNS Diseases (Parkinson).
- 3. OWL is interested in Pharma, Biotech companies and Research Centers that demand metabolomics services for their own R+D, and is also seeking for appropriate partners to establish commercial alliances for new products and markets.

Operon, S.A.

Tomás Toribio. General Manager
Info@operon.es

Address: Camino del Plano, 19 Cuarte de Huerva - Zaragoza

Phone: 34 976 503 597
www.operon.es

To be international leader in 6 technologies relating to In Vitro Diagnosis: Monoclonal antibodies, recombinant antigens, agglutination latex, immunochromotography, ELISA and Molecular Biology tests.

SERVICES:

- Research, development and manufacturing of Monoclonal Antibodies.Research, development and manufacturing of Recombinant Antigens.
- RD&I and manufacturing of In Vitro Diagnostic kits based on immunological reactions.
- RD&I and manufacturing of In Vitro Diagnostic kits based on molecular biology.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Industrial production and purification of monoclonal antibodies and recombinant antigens.

Design and large scale production or with own brand of new In Vitro Diagnostic tests.

Oryzon Genomics S.A.

Carlos Buesa. CEO
cbuesa@oryzon.com

Address: C / Sant Ferran 74. CP.08940 Cornellà de Llobregat - Barcelona

Phone: 34 93 515 13 13
www.oryzon.com

Oryzon is a biomarker discovery company with a Diagnostic and Therapeutic pipeline focused in Oncology and Neurological disorders. Oryzon's mission is the identification of gene functions and proteins so as to design and develop biotechnological products that improve people's health.

SERVICES: The company has an integrated bio-marker discovery and validation platform and develops its own core research program, with an increasing number of projects in selected niches of the biomedicine arena always in partnership with the Academia and Pharmaceutical companies.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Oryzon has several important strategic alliances with food, biotech and pharmaceutical companies and is looking for industrial pharma and food partners to launch new global projects.

Palau Pharma S.A.

Heidi Sisniega
Chief Business Officer
hsisniega@palaupharma.com

Address: Pol. Ind. Riera de Caldes. Avinguda Camí Reial, 51-57. CP. 08184 - Palau-solità i Plegamans - Barcelona

Phone: 34 93 863 04 83
www.palaupharma.com

Palau is a product-driven biopharmaceutical company focused on the discovery and development of revolutionary and differentiated new medicines that are designed to address the unmet medical needs of patients suffering from inflammatory and autoimmune diseases. Its business strategy consists of developing compounds up to the point of obtaining their proof-of-concept in humans, and then establishing strategic alliances with multinational pharmaceutical companies for their subsequent development and commercialization.

Palau Pharma has a broad portfolio of projects at different stages of development from early discovery to the late clinical stages, including two in the market: a drug-coated coronary stent, ACTIVE®-IRIST®, being commercialized worldwide by Iberhopitex; and CIMALGEX®, a product for the treatment of inflammatory pain in companion animals, being currently marketed in Europe and in the near future in US by Vetoquinol Veterinary Pharmaceuticals. For more information about Palau Pharma's and its projects, visit our website www.palaupharma.com.

At Palau, partnering plays a strong role in both our business model and our development philosophy. We are actively seeking to establish partnerships with leading biotechnology and pharmaceutical companies for the late stage development and commercialization of our projects beyond Phase II clinical trials.

PANGAEA BIOTECH, S.L.

Elizabeth Breedlove
Corporate Development
ebreedlove@pangaeabiotech.com

Address: C/ Sabino Arana 5-19 USP Dexeus Instituto Universitario. CP 08028 BARCELONA

Phone: 34 93 546 01 19
www.pangaeabiotech.com

To become a top EU centre for cancer treatment, a worldwide reference for in-vitro diagnostics (IVD) of treatment response, and to develop innovative anti-cancer drugs with major clinical and commercial potential based on targeted approaches (i.e., early identification of the putative target population).

Discovery and development of gene signatures predictive of sensitivity to anticancer agents. Biomarker discovery agreements applicable to drugs under development. Service agreements to third parties. Technology transfer agreements.

Interest areas for futures collaborations/alliances:

Business development and out-license of our predictive models to diagnostic companies.

Strategic alliances with pharma and biotech companies in the field of cancer pharmacogenomics.

Service agreements on pharmacogenomics.

Development of new technologies applicable to cancer pharmacogenomics

Parexel International

Georgina Singleton
Director, Marketing
georgina.singleton@parexel.com

Address: Genova, 17-3 Planta. Madrid

Phone: 34 +44 1895 614530
www.parexel.com

SERVICES: PAREXEL is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.

Pevesa, S.L.

Iñaki Mielgo. General Manager and CEO
imielgo@pevesa.es

Address: Polígono Industrial Poliviso. Avda. de la Industria, s/n El Viso del Alcor - Sevilla

Phone: 34 955 946 024
www.pevesa.es

To be a reference in the design, production and R&D in the area of proteins, peptics and aminoacids and biochemical compounds employing biotechnology as a work tool.

PRODUCTS: Proteins, peptics, biochemical products.

SERVICES:

- Industrial Biotechnology and Biochemical Engineering
- Enzyme and Fermentation Technology
- RD&I Laboratories and Pilot plant

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Contract manufacturing, custom made manufacturing
- Product development
- Collaboration, research and development agreements for new products
- Joint Ventures
- Investment in biotech projects

Pharmamar, S.A.U.

pharmamar@pharmamar.com

Address: Avda. De los Reyes, 1 Pol. Ind. La Mina-Norte C.P.28770 Colmenar Viejo - Madrid

Phone: 34 91 846 60 00
www.pharmamar.com

PharmaMar, founded in 1986 and part of Grupo Zeltia, is a biopharmaceutical company which explores the seas to find innovative treatments. PharmaMar is conducting a pioneering marine biotechnology programme in search of new marine-based drugs. The company's research taps the sea, whose enormous biodiversity makes it a model for discovering new anti-tumour drugs.

PRODUCTS: PharmaMar currently has six compounds under clinical development for different indications. The sea´s potential as a source of medicines was confirmed with the 2007 approval of the first marine-based drug; PharmaMar obtained marketing authorisation for the treatment of advanced soft tissue sarcoma in adults throughout the EU and Switzerland, and also in countries where our partners undertake development and commercialisation. In 2009, the drug was approved by the European Comission for platinum-sensitive relapsed ovarian cancer.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Our business strategy is to find co-development partners who are able to successfully contribute to a joint development. To this end, we seek partners who can contribute to successfully develop our product portfolio of marine origin in Europe, USA and Japan. PharmaMar retains commercialization rights for Europe while granting licenses for all territories outside of Europe.

Pioneer Hi-Bred Spain, S.L.

Alberto Ojembarrena
Operations Manager.
Alberto.Ojembarrena@pioneer.com

Address: Avda. Reino Unido, s/n. Edificio ADYTEC - Euroficinas, 2ª Planta Sevilla

Phone: 34 954 298 300
www.pioneer.com

The development, production and commercialisation of agricultural seeds and inoculants for the conservation of animal fodder.

PRODUCTS: Maize, Sorghum, sunflower, cotton, soybean, corn, lucerne, rape seeds Lactic bacteria inoculants for animal fodder conservation.

SERVICES: Comprehensive agronomic services of complete advisory service to agricultural users of the plant species marketed.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: The development of varieties of plant species and inoculants for agriculture and stock farming. Development of methods and knowledge concerning stock feeding. Development of varieties of plant species for human nutritional use Development of varieties and processes for the bio-energy industry Development of processes for improving and knowing the agricultural crop environment better (soils, waters, efficiency and irrigation methods, abiotic factors, pest control, etc.).

Plant Response Biotech S.L.

Marisé Borja. Head of R+D
marise.borja@plantresponse.com

Address: Centro de Empresas Parque Científico-Tecnológico UPM Montegancedo 28223 Pozuelo de Alarcón Madrid

Phone: 34 91 452 4839
www.plantresponse.com

Plant Response Biotech S.L. develops new products, methods and bioassays for plant protection to promote sustainable agriculture based in science. PlantResponse strategy is based in a strong Intellectual Property portfolio from an international network with excellence public and private research groups. Our vision is to bring these products and traits form the lab to the greenhouse, from the scientist to the grower. Our products are routinely trialed under real production conditions.

PlantResponse has launched its first-in-class elicitor after completion of the field/greenhouse tests for proving wide pathogen resistance and yield increase in garlic and pepper both in ecological and integrated management. A platform for systematic High Throughput Screening (HTS) to identify Elicitors has been developed by our scientists. Validation in target crops is carried out in real production conditions both in field and greenhouse trials to guarantee the success and yield performance PlantResponse has wide experience in building bridges between academic researchers and industry. One of our mail goals is to bring exciting discoveries from the lab to the market.

Plebiotic

Álvaro López Medrano. CEO
alvaro.lopez-medrano@plebiotic.com

Address: C/ Gobelas 17, Planta baja 28023. Madrid

Phone: 34 917081076
www.plebiotic.com

Plebiotic focuses on the simulation of complex biological systems (protein-ligand and protein-protein interactions, amongst others) by means of Docking and Molecular Dynamics. Plebiotic owns a proprietary hardware and software system, based on GPUs. Plebiotic product has been used, with positive results, in pre-clinical simulations for drug design (neurodegenerative diseases, cancer...) .

Plebiotic focuses on the simulation of complex biological systems by means of Docking and Molecular Dynamics.

Plebiotic owns a proprietary hardware and software system, based on GPUs (Graphics Processing Units), called PleMD, that achieves high simulation rates at a very reduced cost. With PleMD, long and efficient protein-ligand, protein-protein... simulations are feasible. Plebiotic offers complete pre and post sales services, spanning from standard screening of chemicals libraries to end to end projects comprising structural design and analysis of new molecules (enzymes, ligand mutations...).

Plebiotic product has been used, with positive results, in pre-clinical simulations for drug design (neurodegenerative diseases, cancer...).

Probelte Biotecnologia

Pedro Martinez Ortiz
Managing Director
pedromartinez@probelte.es

Address: Ctra. Madrid, km. 384.6. Pol. industrial El Tiro, c/ Antonio Belmonte Abellán s/n. Espinardo Murcia

Phone: 34 968 307 250
www.probelte.es

PROBELTE BIOTECNOLOGIA has been defined, right from the start, like an competitive and innovative company with the corporate purpose of researching, developing, innovating and commercialising natural bio-active principles, either, functional or technological, obtained through green technologies and, addressed to the food, cosmetic, pharmaceutical and veterinarian sectors.

PRODUCTS: Natural bio-actives principles like POMANOX and MEDITEANOX of high concentration and purity, obtained through physical procedures. Develop of applications of the bio-actives principles for uses like either functional or technological ingredients in the food, cosmetic, pharmaceutical and veterinarian industries. Obtaining of natural and systemic vaccines for using in aquaculture; developing of effective and efficient ways of administration.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: New developing of applications and uses of the bio-actives principles in the food and pharmaceutical sectors. Developing of new natural bio-actives principles through green technologies. Developing on new fish vaccines

Promega Biotech Ibérica S.L.

Joan Garrell. Sales and Marketing Manager
joan.garrell@promega.com

Address: Avenida Bruselas, 5 – 3ª planta 28108. Alcobendas - Madrid

Phone: 34 902.538.200
www.promega.com/es

Our mission consists of providing reliable and competitive solutions to promote the progress of life science research, biotechnology and genetic identification, while offering a personalized service of high quality through sustainable practices.

Promega is a company that provides reagents and instrumentation to the scientific community to promote progress in life sciences, offering at the same time a personalized customer service and scientific advice.

The over 2,000 products in our catalogue allow scientists all around the world to enhance their knowledge through life science research, in particular in the areas of genomics, proteomics, cellular analysis and drug discovery. Our products are also used for specific applications in molecular diagnostics and human identity.

The mother company, Promega Corporation, was founded back in 1978 in Madison (Wisconsin, USA), and designed to provide an environment for innovation and creativity. Promega has proprietary branch offices in 15 countries and over 50 distribution agreements worldwide. One of these subsidiaries is PROMEGA BIOTECH IBÉRICA S.L. that started its activities in Spain in the year 2005.

ProRetina Therapeutics, S.L.

Stuart Medina.
General Manager stuart.medina@proretina.com

Address: Pza. CEIN, 5 Noáin - Navarra

Phone: 34 948 317 345
www.proretina.es

Development of drugs for treatment of retinal diseases

PRODUCTS:

- PRO-001. Neuroprotective agent for treatment of retinitis pigmentosa.
- PRO-015. Gene therapy for treatment of retinitis pigmentosa

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Novel molecules with potential ophthalmological indications
- Sustained release technologies for intraocular delivery of therapeutic agents

Proteomika, S.L.

Juan Buela
Communication Liaison
comunicacion@progenika.com

Address: Parque Tecnológico Bizkaia - Building 504. CP 48160 Derio Bizkaia

Phone: 34 944 064 525
www.proteomika.com

Kits development and production for in vitro diagnostic and treatment response evaluation. Protein biomarkers identification. Development and identification of new technologies for protein biomarker validation Design and development new technologies for biomarkers quantification.

Kits for in vitro diagnostic and therapeutic response monitoring for different cancers and autoimmune pathologies.

Methods for molecular typing in microbiology. Services of proteomic and citomic analysis.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Looking for partnerships in the medical field in order to develop products focused on assays which detect and quantify protein and autoimmunity biomarkers. Development of monitoring systems to follow medical treatments with biological drugs. Those partners can be specialized in the development of new technologies and instrumentation to run internal products.

PROTEOS BIOTECH, S.L.

Alina Girigan. Life SciencesMarketing Responsable
info@proteosbiotech.com

Address: 14 Almansa Str. - Bioincubator Albacete Albacete

Phone: 34 915417000
www.proteosbiotech.com

Production and commercialization of recombinant enzymes for their application in research, cosmetics and biomedicine.

PRODUCTS Recombinant enzymes and proteins – Collagenase, Keratinase, Pz-Peptidase, Subtilisine, Lipase, INF alpha 2b, INF beta 1b, G-CSF.

SERVICES Bioprocesses and biocatalisys using recombinant enzymes.

INTEREST AREAS FOR FUTURES COLABORATIONS/ALLIANCES: Cosmetics, Biopharmaceutical, Recombinant Enzymes and Proteins Production and Commercialization.

Proyecto de Biomedicina CIMA, S.L. (BITA)

Antonio Martin. General Manager
amartin@proyectobiocima.com

Address: Avda. Pío XII, 22. Ofic. 1 Pamplona Navarra

Phone: 34 948 287 561
www.proyectobiocima.com

Managing, patenting and exploiting all the results coming out from the research activity carried out in the CIMA project, a joint venture between a group of several first class spanish companies and the CIMA(Research center for applied medicine owned by the University of Navarra

PRODUCTS: See the web www.proyectobiocima.com

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Licensing for the development of the results owned by the company, through licensing agreements with biotech companies or by setting up new companies to develop these results

Rekom Biotech S.L.

Ana Camacho
General Director
agcamacho@rekombiotech.com

Address: Edificio BIC-Granada, 203. Avda. De la Innovación, 1. Parque Tecnológico de la Salud. C.P. Armilla - Granada

Phone: 34 958591887
www.rekombiotech.com

In Rekom Biotech our mission is to offer a high quality proteinic and genomic products related with infectious diseases, and also to offer advanced biotechnology services regarding design and development of new proteins and enzymes. Rekom Biotech expects to be a reference company for obtaining antigens coming from human and animal infectious agents.

For this reason our main aim is to obtain a wide antigen spectrum from all over the world, including both the most known diseases and less known locally important diseases, thus covering different potential markets.

Rekom Biotech is a biotechnology company focuses in the production of recombinant antigens as biomarkers of microorganisms responsible of human and animal infectious diseases. We also offer support of genomic design and process development for purification of native and recombinant proteins. We design and produce recombinant antigens as infectious diseases biomarkers with and without tags in order to make them versatile enough to perform their application in the different platforms of the IVD market. Also, we produce positive DNA controls focused in infectious diseases, which contains genes or gene fragments which can be used as positive controls in PCR and q-PCR assays. We are a biotechnology-based company, which consist of a multidisciplinary group of scientists coming from private industry and the University of Granada. This symbiosis makes us highly competitive in several areas.

The products of Rekom Biotech are designed, developed, produced and distributed according to our Quality Management System that is certified for compliance with ISO 9001 standards.

Repsol

Enrique Espí
Bioenergy Consultor
eespig@repsol.com

Address: Centro de Tecnología Repsol Ctra. De Extremadura,A5 - km 18
28935 Móstoles - MADRID

Phone: 34 917536457
www.repsol.com

Repsol es una compañía energética global que desarrolla su actividad en el sector de los hidrocarburos. Trabajamos cada día para desarrollar soluciones energéticas para nuestro planeta. Nuestro objetivo es satisfacer las necesidades de energía que permitan un desarrollo económico y social equilibrado en todo el mundo.

Creemos firmemente que la innovación y la tecnología son piezas clave para construir este nuevo modelo energético seguro, sostenible y competitivo.

Repsol está interesada en el sector de la bioenergía en toda su cadena de valor, desde la producción de materia prima a través de cultivos terrestres o acuáticos (algas) como en la transformación de la biomasa en biocombustibles, principalmente líquidos (del rango gasolina-queroseno-diesel) pero también gaseosos (biogás, biopropano...) o sólidos (pellets, torrefactado...) y tanto a través de procesos termoquímicos como biológicos

RJ Biotech Services

Carlos Nieto
R&D Strategy Director
carlos.nieto@reigjofre.com

Address: Gran Capita 6
08972. Sant Joan Despí
Barcelona

Phone: 34 93 480 67 10
www.reigjofre.com

RJ Biotech Services, is part of Reig Jofre Group, a leading European Development, Manufacturing and Marketing group of finished pharmaceutical forms with own presence in Spain, Nordics, UK and currently more than 180 clients and distributors in more than 52 countries. The main therapeutical areas of interest for internal developments as well as third-party development collaborations are dermatology, gynaecology, respiratory and anti-infectives.

RJ Biotech Services provides solid expertise in designing formulations and lyophilisation process for chemical and biological products with a "Centre of Excellence in Freeze-Drying", development and optimization of upstream and downstream processes, development of analytical methods for API and finished formulations, fill and finish for clinical batches with a GMP manufacturing site for investigational products, designing of advanced drug delivery systems for injectables and regulatory support for every stage of the clinical phases

Roche Applied Science

Carlos Freixas. Director
carlos.freixas@roche.com

Address: Avda Generalitat, 171-173 Sant Cugat del Valles - Barcelona

Phone: 34 935 83 40 00
www.roche-as.es

"Roche Applied Science provides superior bioanalytical solutions for the life science market", the business areas offers integrated solutions for research applications, including all experimental steps that lead from sample to results.

PRODUCTS:

- With more than 2000 products for:
- Genomics: Instruments and reagents for qPCR , nucleic acid extraction and analysys, pirosequencing and microarrays.
- Proteomics reagents and cellular analysis.
- Raw materials and industrial GMP Grade products, contract manufacturing and customized/dedicated products .

RPS RESEARCH IBERICA, S.L.U. (Grupo RPS)

Esther Ramirez
Director General
eramirez@rpsweb.com

Address: C / Via Augusta 21-23, 5ª y 6ª planta, CP 08006. BARCELONA

Phone: 34 93 2158008
www.rpsweb.com

RPS, the Next Generation CRO, provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries. By combining our highly experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project teams providing innovative, seamless, cost-effective and high quality services.

Early Development Support Services: Protocol Development, Study Design, Regulatory, Pharmacokinetic/Phamacodynamic, Data-Management, Biostatistics, Integrated Report Writing, Multi-disciplinary consultation services...

Full Service Clinical Development Phase I-IV: from study design through final clinical study report.

Outsourcing Solutions in Clinical Development: R+D, Regulatory Affairs, Data-Management, Biostatistics, Pharmacovigilance, Monitoring, Quality Assurance.

Interest areas for futures colaborations/alliances: RPS provides scientific support and clinical expertise to participate in the Phase I-IV clinical development with Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries

Salupharma Biosimilars S.A.

Mireia Pasalamar
Management Assistant
salupharma@salupharma.com

Address: Edificio EUREKA, Planta 1, Módulo 5.2, Parc de Recerca UAB, Universitat Autònoma de Barcelona Bellaterra

Mobile Phone:
34 650 814 417
www.salupharma.com

We are a biotechnology start-up founded by promoters with experience within the national and international pharmaceutical markets, and in close strategic alliance with the Universitat Autònoma de Barcelona.

Our mission is to allow patients to benefit from biotechnology medicines through the development and commercialization of biosimilars (low-cost versions of existing biotechnological medicines whose patents have expired), characterized by a high standard of quality, security and efficacy (being authorized by the European Medicines Agency), at a more affordable prices.

We are looking for partners interested in either develop or commercialize biosimilar products in the European market and in other regulated markets.

We develop and market high quality and highly competitive (cost-efficient) biosimilars based on:

Betting on innovative and highly cost-efficient expression platforms for the development and production of biosimilars.

Approaching the development of biosimilars in a smoothly designed scientifical-technical and regulatory-conscience manner in order to minimise risk, time, and investment.

Obtaining EMA scientific advice at crucial steps: e.g., cost advantages per Small and Medium Enterprise opportunities.

In addition we offer the following services to other companies: consulting services. pre-clinical and clinical studies.

SARTORIUS STEDIM SPAIN, S.A.U.

Carlos Císcar Escolà
Bioprocess Sales Manager
carlos.ciscar@sartorius-stedim.com

Address: C/ Isabel Colbrand, 10-12 local 70, Pol. Ind. de Fuencarral 28050. Madrid

Phone: 34 91.358.6091
www.sartorius.com

Sartorius is one of the world's leading providers of laboratory and process technologies and equipment. Our innovative products and high-quality services help customers around the globe implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way.

Our key customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. Strongly rooted in the scientific and research communities and closely allied with customers and technology partners, the company is dedicated to its philosophy of "Turning science into solutions" every single day.

Main business areas:

Filtration Technologies

Fluid Management

Fermentation Technologies

Purification Technologies

Integrated Solutions

Process Analytical Technology

Validation and technical service

Secugen, S.L.

Begoña López Gimaré
Sole Officer
b.lopez@secugen.es

Address: C/ Santiago Grisolía, nº 2 (Parque Científico de Madrid) Tres Cantos - Madrid

Phone: 34 918063105
www.secugen.es

The company's main objective is the development of methodologies for DNA analysis applied to research and genetic diagnostics tests. We market analytical applications for the diagnosis a la carte of any genetic disease using the most advanced DNA sequencing technologies, also providing a genetic counseling service. We provide molecular genetic testing services, among others, to hospitals, the pharmaceutical sector, the food sector and, in general, to all public and private research centers.

SERVICES:

- Clinical Services: Human Genetic Diagnoctics Tests. Genetic Counseling. Rare Diseases. Molecular Genetic Analysis a la carte.
- Molecular Biology Services: DNA Sequencing. Genetic analysis on demand (Animals, plants, microorganisms). Massive sequencing of genomes. Transcriptomics. Metagenomics.
- Research Services: Development of R & D projects in the field of genomics.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Our company is actively working with various companies and public and private research institutions for the development research projects in any scientific area where our expertise in Genomics, Genetics, Biochemistry and Molecular Biology can be helpful.

The company has been a pioneer in DNA sequencing and in particular in the introduction of new massive sequencing technologies and in 2007 founded the company Lifesequencing SL who settled in Spain the first massive sequencing platform's most advanced in the market, the GS-FLX (454) Sequencer, with the aim of making available to the companies and the scientific community one of the most powerful tools that currently exist for better understanding of the genomes of living organisms from man to microorganisms.

Sensia, S.L.

Iban LARROULET
General Manager
jsruiz@genetrix.es

Address: Plaza de la Encina, nº 10-11 (Edif. La Encina), Núcleo 1, Planta 3º, CP 28760 Tres Cantos Madrid

Phone: 34 91 806 30 89
www.sensia.es

Sensia is the first Spanish Initiative to set up a leading company in the instrumentation sector for life science research laboratories and for environment measurement.

Sensia develops and commercialises portable, mulitbiosensor systems, based on technologies developed by the Biosensors Group of the National Microelectronics Centre, belonging to the Higher Council for Scientific Research.

PRODUCTS: SENSIA 2-SPR is an instrument based on Surface Plasmon Resonance(SPR) which enables comparative measurements to be made by incorporating channels. It also includes computer-controlled pumps and microfluid valves for sample injection. The Surface Plasmon resonance is a powerful technology for measuring biomolecular interactions, allowing real-time measurements without having to brand the analytes. The 2-SPR system has a large number of applications; in general all those studies based on biomolecular interactions: biochemical and chemical detection, discovery of medicines, diagnostics, proteomics, genomics, forensic medicine, food analysis, environmental monitoring, etc.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- The development of biosensors and their components
- The development of new biosensor applications
- Basic and clinical research
- Diagnostic applications

Seprox Biotech

Yago Romero
Commercial Director
yromero@seprox.es

Address: Conde de Aranda 16 1º Dcha Madrid

Phone: 34 914362036
www.seprox.es

SEPROX BIOTECH is a Spanish company created in December 2008. Between its main business areas is the production at industrial level of Hydroxytyrosol, Hydroxytyrosol Acetate and 2-3,4 Dihydroxyphenilacetic Acid.

SEPROX BIOTECH has developed its own production process using chemical synthesis and enzymatic biocatalysts.

The great power of these compounds is its high antioxidant capacity together with its powerful free radical scavenging activity. Historically, these compounds were extracted from olive leafs, reaching lower purity levels than SEPROX BIOTECH products. They can be applied in cosmetics, nutrition, and pharmaceutical and food industries.

Its brand new production method gives SEPROX BIOTECH a competitive advantage over its competitors dedicated to extract polyphenolic compounds from natural sources, due to the quality levels (in terms of purity – over 99.7%- and deep control of impurities) that our products reach, and the reproducibility, which is extremely important when applied to nutrition, cosmetics or pharmaceuticals.

SEPROX BIOTECH offers its products to interested companies, looping for long term and strategic relationships for the development of new products

Sermes CRO

Antonio Berlanga
General Director
aberlanga@sermes.org

Address: C/ Rufino González 14 Esc 1 2ºDcha Madrid

Phone: 34 913756930
www.sermes.org

Sermes CRO seeks to develop the biotechnology sector offering Start-up, monitoring, data recording and statistical analysis, providing comprehensive coordination in all the organization and technology-based self-development.

Sermes CRO offers in Spain and International the following products and services:

- Full and complete Start-up Service
- Design and development of clinical research protocols
- Design and development of paper and electronic CRFs
- Monitoring Phase II trials, III and IV and post-approval studies
- Management of clinical trial data
- Using of Oracle Clinical as database, including Electronic-CRF service with WhoDrug and MedDRA Dictionaries.
- Statistics and Publications

Also, Sermes CRO is a founding member of the organization Pharmaceutical Service Network (PSN), which provides global coverage for any clinical trial.

Sigma Aldrich Química, S.A.

Javier Márquez
General Manager
Javier.marquez@sial.com

Address: Ronda de Poniente, 3 Tres Cantos - Madrid

Phone: 34 91 661 9977
www.sigmaaldrich.com

Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research and pharmaceutical development and our mission is to facilitate the science that makes the life better.

PRODUCTS: Our chemical and biochemical products and kits are used in scientific research, including genomic, functional genomics and proteomic research, animal models, biotechnology, pharmaceutical development and the diagnosis of diseases: Antibodies. shRNA & siRNA. Oligonucleotides. Media, reactives and sera for cell culture. Zinc Finger Nucleases for Gene Editing. Animal Models. Reactives for iPS cells, etc

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Sigma-Aldrich has developed an aggressive initiative for the evaluation of novel technologies that can enable the scientific community. This initiative provides Sigma-Aldrich with the opportunity to continue to offer new and novel technology-based products to researchers in academic, medical and industrial institutions, throughout the world. Technologies of Interest: Functional Genomics, RNAi, Gene Editing, Cell Biology, Live Cell Biosensors, Gene Expression, Proteomics, Stem Cells, Analytical and Material Science.

SINOPTIA, S.L.

Eulalia Clos Cañellas
Director for Europe and Latin America
eulalia.clos@sinoptia.com

Address: Balmes, 150 2º 1ª CP 08008 Barcelona -

M Phone: 34 678 694 285
www.sinoptia.com

Transmit our experience so that healthcare companies can grow, offering society innovation for people's health and quality of life.

We are a global firm focused in advising and connecting the right parties to solve problems for clients.

We focus on the companion diagnostics, in vitro diagnostics, medical devices and Biotechnology industries.

We are a broker for business connections, with deep knowledge in innovation and the industry.

We work with people and for people to get better results.

The most important differentiation of SINOPTIA is our involvement in the implementation of the solutions.

We do not sell reports, we sell solutions.

Three phases METHODOLOGY:

SINOPTIA Strategy: Studying the client in depth and defining a strategic plan.

SINOPTIA Management: Studying the client in depth and defining a strategic plan.

SINOPTIA Connect: Studying the client in depth and defining a strategic plan.

We are managers with hands on experience who get involved with our clients with formulas like Interim Management, specialized headhunting, process improvement or mediator of business connections.

Sistemas Genómicos, S.L.

Mayte Gil. Project Manager
mayte.gil@sistemasgenomicos.com

Address: Parque Tecnológico de Valencia. Ronda G. Marconi, 6 Paterna. Valencia

Phone: 34 902 364 669
www.sistemasgenomicos.com

Our main activity is research, development and commercialization of analytical applications based on genomics technology. We provided high added value services and products, as well as customized R&D projects addressed to Food analysis, Human Health, Biopharmaceutical and Genomic Research.

PRODUCTS: SG Food Analysis: GMO Analysis. Food Allergens Detection. Genetic Authentication in Food. Rapid Pathogen Detection. Genomic Identification and Typing. Water Analysis. Molecular Analysis Kits SG Human Health: Genetic Counseling. Genetic Diagnostics. Prenatal Genetic Diagnostics. Rare Diseases. Molecular Oncology. Genetics in Oncohematology. Preimplantation Genetic Diagnosis (PGD). Molecular Diagnosis Sets SG Research: DNA Sequencing. Ultrahigh throughput Sequencing Projects. Bioinformatics.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Our company actively seeks the stablishment of strategic allilances to promote R¬D projects in Genomics. In 2008 the company has purchased the Ultrahigh Throughput Sequencing highest technology equipment available in the market: SOLID platform. And it allows us to collaborate and offering this new and exclusive technology to the whole scientific community

SmartLigs

Rosa Nieves. Business Development Director
rnieves@smartligs.com

Address: c/ Faraday 7, Campus de Cantoblanco. 28049 Madrid Madrid

Phone: 34 910 075 722
M Phone: 34 673 066 672
www.smartligs.com

Smartligs is a biotechnological company focused on the discovery and development of new drugs. We collaborate with the pharmaceutical and biotechnological industry in the search of pre-clinical candidates, with the aim of reducing costs, risks and time to market as well. We use innovative computational chemistry technologies, integrated with other disciplines in the research process (molecular biology, organic chemistry, medicinal chemistry and pharmacology), which accelerate development processes while making them more cost efficient.

We base our competitive advantage on our proprietary bioinformatics platform for high throughput virtual screening. From a chemical library with millions of compounds, we identify those molecules with the maximum activity for a given therapeutic target. Furthermore, we can optimize the candidate drugs by increasing their potency and specificity, enhancing their scalability, improving their pharmacological properties and reducing their toxicity. This strategy allows us achieving high success rates in the clinical development.

Our technology is suitable for drug discovery projects in all therapeutic classes.

INTEREST AREAS FOR FUTURE COLLABORATIONS

We are looking for partners with expertise in the following fields:

- Therapeutic targets identification and validation.
- In vivo and in vitro assays.
- Evaluation of pharmacological properties.
- Toxicity studies.

SOM Biotech SL

Raúl Insa Boronat. CEO
insa@sombiotech.com

Address: Parc Científic de Barcelona, Baldiri Reixac, 4 Barcelona

Phone: 34 934020150
www.sombiotech.com

Our objective is to discover, confirm, patent and develop or license the application of already known drugs in unknown indications (re-profiling). The aim of SOM is to perform at least 25 projects the first year, filing at least 6 patents and reaching licensing agreements.

PRODUCTS: The final product of SOM is a patent of use of a new indication for a known pharmaceutical drug and the know-how developed by the company for that achievement.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: The in-silico computerized platform can be dedicated to any therapeutic area. We plan strategic collaborations with in-vitro and in-vivo screening platforms and large pharmaceutical companies with commercial interest for further development of the reprofiled compounds.

Stem Center, S.L.

Yolanda Alemany
yalemany@stem-center.com

Address: CAMÍ DELS REIS, 308 Palma de Mallorca - Palma de Mallorca

Phone: 34 971 910074
www.stem-center.com

Research and use of adipose derived stem cells in different clinical conditions.

Products and Services: Extraction of adipose derived stem cells from lipoaspirates and autologous re-implantation into the patient for aesthetic or regenerative purposes.

Suanfarma Biotech S.G.E.C.R. S.A.

Gonzalo Marin
Managing Director
gonzalomarin@suanfarma.com

Address: Calle Einstein 8-3ª Pl Alcobendas - Madrid

Phone: 34 91 567 15 56
www.suanfarmabiotech.com

Suanfarma Biotech SGECR is a venture capital asset management company specialized in biotechnology authorized by the Spanish CNMV (equivalent to US SEC) in July 2007 and registered with number 66. Our mission is the management of biotechnology specialized funds and consultancy to biotechnology companies in several areas, such as business and commercial activities, industrial and R&D support, as well as regulatory guidance and financial advice.

Suan Biotech I FCR authorized by CNMV in September 2007. The current portfolio of investments already managed by Suanfarma Biotech SGECR SA includes the companies: Vivia Biotech, 3P Biopharmaceuticals, Pevesa, Halotech, Salupharma, Biomedal, Clave Suan, Agrenvec & Noscira.

Suan Biotech II FCR in process.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: SUANFARMA BIOTECH SGECR, S.A. evaluates investment opportunities with a strong and solid science, IP and growth potential. We look for projects and opportunities within universities, tech transfer units, R&D centers and within our national biotech and pharmaceutical market

Sylentis, S.A.U.

sylentis@sylentis.com

Address: Parque Tecnológico PCM C/Santiago Grisolía, 2 (28760) Tres Cantos - Madrid

Phone: 34 91 804 76 67
www.sylentis.com

Sylentis focuses on researching new therapeutic approaches based on gene silencing. Sylentis is specialised in developing therapies via interference RNA, a powerful tool for rational drug design.

We are developing treatments for glaucoma and dry eye syndrome. Sylentis is also focusing on inflammatory bowel disease. Furthermore, Sylentis is focusing on post-traumatic neuron lesions and ischaemia, neurodegenerative diseases and dementia.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Because the release of RNAi in the body is an important part of these technologies, the company has a number of research projects under way regarding the controlled release of drugs, in cooperation with various public and private institutions.

TERACLON IDF, S.L.

Crescencio López de Silanes. Vicepresident
c.silanes@teraclon.com

Address: C/ Capitán Haya, 38 28020. Madrid

Phone: 34 915700055

Investigation, development and production of pharmacy and biotechnological products.

Basic investigation and development of pharm products to develop, patent, experiment, carry out clinic test, sanitary registers, manufacture and commercialize pharms, biotechnological products and other products or medicinal mixes which have positive effects for health and human being wellness, as well as similar investigation activities, manufacturing and commercializing any medicinal product or mixed.

Thrombotargets Europe, S.L.

Ramón Béjar bejar@thrombotargets.com

Address: TTE-BARCELONA: Parc Mediterrani de la Tecnologia, Av Canal olímpic s/n, Edif B6, 2ªPlanta, 08860-Castelldefels Barcelona

Phone: 34 93 664 20 40
www.thrombotargets.com

Thrombotargets Europe is a Biotech company focused on the development of new therapeutic treatments in the field of haemostasis. To achieve this goal Thrombotargets has developed proprietary High Throughput Screening Technologies that allow the Speedy-up of the Drug Discovery phase for the identification of innovative drugs that may improve the quality of life of the human being.

PRODUCTS: Drug Development: TT-173 (Topical Hemostat), and several programs focused on haemostasis and coagulation.

Technological Platforms: BIOPLATFORMSCREEN (High Throughput Screening in haemostasis for the detection of anticoagulants, procoagulants, fibrinolytics, antifibrinolytics...)

FILDS OF INTEREST FOR FUTURE COLLABORATIONS: Collaborations in HTS projects; identification and development of new drugs in haemostasis; and diagnosis in haemostasis and cardiovascular.

Alliances: with several public and private research centres and universities in Spain (CNB-CSIC, ICCC.CSIC, IQAC-CSIC, LIPPSO-UdG, CER-EMET-UB, IUCT, CRC-CIM, Hosp. Vall Hebron...) and with international research centres (HEMO-CENTRO Univ. Campinas...), and diverse companies for the screening and development of new drugs (SPECS, ASINEX, Instituto BIOMAR...).

.

TIGENIX NV

María Pascual. VP of Regulatory Affairs and Corporate QA
jacqueline.curros@tigenix.com

Address: Marconi, 1. Parque Tecnológico de Madrid . CP 28760 Tres Cantos Madrid

Phone: 34 91 804 92 64
www.tigenix.com

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with two marketed products and a strong clinical stage pipeline of adult stem cell programs. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), Cambridge (UK) and Sittard-Geleen (the Netherlands).

The company's lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix's adipose derived allogeneic stem cell platform has been extensively validated. The company is preparing a Phase III clinical trial to treat complex perianal fistula in patients with Crohn's, has a Phase IIa trial in rheumatoid arthritis ongoing, and will start a Phase I trial to investigate intralymphatic administration in autoimmune disorders.

Valentia Biopharma S.L.

M. Carmen Álvarez
Technical Director
mc.alvarez@valentiabiopharma.com

Address: Parc Cientific Universitat de Valencia. Pol. industrial La Coma, s/n Paterna - Valencia

Phone: 34 96 354 38 42
www.valentiabiopharma.com

Biotechnology company focused on developing models of human genetic diseases in Drosophila and obtaining drugs by automated screening of compounds in in vivo models of Drosophila melanogaster.

Products:
We have a unique technology for drug discovery generated by the integration of a in vivo High Throughput Screening platform (in vivo HTS platform) with different Drosophila biomedical models.

Services:
- Generation of Drosophila biomedical models
- Screening of compounds in our HTS platform
- Hit validation in in vivo models.

Interest areas:
Rare diseases, genetic base diseases.

VALIDATEC SL

Maika Chillón
Technical Director
mchillon@validatec.es

Address: Dr Diaz Emparantza, 39 48002 Bilbao

Phone: 34 944702693
www.validatec.es

AIM: Contribute to keep our customers quality standards, providing current rules compliance and this way increasing their competing skills.

VALIDATEC, ALBIAN GROUP member company offers an overall consulting solution from the beginning of the project to the validation final stage aimed to all health sectors, biotechnological, pharmaceutical an microelectronics industry which are ruled by strict quality parameters.

We provide solutions in the GMP Compliance field. Our services include validations, qualifications, calibrations, documentation, consulting and training.

Our customized "in place" training courses are attended by professionals with a wide experience in the field of industries that require controlled atmospheres and processes.

VALIDATEC, with central office in Bilbao has also local offices in Madrid and Barcelona

VENTER PHARMA SL

José Luis Martín. CEO
jlmartin@venterpharma.com

Address: Almagro, 1
Madrid

Phone: 34 914 467 897
www.venterpharma.com

Venter Pharma SL is a biotech Company created in 2003 with the aim of developing products in the field of gastroenterology to help patients and professionals.

Venter Pharma SL was founded in 2003 under the name of Lactest SL, upon the development work carried out in the Universidad Autónoma de Madrid and Consejo Superior de Investigaciones Científicas (CSIC).

During these years, in deep collaboration with UAM and CSIC, the company has developed the method for the evaluation of lactose intolerance, completed the preclinical and clinical studies to determine the toxicity and efficacy of the product and finished the scaling up of the product.

Venter Pharma has developed LacTEST 0.45 podwer for oral solution, a diagnostic drug for the diagnosis of lactose intolerance that overcomes the deficiencies of current methods. LacTEST is based on a new molecule which INN is gaxilose.

LacTEST finished the development process in 2009 and the European authorization process in 2011. Now the company is waiting for the approval of the Spanish and German health Agencies.

VETGENOMICS, S.L.

Armand Sánchez. CEO
armand.sanchez@uab.cat

City: Bellaterra Barcelona

Phone: 34 935868978/99
www.vetgenomics.com

Animal Genomics and Veterinary Molecular Diagnostic.

VETGENOMICS aims in the field of veterinary genetic diagnosis are: (i) to develop innovative analytical services in companion animals and (ii) collaborate with technology partners that enable us to develop genetic diagnostic products with higher added value for end users.

VETGENOMICS is a company with experience in animal genomics, with capacity for innovation and flexibility to adapt technology to customer needs, increasing the added value of its products and becoming a partner of choice in R + D+ i.

Vetgenomics is a SME spin-off of the UAB. With a team of 8 people including technicians and PhD dedicated exclusively to R&D, Vetgenomics is devoted to molecular diagnostic in companion animals. One of the company skills is the in-house design of real time quantitative PCR assays for diagnostic of several pathogens. Vetgenomics skills and competences are:- Expertise in genetic veterinary diagnostic; - In-house design of real time PCR assays for pathogen detection; - Network of veterinarians; - Research group focused on canine genomics (LUPA, 7FP).

VidaCord, S.L.

Angel G. Alvarez Ramos.
Presidente y Fundador
agar@vidacord.es

Address: Oficinas: C / Puntonet, 4-bajo dcha. Laboratorio: Edificio Zye bajo dcha. Tecnoalcalá (Alcalá de Henares, 28805-Madrid)

Phone: 34 91 830 57 85
www.vidacord.es

To process and criopreserve the cord blood that parents entrust VidaCord. To offer their children in the future the possibility to use these cells or their derivatives to treat certain diseases.

SERVICES: Obtaining, processing and criopreserving stem cells from blood cord

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Cell Therapy
- Regenerative Medicine

Vircell, S.L.

Almudena Rojas
Technical Manager
arojas@vircell.com

Address: Plaza Domínguez Ortiz, 1.Pol. Ind. 2 de Octubre Santa Fé - Granada

Phone: 34 958 441 264
www.vircell.com

Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology-. Vircell has been a successful market player worldwide distributing its products in 75 countries.

Since its foundation in 1991, the three main objectives of the company are: to produce reagents of the highest quality, to provide highly-specialized technical support and to develop innovative diagnostic solutions that bring significant advances to the market.

The in-house production of all the antigens needed for the development of its kits enables Vircell to work with independence from external suppliers. This peculiarity makes it a flexible company able to guarantee the quality of its products. The reliability of its kits is the result of a strict quality control according to international standards. All tests distributed are validated and CE-marked complying with the European directive 98/79/CE. Vircell is ISO 13485:2003 and ISO 9001:2000 certified and is involved in the process of implementation of GMP standards.

Vircell offers nearly 300 references grouped into several product lines (ELISA, Brucellacapt®, IFA, monoclonal antibodies, cell lines, transport medium, rapid tests, PCR controls and oligochromatography tests). All products are intended for the clinical diagnosis of infectious diseases. Vircell also has a raw material catalogue that includes native and recombinant antigens.

Among the strategic objectives, it is worth highlighting Vircell's efforts to increase its penetration in the BRIC countries (Brazil, Russia, India and China), entry into new diagnostic technology platforms and improve its business alliances in countries such as Germany, Japan and the United States.

Vita Aidelos

Melania Rosique
Investigation Manager
info@vita-aidelos.com

Address: Parque Tecnológico de Bizkaia, Edificio 801A - 2ª planta Derio Bizkaia

Phone: 34 944 069 689
www.vita-aidelos.com

VITA AIDELOS is a biotechnology company located in the BizkaiaTechnology Park. It was set up with the aim of creating a positive social perception of biotechnology, while maintaining scientific rigour.

VITA AIDELOS has a consolidated range of products – portable biotechnology kits – and it has been granted three European patents. The company is now focussing its unceasing R & D activity in the field of forensics and human health.

VITA AIDELOS has collaborated with prestigious R&D investigation groups and with prestigious foundations in order to bring biotechnology closer to the general public by bridging the gap between investigation and society.

VITA AIDELOS works with educational institutions, science museums and foundations that promote scientific knowledge to make society aware of the importance this discipline has on development and progress.

PRODUCTS: Patents, know-how Practice Kits in Biotechnology: Molecular Biology and Microbial Biotechnology Multimedia Products

SERVICES: Spreading and qualification in Biotechnology Practical consultancy Taking part in events and activities aimed at spreading Biosciences. Microbiological analysis.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Commercialization agreements. Taking part in R & D & I projects. Projects aimed at spreading science

Vivacell Biotechnology España, S.L.

Dra. M. Luz Bellido Cabello de Alba
Managing Director
m.bellido@vivacellspain.com

Address: Parque Científico Tecnológico de Córdoba, Rabanales 21 C/ Astrónoma Cecilia Payne, ID8.1, Edif. Centauro, 1ª Planta CP 14014 Córdoba

Phone: 34 957290666
www.vivacellspain.com

Founded in 2003, VivaCell has been positioned as a leader biotechnological spanish company for preclinical development of non-psychotropic cannabinoid compounds with therapeutic use in chronic pathologies such as obesity, neurodegeneration and cancer. The activities of the company are concentrated in the preclinical phase of drug discovery.

From a large collection of plant-derived extracts and a library of natural compounds biologically tested, VivaCell has developed a strong pipeline. Nowadays, it is composed by VCE-003, which is being developed against multiple sclerosis and it is expected to reach clinical phase in 2015. VCE-004 is being developed as neuroprotector. And finally CDE-001 is a standardized cannabis phytoextract with application in atopic dermatitis. In addition, the company provides specialized in vitro and in vivo models for testing and developing pharmaceutical, nutraceutical and phytopharmaceutical compounds.

Vivia Biotech, S.L.

Andrés Ballesteros
Directot General
admin@viviabiotech.com

Address: C/ Santiago Grisolia, nº2, of.205. C.P.28760 Tres Cantos - Madrid

Phone: 34 91 129 31 51
www.viviabiotech.com

Vivia Biotech pioneers the screening of thousands of drugs directly in patient´s blood samples,an innovative Systems Biology research model, really translational, which has allowed implementing for the first time in the world the Exvitech Tecnological Platform, property of Vivia Biotech.

"Smart" Reprofiling: by analyzing thousands of drugs on a patient's sample, we identify potentially effective drugs for a disease in the most direct way which, until now, was not possible.

The result of this process is to discover and bring to the market, for the benefit of the patient, new potential treatments against the disease based on new indications of already existing drugs comprising a faster and safer model to discover new treatments.

Personalized Medicine Test: or Hematological Cancers which can predict the best protocol treatments for each patient before its administration.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Hematologic Cancer
- Obesity
- Autoimmune Diseases
- Drug Screening

Vivotecnia Research, S.L.

Antonio Vila Coro. Head of Business Development
vilacoro@vivotecnia.com

Province: Madrid

Phone: 34 91 728 07 15
www.vivotecnia.com

Vivotecnia performs pre-clinical research on a contract basis. We offer reliable high quality investigation for the cosmetic, pharma and biotech industry.

SERVICES: We offer solutions to research and development projects. We can perform a wide range of efficacy and toxicity studies. We are certified to work under GLP standards and can work with rodents, non rodents and dogs as required by FDA, EMEA and the rest of agencies around the world.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

- Activity, efficacy and toxicity studies in in vitro and in vivo models.
- Managing services for animal facilities and animal models.
- Animal facility services and rooms to rent.

VLP Bio

Emilio Gutierrez. Business Development Manager
emilio@start2up.es

Address: Velázquez, 4 - 5º A Salamanca – Salamanca

The strategic goal of VLP BIO is developing innovative vaccines, for the major pharmaceutical markets, based in our propietary platform named Q-VLP (virus like particles)

VLP BIO activity: Design and production of chimerical particles pseudo-viral "Virus Like Particles" (VLP) using in the development of new vaccines for animal and human health.

VLP BIO Products:

- Vaccines platform Q-VLP ®.
- CIN-Cervical Cancer ®: Therapeutic and prophylactic vaccine against cervical cancer.
- New therapeutics and/or prophylactics vaccines candidates (in development).

Voyer Iberoamérica Executive Search

Luis Truchado
Partner-Director
voyer_madrid@euroga-lenus.com

Address: Avda. Alberto Alcocer, 7 Madrid Madrid

Phone: 34 91350 55 56 / 74 14
www.voyeriberoamerica.es

Voyer Iberoamérica / EuroGalenus is an executive search firm specializing in the Biotechnology field.

Since the founding of EuroGalenus in 1992, we are focused on the Executive Search profession. We expanded horizons in 1999 when we joined the network PENRHYN International and this year strengthened still further by partnering with the Voyer International group, merging our activities as Voyer Iberoamérica and covering both sides of the Atlantic with the same level of service and professionalism.

ZABALA INNOVATION CONSULTING S.A.

Ainhoa Zabala

Address: Paseo Santxiki, 3 bis Mutilva Navarra

Phone: 34 948 198000
www.zabala.es

Mission: making innovation the key factor of competitiveness for Companies, R&D Stakeholders and Public Administrations.

Services:
Analysis and management of investments and business activities to obtain the maximum aid in Regional, National and European programmes.

Financial Support: RTDi, Investment and Competitiveness, Energy efficiency, environment.

Tax relief: RTDi, environment, Patent-Box.

Project management: national and international cooperative projects.

Other services: tenders, strategic plans, etc

Zeltia

Carmen Eibe
Projects Coordination
Director ceibe@zeltia.com

Address: Plaza Descubridor Diego de Ordás, 3, 5ª planta, (C/ Santa Engracia, 120) Madrid

Phone: 34 91 4444 500
www.zeltia.com

Founded more than 70 years since its origin Zeltia group has been involved in the biopharmaceutical and chemical. Investigated to improve the quality of life for patients, so each year we invest more resources in R + D + i in order to provide innovative treatments.

In the biopharmaceutical sector differ several lines of research: Oncology, Central Nervous System, molecular diagnostics and genetic identification and RNAi (RNA interference)

In the field of consumer chemical there are several business lines: manufacture and sale of products for home care, manufacturing and sale of paints and protective coatings timber for professional and DIY.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Zeltia since its beginnings has collaborated and continues collaborating actively with academics and public centers, with same and large businesses of the sector biopharmaceutical and of the chemical, so much national as international sector.

ZURKO RESEARCH SL

Sabina Giovannini. COO
sabina@zurkoresearch.com

Address: Calle Gran Vìa, 62 – 4° Izq 28013. Madrid

Phone: 34 915211588
www.zurkoresearch.com

ZURKO Research is a BIOTECH independent company specialized in the development of RESEARCH projects. ZURKO Research stands out in areas related to the fields of Biotechnology and related areas as: Cosmetics, Pharma, Health, Agrifood, Environment, Agriculture and Renewable Energies.

ZURKO Research's strategy focuses at the development of personalized biotechnological solutions targeted to entreprises, SMEs and large companies, for the identification and the use of their R&D potential, with the aim of transforming it into tangible results for their industrial explotation.

ZURKO Research offers as well to its custumers a wide profesional advising service in the identification of specific fundings, directly or indirectly related with the biotechnological identified solutions.

ZURKO Research, with its team of experts, offers a list of services with an high added value for biotech sector and the related sectos, which includes:

- R&D Projects funding.
- R&D Proposals revision.
- Technology assessment and Market studies.
- Business services.
- Selección of personel.
- Indirect benefits of R&D.
- Training on laboratory techniques and equipments' use.

In the area of cosmetics, ZURKO Research offers to its customers:

- Clinical Essay of cosmetics and parapharmaceutical products (in vitro and in vivo).
- Specialized advising service on the requirements of the EC Regulation 1223/2009 .

asebio

Other Organizations

Agencia de Innovación y Desarrollo de Andalucía IDEA

Manuel Arroyo Maestre
Asesor Técnico de la Dirección de Innovación y Sostenibilidad. Sector Biotecnológico
marroyo@agenciaidea.es

Address: Torneo 26 Sevilla - Sevilla

Phone: 34 955 030 816
www.agenciaidea.es

Agencia de Innovación y Desarrollo de Andalucía IDEA (the Agency for Innovation and Development of Andalusia) has been appointed instrumental executor for policies of promotion, economic and social development, as the regional development agency of the Andalusian Government, under aegis of Consejería de Economía, Innovación y Ciencia (Regional Ministry of Economy, Innovation and Science). Its mission is to contribute to the economic and social development of the region, offering services to andalusian companies, employers and Junta de Andalucía (Autonomous Government of Andalusia) itself, promoting spirit of business, innovation and cooperation within science-technology-business system and competitiveness of our production structure.

Objectives and Performance Principles are:

- Implementation of new methods and models of governance.
- Support for Innovation and Territorial Intelligence.
- Promotion of public-private partnerships.
- Development of the spirit of enterprise and innovation.
- Design and implementation of quality support services.
- Provision of capital resources for the support and finance of businesses.
- Establish an appropriate administrative environment adapted for the creation of business.
- Promotion of cooperating networks between agents of the Innovation-Science-Enterprise system.
- Incorporation of criteria which are cultural, environmental and improve the quality of life.
- Support of benchmarking

Agencia Estatal. Consejo Superior de Investigaciones Científicas, CSIC

Ángel Caballero Cuesta
Vicepresidente Adjunto de Transferencia del Conocimiento
angelc@orgc.csic.es

Address: C/ Serrano, 142, CP 28006 Madrid - Madrid

Phone: 34 91568 15 31
www.csic.es

CSIC is the largest public research organisation in Spain and the third largest in Europe. Our 6000 researchers, located in 130 centres and institutes across Spain give us the capacity to cover all knowledge fields and generate annually close to 20% of the national scientific production and 180 patents. Moreover, we are the first Spanish applicant in the ranking of PCT ("international") patent applications. Over and above, our research capacity is the basis for our contribution to the society via dissemination, training and knowledge and technology transfer to both Spanish and foreign companies through individually-tailored collaboration approaches, including more than 60 patent licenses in a yearly basis.

CSIC is the largest public research organisation in Spain and the third largest in Europe. Our 6000 researchers, located in 130 centres and institutes across Spain give us the capacity to cover all knowledge fields and generate annually close to 20% of the national scientific production and 180 patents. Moreover, we are the first Spanish applicant in the ranking of PCT ("international") patent applications. Over and above, our research capacity is the basis for our contribution to the society via dissemination, training and knowledge and technology transfer to both Spanish and foreign companies through individually-tailored collaboration approaches, including more than 60 patent licenses in a yearly basis.

Banco Español de Algas

Guillermo García Reina
Director
ggreina@marinebiotechnology.org

Address: Muelle de Taliarte, s/n 35214 Taliarte Telde. Gran Canaria

Phone: 34 928 133 290
www.bea.marinebiotechnology.org

The Spanish Bank of Algae (BEA-Banco Español de Algas) is a national R&D service attached to the Marine Biotechnology Center (CBM-Centro de Biotecnología Marina) of the University of Las Palmas de Gran Canaria (ULPGC)

OBJECTIVES: To offer to companies and R & D institutions a vast biodiversity of microalgae and cyanobacteria. Stablish the bases for the development of a new ecosystem-based agro-industrial production of microalgae biomass and bioactive.

MISSION: Isolation, identification, characterization, conservation and supply (to companies and institutions) of microalgae and cyanobacteria. Conservation of microalgae for business purposes and for bio-industrial patents. Training, dissemination and assesment in microalgae biotechnology

SERVICES: Strain identification by microscopy. Strain identification by DNA analysis. gDNA "à la carte" Strain isolation and purification. Patent depository. Deposit for maintenance. Flow Cytometry. International Courses. Acceptance of strain donations

PRODUCTS: Strains: Main catalog. Axenic strains. gDNA Strains. Sequenced DNA strains. g-Strains "easy-to-grow". Genomic DNA. Culture media and seawater

AREAS OF INTEREST: anti-neurodegenerative diseases. Anticarcinogenic. Antioxidant / free radical Arteriosclerosis. Antiallergic. Anticoagulant. Antihepatotoxi. Anti-inflammatory. Cardiovascular. Hypoglycemic. Hypolipidemic. Bactericide. Immunostimulant. Anti-viral /-retroviral (herpes, HIV). Anti-osteoporotic. Anti-mycoplasma (veterinary). Cosmetic Dermatology. natural anti-UV Protectors. Production of recombinant proteins and monoclonal antibodies glycosylated

BioBasque, la Bioregión Vasca

Dr. María Aguirre. BioBasque Agency Managerbiobasque@spri.es

Address: Parque Tecnológico de Bizkaia. Edificio 801 - 2º Derio - BIZKAIA

Phone: 34 946 555 155
www.biobasque.org

To develop a new business sector related to life sciences, contributing to diversify the current industrial tissue and to maintain competitiveness in an international context.

PRODUCTS: BioBasque is represented by the BioBasque Agency, a one-stop location for biosciences in the Basque Country, and the instrument created to implement the strategy and to coordinate the relevant stakeholders.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: BioBasque is interested in establishing contacts with equivalent organisations, and other type of entities, that contribute to support the growth of the biocluster. It is equally interested in contacting companies wishing to establish operations in southern Europe

.

BIOIB
(Cluster biotecnológico de las Islas Baleares)

Pep Lluis Pons Hinojosa
General Manager
info@bioib.org

Address: Parc Bit Edifici Europa Crtra. Valldemossa, km 7'4 Palma de Mallorca ISLAS BALEARES

Phone: 34 871230022
www.bioib.org

BIOIB´s mission is to promote biotech sector in Balearic Islands and help to create a suitable environment for adding value in Balearic research.

Activity: Identify projects to increase biotech companies competitiveness and generation of public-private initiatives.

Competences and fields intervention: Fostering relationships and synergies between all the stakeholders located in the area and encourage networking with other clusters and agencies. Internationalizations, promotion the participation of Balearic island companies in International fairs and congresses in the sector.

SERVICES:

Research and Knowledge consulting for its members: Organize government subsidies, research grants and other sources of financing. Organize biotechnological events. Provide an employment and internship database to assist both employers and possible candidates. Offer consulting services on technical, legislative and market aspects. Promote internationalization and the establishment of alliances an R&D collaborations

Assistance on the creation of SMEs biotechnology companies.

Represent the sectors interest in front of Governmental agencies.

Facilitate the transfer and implementation of biotechnology into sectors where it is traditionally used as well as untraditional sector

BioMadrid

Juan Sebastián Ruiz
Vicepresident

Paula Andrea Certuche.
Project Manager

info@biomadrid.org

Address: Santiago de Grisolía 2 (Recinto PTM), despacho 110 Tres Cantos - Madrid

Phone: 34 673 574 752
www.biomadrid.org

BioMadrid is an association of biotech companies in Madrid.

Our main goal is to encourage the growing and consolidation of biotechnology in Madrid promoting dialogue between different social and economic agents, involved in the development of the sector.

Biomadrid has focused its activities on representing their members off the public administration and communicating specific information relevant for them.

Currently, 50 companies are part of BioMadrid, most of them are SME's. These companies spend much of their resources to carry out R&D in different areas such as biomedicine, bioinformatics, clinical genetics, biotechnology, food processing, production of recombinant proteins, cancer etc.

BioMadrid has partnerships with public and private entities such as Parque Científico de Madrid, Fundación Madri+d, CDTI and PromoMadrid.

These partnerships allow us to support company internationalization, applications for subsidies and grants acting as a representative between the companies and the public administration as well as supporting the bio-entrepreneur in their first steps, mentoring their start-up in Madrid.

Bioregió de Catalunya (BIOCAT)

Montse Daban
Communications and External Affairs, Director
mdaban@biocat.cat

Address: Pg. Lluís Companys, 23
Barcelona - Barcelona

Phone: 34 93 310 33 30
www.biocat.cat

Biocat is the Catalonia biocluster organization with the aim to promote biotechnology and biomedicine in Catalonia. It is fostered by the Government of Catalonia and it is participated by companies and public research institutions

Our main goals are:

- Facilitate networking among the different stakeholders
- Foster biotechnology as a key economic driver for the country
- Promote Catalonia biotechnology at the world stage
- Inform and contribute to a better understanding and perception of biotechnology

BIOVAL

info@bioval.org

Address: Parque Científico .Cl. Catedrático Agustín Escardino, 9. 2ª Planta-dpcho.11 Paterna Valencia

Phone: 34 902 88 99 90
www.bioval.org

BIOVAL was formed at the end of 2006 to increase the opportunities and further develop the biotechnology sector and become a means of growth, both socially and economically, for the Valencian Region.

BIOVAL is composed of more than 50 biotechnology companies located in the Valencian Region, as well as research and technology centers, universities, and hospitals whose R&D are oriented towards biotechnology.

Is the Valencian Community BioRegion.

Bioval was created as a private initiative in 2006, since then it has dynamized the Valencian Biotech Sector through its more than 70 companies, universities, research centers and hospitals

In 2010 an arrangement was signed with the Generalitat Valenciana to convert Bioval in the interlocutor with the Administration in any matter related with Biotechnology.

In addition to promote collaboration inside and outside the Valencian Community, Bioval makes effort to train Bioentrepreneurs and professionals with the annual Biotech Superior Course. And it is also powering BioBreakfast aimed to create synergies with international groups, promoting not only research projects but business deals too.

In 2011 Bioval stablished alliances between traditional sectors and Biotech sector in order to bring on innovative proccesses in mature sectors, opening new business opportunities. In other hand, Bioval is working closely with the M.I.T. and Boston area companies to let Valencian companies show into their Biotech network.

Bioval supports Biotech companies in R&D project management, networking, divulgation, international visibility, etc...

Everything free standingly done and with a complete business mind, acting as catalyst of the sector.

Centro Nacional de Análisis Genómico (CNAG)

Mònica Bayés
Programme Manager
mbayes@pcb.ub.es

Address: Baldiri Reixac 4 08028. Barcelona - Barcelona

Phone: 34 934020564
www.cnag.eu

The Centro Nacional de Análisis Genómico (CNAG) was created in September 2009 with support from the Spanish and the Catalan governments. It is situated within the Parc Cientific de Barcelona (PCB), occupying approximately 1200 square meters and with a headcount of 40 staff. It is directed by Dr Ivo Gut.

CNAG vocation is to carry out large-scale projects in DNA and RNA sequence analysis in collaboration with the Spanish, European and International Research Community. The integrated CNAG infrastructure has one of the largest DNA sequencing capacities in Europe.

CNAG covers a range of capabilities including whole-genome de novo sequencing, whole genome re-sequencing, targeted re-sequencing, profiling of mRNAs or small RNAs, localization of DNA or RNA binding sites (ChIP-Seq) and DNA methylation profiling.

We have currently a park of twelve 2nd generation DNA sequencers that produce more than 500 Gbases of sequencing data per day. The sequencing operation is supported by an extensive informatics infrastructure and multiple connections to the Barcelona Supercomputing Center (BSC).

CNAG participates in large national and international collaborative research projects in genome research and particularly in disease-related genetic studies, such as FP7-projects READNA, ESGI, EVA, GEUVADIS, BLUEPRINT, SYBARIS, AirPROM, RDCONNECT and IBDCHARACTER, and in the International Cancer Genome Consortium (ICGC). Other projects include de novo sequencing of endangered species, diagnostics using exome and target resequencing in several medical conditions, and sequencing plant cultivars for the agriculture community. A significant amount of these projects has been successfully completed in cooperation with industrial partners.

Centro Nacional de Investigaciones Oncológicas, CNIO

José Ignacio Fernández Vera
Director of Support to the Investigation
vera@cnio.es

Address: Melchor Fernández Almagro, 3 Madrid - Madrid

Phone: 34 91 224 69 00
www.cnio.es

Basic and applied research under an integrated approach, fostering the interaction of basic research with of molecular diagnostics programmes and of the discovery of new drugs, all supported by a solid equipment and technical services infrastructure.

SERVICES: Undertaking research to enable the new, more efficient diagnosis and treatment methods to be obtained for oncological diseases. The transfer of scientific knowledge into clinical practice, so that scientific progress has an effect on our healthcare system as early as possible, and thus on patient welfare. The transfer of technology developed in the CNIO to innovating companies. To set up a new and more effective management system in the European scientific environment.

Centro Tecnológico LEITAT

Joan Parra
General Manager
info@leitat.org

Address: Passeig 22 de Juliol 218
Terrassa Barcelona

Phone: 34 937882300
www.leitat.org

LEITAT Technology Centre aims to collaborate with companies through research initiatives, developments and innovation pathways to add value to products, processes and tasks in different economic sectors, including the pharmaceutical, cosmetic, biomedical, cancer, biotechnology, nanotechnology and biomaterials and others. In addition to the promotion of R+D+i, LEITAT's objectives are the technology transfer and scientific development under sustainability, responsibility, integrity and independence criteria.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Identification and validation of therapeutical targets.

Generation and characterization of new drugs.

Targeting and drug delivery.

Micro and nanoencapsulation of active ingredients.

New biosensors.

Studies of toxicology, ecotoxicology and efficacy of nanoparticles.

Development of in vitro cellular models to predict efficacy, safety and mechanism of action of compounds in development for biotech, pharmaceutical, cosmetic and chemical industries.

Extraction of the active ingredients from microalgae and renewable sources for food, cosmetic and pharmaceutical industries.

Design and application of bioprocesses in industrial environments

Industrial microbiology: Isolation, selection and characterization of microorganisms with different industrial applications. Microbiological studies.

Biofunctionality studies: Screening of new molecules or extracts with different biofunctionality.

Microencapsulation - Development of micro and nanocapsules for applications in different industries: cosmetic, food, textile, detergents...

Synthesis and processing of biopolymers.

CIBER BBN

Begoña Pérez. General Manager bperez@ciber-bbn.es

Address: Campus Río Ebro - Edificio I+D Bloque 5, 1ª planta c/ Poeta Mariano Esquillor s/n Zaragoza

Phone: 34 976 51 23 68
www.ciber-bbn.es

To increase research capabilities of the component groups (sharing resources, coordination and promotion of synergies).

To enhance greater and better use of advanced technologies in the National Health System.

To improve the technological

To improve the technological level of national industry in this field.

To favour the emergence of specialists with a high level of training in health technologies.

To increase the presence of Spain in decision-making forums and international research networks in this field

PRODUCTS: CIBER-BBN Research Infrastructure on Biomedicine: Production of Biomolecules Platform; Production of Biomaterials and Nanoparticles Platform; Tissues, Biomaterials and Surfaces Characterization Platform; Bioimaging Platform; High-performance computing Platform.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

BIOENGINEERING AND BIOMEDICAL IMAGING -Multimodal diagnosis -Intelligent devices BIOMATERIALS AND TISSUE ENGINEERING -Regenerative medicine (Scaffold-based Tissue Engineering; Cell therapy; Cell biophysics) -Endoprostheses and implants NANOMEDICINE -Molecular diagnosis and biosensors. -Therapeutic nanoconjugates and drug delivery systems.

CIBERER

Ingrid Mendes
Project Manager
imendes@ciberer.es

Address: C/ Álvaro de Bazán, 10 - Bajo Valencia - Valencia

Phone: 34 96 339 47 89
www.ciberer.es/

CIBERER's main objective is to become an international reference centre for research on rare diseases, with emphasis on translational research. The scientific knowledge generated by the groups in CIBERER is intended to be applied in clinical practice in the patient's benefit.

SERVICES: The CIBERER main services are related to: Collaborative research projects on rare diseases. Research platforms infrastructures. Knowledge/Technology transfer

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Genetic and molecular diagnosis

Development of advanced therapies. Gene therapy and cell therapy.

Clinical trials and orphan drugs.

Training Programmes

Research collaborative projects

Fundación GAIKER

Maitane Ipiñazar
Biotechnology Area Market Coordinator
mark@gaiker.es

Address: Parque Tecnológico de Bizkaia, Edif. 202 Zamudio - Vizcaya

Phone: 34 946 002 323
www.gaiker.es

GAIKER is a Technology Centre whose objectives are to carry out research and supply reliable, innovative technological solutions which give value to the company, contributing to its technological development and its competitiveness through the generation, gathering, adaptation and transfer of innovative technologies in a sustainable manner. It also assumes the development of opportunities in emerging economic activities, all within a framework of collaboration with other agents.

Cell culture

Proteomics/ Genomics

Microbiology

Fluorescence Microscopy

Surface Plasmon Resonance (SPR)

Applied Molecular Biology (PCR, RT-PCR, etc.)

In order to carry out "In Vitro Toxicology" studies in pharmaceutical products, we have the Good Laboratory Practice Certificate (GLP). We are mainly focused on Health, Pharmaceutical, Food, Fine Chemistry and Agriculture, Industrial Chemistry and Services sectors.

Interest areas for futures colaborations/alliances:

Our main fields of work are the following:

1. Biodetection systems: BioRecognition molecules immobilization processes on surfaces. BioDetection systems development. Identification and development of target molecules

2. Omics: Genomics. Proteomics

3. In Vitro Test: Efficacy evaluation. ADME. Toxicity of drugs and nanoparticles

Fundación Inbiomed

Jose Manuel Franco
General Manager
jmfranco@inbiomed.org

Address: Paseo Mikeletegi, 61. CP 20009 San Sebastián San Sebastián

Phone: 34 943 309 074
www.inbiomed.org

Development of new products and cell therapy medicinal products, focusing on the biology of adult stem cells and embryonic / reprogram (iPS) and its application in three fields, cancer, neurodegenerative diseases and cardiovascular diseases.

Provision of research services and / or consultancy on advanced cell therapies related to three therapeutic areas, cancer, neurodegenerative diseases and cardiovascular diseases.

Cell production in GMP conditions and related technical services.

Service of viral production, cell separation (sorter), cell reprogramming and animal models for preclinical testing.

Models in vitro reprogrammed cells (iPS) for drug testing.

Interest areas for futures colaborations/alliances:

Partnerships with nanotechnology companies to develop specific biomaterials for future combination with cell therapy and / or paracrine factors of regeneration.

Partnerships with organizations or companies for the development of areas related to our research programs in the field of tissue engineering and personalized medicine

Fundación MEDINA
(Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia)

Olga Genilloud
Scientific Director
olga.genilloud@medinaandalucia.es

Address: Edificio Desarrollo Farmacéutico. Avda. Conocimiento s/n, Parque Tecnológico Ciencias de la Salud ARMILLA GRANADA

Phone: 34 958 993 965
www.medinaandalucia.es

Fundación MEDINA is a non-profit public-private partnership between Merck Sharp and Dohme de España S.A., the Junta de Andalucía and the University of Granada, to discover innovative compounds and therapies for unmet medical needs. Research activities at MEDINA are focused on: I.Discovery of new compounds and therapies that could be offered as new leads for development by industrial companies Offer of high throughput screening services for lead discovery on therapeutic targets developed by customers and compound profiling services for their drug candidates

PRODUCTS: New leads from microbial natural products collections in therapeutic areas identified as top priority by the national and regional Spanish Health Systems. Highly automated screening platform: evaluation of potential cardiovascular toxicities and adverse drug metabolism effects (ADME/TOX) of drug candidates in development. Ion channels assays (hERG, Cav1.2, Nav1.5) Drug metabolism assays(CYP inhibition and induction) Off-target interactions (neurotransmisor receptors, PPARs)

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Discovery of novel therapeutics from microbial natural products collections in: infectious diseases (including tuberculosis and parasitic diseases), oncology, immunoregulation and rare diseases. Study of potential cardiovascular and neuronal safety risks, and drug-drug interactions of new leads in early stages of the drug-discovery process.

Fundación Parque Científico de Madrid (PCM)

Antonio R. Díaz.
General Manager
parque.cientifico@pcm.uam.es

Address: Campus de Cantoblanco . C / Faraday, 7 CP 28049 Madrid Madrid

Phone: 34 91 4116 99 40
www.fpcm.es

To foster scientific research

SERVICES:

Business Development: Support for entrepreneurs, Business Creation, Business Incubator, Bioincubator, Access to financing, scientific and university environment.

Scientific Services: Genomics, Proteomics, Micro-analysis of materials, Bio-IT, Biotransform

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

The creation of companies with a technological base

Science services to biotech companies

Large scientific facilities

Technical assistance for the creation and management of science and technology parks.

Fundación Parque Científico Tecnológico Agroalimentario Aula Dei (Fundación PCTAD)

Susana Martínez Hernández
Fundación Aula Dei Director
smartinez@pctad.com

Address: Avenida Montaña, 930 Zaragoza Zaragoza

Phone: 34 976 716 976
www.pctad.com

To connect de research centres and the companies.

To support and encourage the companies within the agricultural and environmental sector to look for scientific and technological solutions.

To transfer the results of the research centres linked to the Park to the production fabric.

To spread the researcher's work to enhance its visibility.

To arrange and promote the existing technology offer.

To detect and give solution to the new technologies needs

To encourage the creation and consolidation of innovative companies within the sector.

PRODUCTS: Management of R + D + i contracts between companies and research centres. Advice regarding R & D projects. Business incubator. Innovation and Creation of new technology based firms Programme. Spin off Programme. Cooperation networks for knowledge and technology transference.

Transferring and putting the technology on the market. Regional, National and International Financing of R + D + i projects. Training: specialised postgraduate and advanced courses for professionals.

MOLECULAR BIOLOGY SERVICE: Genetic Plant Improvement. Genetic fingerprinting of individuals, varieties and species. Varietal Identification and filogenetic relationships. Analysis of genetic diversity in natural and improved populations. Identification of genes associated with agronomic traits of interest (disease resistance, increased production, improved organoleptic and nutritional properties ...)

FOOD SAFETY SERVICE: Analysis and detection of food residues

SERVICE OF QUALITY AND TECHTECHNOLOGY OF VEGETABLE FOOD: Solutions for the industry to improve product quality and optimize production processes. Control, measurement and analysis of quality parameters of fruits and vegetables

Fundación Parque Tecnológico de Ciencias de la Salud de Granada (PTS)

Jesús Quero Molina. Manager
jquero@ptsgranada.com

Address: C / Recogidas, nº 24. Portal B, Esc. A - 1ºB Granada - Granada

Phone: 34 958 53 50 50
www.ptsgranada.com

"The promotion of interdisciplinary research in biomedicine at an international level. "The protection and transfer of knowledge. "The consolidation of health sciences business framework based on technology and aimed at clinical practice. "Being a centre of excellence for healthcare.

SERVICES:

RESEARCH SERVICES - Library - Cell Culture - DNA Sequencing - Genomics and Proteomics - Oligonucleotide Synthesis SERVICES OF TECHNOLOGICAL INNOVATION -Funding of the I+D+i -Transfer of Technology -Industrial Property -Technological Alertness -Strategic R&D Management MANAGERIAL SERVICES -Services of EIBTs's creation -Services of incubation -Services of managerial development

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Biotechnology and Human Health

Fundación Pública Andaluza Progreso y Salud

Javier Montero Plata
Director of the Technology Transfer Office
fundacion.progreso.salud@juntadeandalucia.es

Address: Avda. Américo Vespucio, 5, bloque 2, 2ª planta 41092 Sevilla

Phone: 34 955040450

http://fundacionprogresoysalud.junta-andalucia.es/

The Fundación Progreso y Salud (FPS), which belongs to the Andalusian Regional Ministry of Health, is the central entity which supports and manages Public Health System research in Andalusia (SSPA), which main aim is to effectively promote health research and innovation in the region.

FPS provides to all centers and researchers from the SSPA with necessary services and tools for management, development and transfer of scientific production in health, becoming a backbone of biomedical research in Andalusian Public Health System

FPS is in duty of technology transfer of the SSPA that is managed by Technology Transfer Office (OTT-SSPA) that is organized as a network structure that collaborates with the Network of Research Management Foundations (RFGI) which operates at a local level.

The OTT-SSPA offers specific services to companies in order to promote interactions between the industry and our research groups and a transnational scientific research

- Research groups identification
- Technology Offers. Our office manages commercialization of all technologies generated in the SSPA
- Reverse Technology Transfer
- Public-private financing
- Business attraction

Fundacion Vasca de Innovacion e Investigacion Sanitarias

Lorea Mendoza Arteche
Chief of the Demostration Unit of Innovative Technologies in Health Care
lmendoza@bioef.org

Address: Plaza Asua, 1 SONDIKA BIZKAIA

Phone: 34 94 4538500

http://www.bioef.org

The Basque Foundation for Health Innovation and Research (BIOEF, from the Basque Berrikuntza + Ikerketa + Osasuna Eusko Fundazioa), set up by the Department of Health of the Government of the Basque Country, is an instrument to support the health authorities of the Basque Country. Its mission is to promote innovation and research in the Basque Health Service, Osakidetza, to achieve continuous development and improvement in the capacity of the service to care for the health of the people in the region. In particular, to enable it to fulfil its mission, the Foundation seeks to provide a framework for collaboration, cooperation and communication between the sectors involved in health research, development and innovation at regional, national and international levels.

The work of the Foundation is carried out through two institutes:

The Institute of Health Research (O+Iker) is responsible for the activities of the Foundation that are most directly related to biomedical research and The Institute of Health Innovation (O+Berri) focused on the continuous innovation in the health service, both of organisational systems and of management instruments.

Within BIOEF, there are different specialized management units that actively collaborate with industry:

• Basque Research BioBank (O+Ehun): responsible for collecting, storing and distributing biological samples for biomedical research.

• Demonstration Unit of Innovative Technologies in Health Care (DEMOTEK): that provides research services focused on the design and execution of evaluation trials, to assess the effectiveness and economic impact of healthcare related-products.

• Office of Clinical Trials Management (O + SAIK).

• Integrated Services Unit of Technology Transfer (USITEC): that manages intellectual and industrial property rights and coordinates the collaboration with other entities for the co-development of new products.

GENMIC: Grupo de Investigación de Genética y Microbiología

Lucía Ramírez.
Professor of Genetics and Plant Breeding
lramirez@unavarra.es

Address: Grupo de Investigación de Genética y Microbiología Departamento de Producción Agraria Edificio "Los Olivos" Universidad Pública de Navarra 31006 Pamplona Pamplona

Phone: 34 948169107

www.unavarra.es/genmic

The primary goal of GENMIC is to train Master and PhD students in the fields of Biotechnology and Public Health through the development of research projects in genetics and microbiology based on the application of genomic and transcriptomic technologies applied to the fields of agriculture, industry and health. This training is carried out in the frame of large research projects funded by the National Research Plan and by international genome and transcriptome sequencing projects. This training objective is expanded to other interested people through ad hoc courses and the development of joint research projects.

Products / Services:

- Training courses in genetics, microbiology, omics techniques and genetic breeding for professionals in agriculture, industry or health.
- Development of projects using genetic and genomic techniques for companies with an agricultural, industrial or healthcare biotechnology base.
- Production of new agricultural varieties.

Areas of Interest: Genetics and genomics applied to the improvement of industrial processes and plant breeding. Genomics and transcriptomics applied to the identification of genetic conditions in human health.

Collaborations: Sequencing of genomes, metagenomes, and transcriptomes in the fields of agriculture, industry or health

Genoma España

Belén Gilarranz
Communication Officer
belen.gilarranz@gen-es.org

Address: Pedro Teixeira 8, 2ª Planta
Edificio Iberia Mart I Madrid Madrid

Phone: 34 91 449 12 50
www.gen-es.org

Promote the creation of value from knowledge in strategic areas of the National R&D&I Plan,, especially in biotechnology, through technology transfer and training with the goal of improving the health and quality of life of citizens and the competitiveness of businesses, while establishing the framework for public-private partnerships.

SERVICES: Our main goals are: Promote the active support and coordination of research carried out in Spain. Make better use of research resources and results by promoting technology transfer and supporting the creation of technology-based companies. Undertake tasks of technology watch, prospective and strategic analysis. Help in the internationalization and in the promotion of the Spanish biotechnology sector. Bring biotechnology closer to society.

Gobierno de La Rioja. Dirección General para la Innovación

Julio Antonio Herreros Martín
Director General para la Innovación
dg.innovacion@larioja.org

Address: Centro Tecnológico de La Rioja. Avda. de Zaragoza, nº 21
LOGROÑO LA RIOJA

Phone: 34 941 291 684
www.larioja.org

R+D and Innovation Policies Design

Communication of the relevance of the R+D and Innovation issues

Regional coordination of those activities

Push up of the technology transfer

Facilitate the growing up of new innovative companies

Enlarge the research activity in La Rioja

Be in the European R+D and Innovation Network

Focus the local companies to the new technologies to improve their competitiveness

SERVICES:

New Third R+D and Innovation Regional Plan 2.008-2.011

New Regional Law for R+D and Innovation

Technology Surveillance and Prospective

Support our companies to participate in R+D and Innovation projects

Develop activities to transfer the biotechnological solutions to traditional companies

Helping companies to reach funds for biotechnological projects

Coordination of the Technologies Centres in La Rioja

Communicate to a public of all ages the relevance of the biotechnology

AREAS OF INTEREST TO FUTURE COLLABORATIONS: All related to the above mentioned objectives.

Institut de Recerca Biomèdica de Lleida (IRBLleida)

Elias Daura Oller. Managing Director
edaura@irblleida.cat

Address: Av. Alcalde Rovira Roure, 80. CP 25198 Lleida

Phone: 34 973 70 22 23
www.irblleida.cat

IRBLleida aims to promote, develop, transfer, manage and disseminate biomedical research and research training in the field of life sciences and health

SERVICES: Research and development collaborative Clinical Trials

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Biotechnology and Human Health

Food and Nutrition

Collaborative research projects

Clinical Trials

Instituto de Salud Carlos III

Julia Medrano Chivite
Area Chief
otri@isciii.es

Address: MONFORTE DE LEMOS, 5
Madrid

Phone: 34 91 822 2125
www.isciii.es

A public research body, whose mission is to foster, develop and render technical scientific services in the field of human health care.

SERVICES:

Research into the different aspects relating to the application of genetic knowledge in diagnosis, therapy, the development of new drugs and epidemiology.

The development of innovation in telematics, bio-IT, genomics and proteomics and other new technologies applied to health care.

The conservation of international standards and the preparation and conservation of national standards.

Awarding aid and subsidies for biomedical research.

Drawing up reports about healthcare technologies and services aimed at consolidating decision-making at the different levels of the National Healthcare System.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Molecular Diagnosis

Telematics and Bio-IT

Proteomics and genomics

Healthcare technologies

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

Carlos González Navarro
Business Development Manager
innovacion@imibic.org

Address: Avda. Menéndez Pidal s/n. Hospital Reina Sofía, Edificio de Consultas Externas, Nivel -1. 14004 Córdoba

Phone: 34 957 736 484 http://www.imibic.org

IMIBIC is a Health Research Institute created April 24, 2008.

Its management body is the Foundation for Biomedical Research of Cordoba (FIBICO).

IMIBIC intends to be a reference Research Centre in Andalusia and the State level within the Institutes of Health recognised by the Health Carlos III.

Its Mission "To develop and promote a multidisciplinary scientific forum in which to develop biomedical research projects that integrate core groups with others whose goals transcend towards translational research"

IMIBIC research focuses on five scientific programs around which different researchers collaborate to generate knowledge that can be used to improve clinical practice and therefore the health of the population. These programs are:

- Cardiovascular disease.
- Obesity and metabolic syndrome.
- Oncology and onco-hematology.
- Chronic inflammatory diseases and infectious diseases.
- Senescence
- Liver and digestive diseases
- Renal and nephrourological diseases
- Given the multidisciplinary nature of IMIBIC, areas of interest for future collaborations focus, generally in the health field, having a greater focus on those of: Nutrition, Metabolic Syndrome and Obesity,

  Inflammation and Oncology.

NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario

Dra. Sonia Castañón de la Torre
Biotechnology Department Head
scdelatorre@neiker.net

Address: Parque Tecnológico de Bizkaia. Parcela 812. C / Berreaga. CP 01080 Arkaute: Vitoria-Gazteiz

Phone: 34 94 512 13 13
www.neiker.net

NEIKER is a Public Institute of Research and Technological Development that seeks generating knowledge and offering services that contribute to the improvement of Agriculture, Food and Environmental sectors. Biosciences and biotechnology are the instruments with which to contribute actively to the economic and social development, improving competitiveness and sustainability.

SERVICES: Activity is focused on R&D, laboratory analysis, technical advice for the Agricultural, Food and Environmental sectors, technical support under emergency alerts, new technology transfer to emerging companies and development of new technology-based companies.

Main working fields: genomics, in-vitro cultures, identification and production of biomolecules, food biosecurity, application of biotechnology to animal health and environment.

AREAS OF INTEREST TO FUTURE COLLABORATIONS:

Industrial applications for new biomolecules.

New applications of genomics and in-vitro cultures.

New drug development for the Animal Health sector.

Diagnosis in Food biosecurity.

Systems of environmental evaluation.

Parc Científic de Barcelona (PCB)

Fernando Albericio
administracio@pcb.ub.es

Address: Baldiri Reixac 4-8 Barcelona

Phone: 34 93 403 44 75
www.pcb.ub.es

To potentiate quality research with the support of a wide range of technologies

To revitalize the relation between university and business

To promote the creation of new companies and institutions

To further the science-society dialogue and encourage careers in science

SERVICES:

Technological facilities by Technology Platforms and Scientific Services of the PCB and UB. Independent access to equipment. Consultancy/ assessment service. Co-Development of specific techniques. Sub-contracting of services. Custom-designed research services. Partnership in research projects. Innovation Consultancy/ assessment service. TTO. Business Creation Center. Patent Center. Valorization and Licenses (AVCRI). General services: Reception, Meeting rooms, Auditorium, Cafeteria / Res¬taurant, Congresses and Meetings Unit, Research Pro¬jects Management Unit, science promotion, networking, etc.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Medicinal chemistry, nanotechnology, structure-based drug discovery, ecotoxicology, proteomics, transcriptomics, animal models of disease.

Red de Entidades de Investigación Clínica Hospitalaria y Biosanitaria (REGIC)

Gloria Palomar / Elena Aristoy
Presidenta / Administración
administracion@regic.org

Address: Avenida Campanar, nº 21
Escuela de Enfermería, 6ª planta
despacho 619 46009. Valencia

Phone: 34 961973453

www.regic.org

To create a collaborative environment between the partners for the promotion and development of valorization management activities and knowledge transfer to the productive sector. Moreover, to provide a forum for coordination, information exchange and integration of policies and interests of the partner entities, developing common strategies and seeking for solutions to the main challenges of the biomedical and hospital sector in relation to the transfer of knowledge.

REGIC is aimed at helping its partners to stimulate research; enhance knowledge of the research and innovation of our partners, promoting the collaboration with enterprises for the transfer of research results, clinical validation of new technologies, etc. In addition, REGIC has among its purposes to collaborate in the creation of policies and good practices for research and innovation.

Sociedad Española De Bioquímica y Biología Molecular (SEBBM)

Isabel Perdiguero
Technical Secretariat
sebbm@sebbm.es

Address: Vitruvio, 8 - 2º Madrid

Phone: 34 91 561 33 81
www.sebbm.es

Created in 1963 and with more than 3500 members, has the following objectives: i) promoting research; ii) boosting transfer of knowledge to the industry; iii) improving teaching; iv) facilitating contacts with interested stakeholders; v) fostering the internationalization of Spanish science; vi) informing the Spanish society about scientific progress; and, vii) contributing to strengthen the social and economical influence of Science.

SERVICES: Technology development and transfer in biochemistry and molecular biology and biotechnology. R&D Research in Biochemistry and molecular biology and biotechnology R&D training in Biochemistry and molecular biology and biotechnology R&D services in Biochemistry and molecular biology and biotechnology

AREAS OF INTEREST TO FUTURE COLLABORATIONS: To promote transfer of results and technology between members of the Society and partners of ASEBIO. To co-organize courses, workshops of interest in Biotechnology To participate in Congresses and Meetings in Biotechnology

Sociedad Española de Neurociencia (SENC)

Juan Lerma
President
secretaria.tecnica@senc.es

Address: C/ Londres 17 28028. Madrid

Phone: 34 913612600
www.senc.es

SENC is a non-profit organization founded in 1985 having as main objectives:

Promote the development of knowledge in the area of neuroscience, bringing together scientists from different disciplines, and facilitate the integration of research directed at all levels of organization of the nervous system.

Promote education in the field of neuroscience.

Promote the relationship with national and international peer organizations and societies.

Inform the public on the results and implications of the ongoing research in the areas of neuroscience.

SENC is a scientific society whose objectives are as above. In order to promote neuroscience research and encourage the transfer of knowledge to the society, the SENC organizes a biennial Congress and monographic conferences (e.g. Cajal Winter Conference), as well as training and outreach activities (global week of brain Spain, etc).

TechBA Madrid

Eugenio Marín, CEO
eugenio.marin@techba.org

Address: Parque Científico de Madrid - Calle Santiago Grisolia, 2 (Recinto PTM) Tres Cantos. Madrid

Phone: 34 91 806 4442
www.techba.org

TechBA (Technology Business Accelerator) created in 2005 by the Ministry of the Economy of Mexico and the United States-Mexico Foundation for Science (FUMEC), has the purpose to support top-tier Mexican companies in bringing their innovative technology, products and services into global markets.

The TechBA Program promotes a series of actions to improve business development in key technological sectors. Our objective is to help individuals and companies identify opportunities at the intersection of technology and markets, allowing them to increase their value capture. Our support extends to the development of a management team & international business plans, risk management, funding, lead customer acquisition and partner development with a global approach.

The TechBA acceleration process facilitates access to market, financial and managerial skills and technological resources of highly entrepreneurial ecosystems. Participant companies are carefully chosen through a rigorous evaluation process. As a result of this process, the companies rapidly increase their value and become players in the international technology business market.

TechBA Madrid is a business accelerator specialized in sectors such as: ICTs, Mobile Technologies, Biotechnology, Advanced Manufacturing & Aerospace; supporting top tier Mexican innovative SMEs to develop global market opportunities from the heart of Europe.

Universidad de Navarra

José Manuel Zumaquero/ María Font.
Legal Representative/ Person for Scientific Contacts
jmzumaquero@unav.es

Address: Campus Universitario, s/n Pamplona - Navarra

Phone: 34 94 842 56 00
www.unav.es

Higher education, basic and applied research and specialised medical attention

Universidad Europea de Madrid

Maria Junco
Area Manager Pharmacy and Biotechnology
maria.junco@uem.es

Address: Tajo s/n Urbanización el Bosque Villaviciosa de Odón Madrid

Phone: 34 91 211 52 77
www.uem.es

Providing students with an excellent university education in order to acquire both academic knowledge and practical skills which will allow them a rapid incorporation into the professional world.

Promoting an international perspective by encouraging students to study at Universities abroad and facilitating internships in foreign companies

SERVICES: A university education that includes Bachelor's and Graduate Degrees in a broad range of programs. Bachelors Degrees and Double Degrees are offered in Pharmacy and Biotechnology, in Health and Biomedical sciences area. Their cutting-edge practical approach prepares students to work both in research and management of biotechnology companies.

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Internships required for students in their final year of studies in Biotechnology companies. Undergraduate and Graduate training in Biotechnology: courses, seminars, etc. Collaboration agreements with private companies to develop research projects at UEM Laboratories

Universidad Francisco de Vitoria

Cristina Benitez
Secretaria de Coordinación
c.benitez@ufv.es

Address: Ctra. M-515; Pozuelo a Majadahonda, Km. 1,800 28223. Pozuelo de Alarcón - Madrid

Phone: 34 91-7091400
www.ufv.es

The School of Biosciences at Francisco de Vitoria University aims to train professionals of the biotechnology and health sciences areas with excellent capabilities that will enable them to be the new generation of men and women who respond to the challenges posed by today's society.

Our goal is to form innovative, critical, creative and demanding people, professionals who understand their science as a service to the society with the objective to improve the quality of life. The training programs provide a solid theoretical, practical, technological and humanistic formation, which allow the appropriate personal and professional skill development

The Faculty of Biosciences at Francisco de Vitoria University currently offer seven Official Degree qualifications: Biotechnology + Course of Expert in Biotechnology Research Methodology. Pharmacy + Course of Expert in Biotechnology Applications and Management of Pharmaceutical Companies. Pharmacy + Biotechnology. Medicine. Nursing. Physiotherapy. Psychology. Two Master Degree programs are offered in collaboration with other higher education institutions. Several research projects in the areas of Biotechnology, Biomedicine, Medicine and Bioethics, are developed at the Francisco de Vitoria Biosciences Research Institute associated to the Faculty

Universidad Pablo de Olavide

Cristina Moreno
Technician of the Strategic Planning Office
planestrategico@upo.es

Address: Ctra- de Utrera Km 1 Sevilla

Phone: 34 954977814
www.upo.es

To achieve such a research dimension that constitutes an outstanding reference at the international level To promote both technology transfer and wealth development To support innovation To promote social development

SERVICES: Education and Training Research Advice on business administration and management

AREAS OF INTEREST TO FUTURE COLLABORATIONS: Collaboration with university research teams. Collaboration agreement for professional training of students and graduates of the university. Location of entrepreneurial firms in the UPO campus

Veterindustria

Santiago de Andrés
Director General
veterindustria@veterindustria.com

Address: San Agustín, 15-1º Derecha, CP 28014 Madrid

Phone: 34 91 369 21 34
www.veterindustria.com

To defend the collective interests of the associated companies that manufacture and/ or commercialise the following products and services in Spain: Veterinary medicines, animal healthcare and nutritional products and additives for animal nutrition, through its different co-ordination, advisory and communication services, to thus promote all the aspects of the Animal Healthcare and Nutrition Industry, benefiting both the sector and society in general.

To promote research, technology development and innovation in the field of animal health through the creation of the Spanish Technology Platform for Animal Health, Vet+i.


GOBIERNO
DE ESPAÑA
MINISTERIO
DE ECONOMÍA
Y COMPETITIVIDAD
ICEX
El mundo es tu mercado


españa, technology for life.


EUROPEAN UNION
EUROPEAN REGIONAL
DEVELOPMENT FUND
A WAY TO MAKE EUROPE